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Summary 
 
A genetically determined high level of intrinsic normal tissue radiosensitivity may account 
for the 5% of patients who experience unexpectedly severe normal tissue side effects 
following radiotherapy. The pre-treatment identification of these individuals by a 
diagnostic test or “predictive assay “ may allow appropriate modification of treatment 
plans and improve the therapeutic index of radiotherapy. 
 
Results from studies of cell-based assays measuring the response of a single cell type taken 
from patients to in vitro irradiation have been inconsistent, leading to the opinion of many 
that they are of no value in the prediction of normal tissue radiosensitivity. 
 
A systematic review of the literature presented here, however, suggests that poor 
methodology of study design often with inadequate control for those factors other than 
normal tissue radiosensitivity which influence radiotherapy toxicity and lack of reporting 
of assay precision means that it is difficult to form any conclusions, positive or negative 
about the diagnostic accuracy of the cell-based assays studied so far. Analysis of 
individual patient data extracted from these studies suggests that at least some of these 
assays may possess some discriminatory value.  
 
This finding justified an attempt to develop a novel cell-based assay based on the kinetics 
of radiation-induced γH2AX in peripheral blood lymphocytes.  Assay failure rate was high 
and intra- and inter-sample assay reproducibility was poor for quantification by 
microscopy but were better for flow cytometric analysis. A study of 8 volunteers, however, 
demonstrated that intra-individual variation was higher than inter-individual variation in 
assay results, strongly suggesting that poor assay reproducibility due to technical or 
biological factors may limit the assay’s potential to identify radiosensitive individuals. 
This suspicion needs to be confirmed in a clinical study of patients of known 
radiosensitivity. As blood sample storage conditions affect assay results these will need to 
be standardized to prevent confounding of results. 
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1. Introduction 
 
The medical use of ionising radiation to treat disease (radiotherapy) is most often used as 
part of cancer treatment. Approximately half of all patients diagnosed with cancer will 
receive radiotherapy during the course of their illness.  
 
It has been estimated that approximately 5% of patients treated with radiotherapy 
experience unexpectedly severe side effects that could not have been predicted from the 
patient-related and treatment-related factors known to influence radiation toxicity. It is 
thought that the normal tissues of these individuals possess an intrinsically high level of 
sensitivity to radiation damage and that this may be genetically determined. If it were 
possible to measure an individual’s normal tissue radiosensitivity before treatment it may 
be possible to predict their likely radiation toxicity and modify their treatment accordingly. 
At present no such predictive assay of normal tissue radiosensitivity exists in clinical 
practice despite over a decade of research interest. The majority of studies published so far 
have examined the role of functional cell-based assays - giving a test dose of radiation in 
vitro to a tissue sample from the individual in question and examining the response. As 
results have been perceived to be disappointing interest has moved away from these cell-
based assays to assays based on genotyping – or “radiogenomics”.  
 
Inadequate study design may have contributed to the apparent failure of cell-based assays 
to deliver a clinically useful diagnostic test. The aims of this project were therefore to 
evaluate the current evidence regarding functional cell-based assays in the predictive 
testing of normal tissue radiosensitivity to determine if the perception that they are of no 
clinical utility is justified and, if then deemed appropriate, to develop a novel functional 
cell-based assay in a methodical and systematic fashion which might have a potential role 
as a predictive assay for normal tissue radiosensitivity in the clinic 
 
1.1 Radiotherapy - clinical importance.  
 
As the population of Scotland ages, with a corresponding rise in cancer incidence, the 
number of patients being treated with radiotherapy annually is set to increase. Over 7000 
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patients were treated with radiotherapy in Scotland in 1999 and it is projected that by 2011 
this will increase to 16 500 (Scottish Executive 2004).  
 
Radical radiotherapy may be used in some cancer types as an alternative to surgery to 
achieve long term tumour control and cure. Long-term tumour control can often be 
achieved with acceptable cosmetic and functional results, which may be superior to those 
following radical surgical resection. Increasingly chemotherapy or other biological 
targeted therapies are being administered in combination with radiotherapy in an attempt 
improve the chances of local tumour control and survival over those achievable with 
radiotherapy alone.  
 
Adjuvant radiotherapy is used in combination with surgery to improve the chance of long 
term tumour control. Radiation is delivered pre- or post-operatively to eradicate 
microscopic residual disease in or around the tumour bed that may be left behind by the 
surgeon.  
 
Palliative radiotherapy also has a key role in the relief of distressing symptoms such as 
pain, breathlessness and bleeding when the cancer cannot be cured. Palliation is the most 
common indication for radiotherapy and can be very effective – for example, 80% of 
patients with pain secondary to metastatic tumour deposit in bone will experience relief 
after palliative radiation treatment (Hoskin, Yarnold, 2001).   
 
1.2 Principles of radiotherapy planning and delivery 
 
The ultimate aim of radiotherapy is to deliver a clinically effective dose of ionising 
radiation to a tumour to kill or limit the proliferation of tumour cells that would normally 
multiply causing the cancer to survive and grow.  
 
Radiotherapy planning is the process by which the target volume for treatment is defined 
within the patient and the optimal arrangement of radiation beams or radioisotope sources 
which will distribute a homogenous radiation dose within this target whilst minimising the 
dose to normal tissue determined. This goal can be achieved using different levels of 
technical complexity. The underlying principles of all radiotherapy planning and delivery 
techniques no matter how complex are the same (Figure 1.1) 
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Figure 1.1 Basic principles of radiotherapy planning (adapted from Dobbs, 1999) 
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The tumour volume to be irradiated is defined according to international definitions for 
tumour and normal tissue volumes ( Figure 1.2) (ICRU 1993; ICRU 1999) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Definitions of target volumes for radiotherapy planning 
 
Organs at risk are defined as those normal tissues likely to be irradiated during the course 
of treatment. 
 
Radiotherapy planners must then determine the beam energy, arrangement of radiation 
beams, and required beam modification, required to achieve the aim of delivering the 
prescribed dose in a uniform distribution to encompass the entire PTV, whilst minimising 
the dose to the organs at risk. This part of the planning process has been greatly assisted by 
the development of sophisticated radiotherapy planning software. 
 
The radiation dose to be delivered to the PTV will vary according to the tumour type, and 
aim of treatment. Treatment is usually fractionated with fractions delivered on a daily basis 
over a number of weeks. The radiotherapy prescription must specify the total dose, number 
and size of each fraction, overall time over which the treatment is to be delivered and the 
point to which the prescribed dose is to be delivered.   
Gross tumour volume 
(demonstrable macroscopic extent of 
tumour) 
Clinical target Volume 
(accounts for potential microscopic 
spread of tumour outside GTV) 
Planning Target Volume 
(extra margin added around CTV to 
account for set-up error and organ 
movement  during radiotherapy 
5 
 
For different tumour types there are generally accepted standard radiotherapy schedules 
usually defined by clinical experience or evidence from randomised controlled trials. 
Radiation dose is defined as the amount of energy absorbed per unit mass and is measured 
in Gray, where 1 Gray is equal to 1 Joule of energy absorbed per kilogram of tissue. As an 
example, radical radiotherapy to the lung may be delivered as 55Gy in 20 fractions over 4 
weeks. Palliative radiotherapy is usually a lower dose delivered more quickly e.g. 20Gy in 
5 fractions over 5-7 days. 
 
The technological systems for planning and delivery of radiation therapy are becoming 
increasingly more sophisticated. 3-D conformal radiotherapy allows precise shaping of the 
radiation beam around the target. Intensity Modulated radiotherapy (IMRT) allow shaping 
of the radiation dose around critical normal structures, and Image-guided radiotherapy 
(IGRT) improves precision of radiation delivery to the PTV by allowing for patient and/or 
organ motion during the course of treatment delivery.  
 
1.3 Normal Tissue Toxicity 
 
Despite technological improvements in radiotherapy delivery it will always be impossible 
to treat a cancer without simultaneously irradiating surrounding normal tissue. Often the 
volume of normal tissue within the planning target volume will exceed the gross tumour 
volume. Radiation beams must traverse normal tissue below the patient’s surface to reach 
deep-seated tumours. The unavoidable irradiation of normal tissues causes the side effects 
associated with radiotherapy.  
 
The pathological processes that lead to radiation injury begin immediately after radiation 
exposure but may not become clinically apparent for days, weeks, months or even years. 
By convention, radiation effects on normal tissues are usually divided into acute and late 
reactions. 
 
Acute effects are those which appear within 90 days of the start of a course of radiotherapy 
as an acute effect (Cox, Stetz et al. 1995) They are usually transient but can cause 
significant morbidity.  
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Acute effects typically involve rapidly renewing tissues with a hierarchical cell lineage 
such as the skin, lining of the GI tract and haematopoietic system. These tissues are 
composed of a stem cell compartment in which the cells divide and give rise to 
differentiating daughter cells. Acute radiation reactions occur when damage to the stem 
cell compartment caused by radiation means that differentiated cells in the tissue lost 
during normal tissue turnover are not replaced at a sufficient rate. The time of onset of 
acute reactions therefore is determined by the lifespan of the differentiated cells. On 
completion of radiotherapy or even sometimes during it, compensatory proliferation of the 
remaining stem cells is followed by replacement of the functional cells and recovery.  
 
If acute toxicity is very severe a course of radical or adjuvant radiotherapy treatment may 
have to be abandoned or interrupted impacting detrimentally on the long term probability 
of tumour control and cure (Hendry, Bentzen et al. 1996). Acute severely symptomatic 
toxicity following palliative radiotherapy is obviously undesirable given that the aim of 
treatment is to improve symptoms and quality of life.  
 
Late normal tissue effects are those which appear more than 90 days after completion of 
radiotherapy and may not appear for months or years after radiation exposure. Once 
established, late reactions tend to be irreversible and their severity can progress with time 
resulting in increasing functional loss and cosmetic changes. Functional loss can be severe 
and have a major impact on an individual’s quality or even duration of life. Examples 
include hemi or quadriplegia in the case of spinal cord damage, loss of upper limb function 
with brachial plexus damage, focal neurological deficit due to brain necrosis, severe 
dyspnoea due to radiation induced pulmonary fibrosis and renal failure due to radiation 
nephropathy. Cosmetic disfigurement such as visible skin changes on the hands or face, or 
retardation of bone or muscle growth in the case of children can result in significant 
psychological or social morbidity. The clinical importance of late normal tissue toxicity is 
growing as long-term survival after cancer therapy continues to improve. 
  
1.3.1 Clinical features of radiotherapy toxicity. 
Acute and late toxicities vary in different organs. The pathophysiology underlying the 
manifestation of radiotherapy toxicity is incompletely understood, particularly for late 
damage. Some examples of normal tissue toxicities of clinical importance are given below: 
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a) Skin and submucosa 
Acute skin toxicity is a well-recognised complication of radiotherapy and before the 
advent of modern megavoltage linear accelerators was frequently the dose-limiting toxicity 
encountered in clinical practice. It is still a frequent complication of treatment of breast, 
head and neck and ano-genital malignancies.  
 
Erythema develops in the 2nd or 3rd week of a fractionated course of radiotherapy followed 
by dry, then moist desquamation due to depletion of the basal stem cell population and 
failure to replace functional cells (Archambeau, Pezner et al. 1995). Moist desquamation 
may lead to ulceration. Acute skin toxicity is accompanied by pruritis, hypersensitivity and 
pain, is distressing for the patient, may require intensive nursing input and can also lead to 
breaks in or curtailment of treatment. It may begin to heal by the end of treatment or may 
not resolve for several weeks after the completion of therapy.  
 
Late changes in the skin and submucosa are characterised by atrophy, fibrosis and 
telangiectasia, which are thought to be a result of vascular injury with endothelial cell loss, 
vessel dilation and increased blood flow in remaining vessels. Marked fibrosis has obvious 
cosmetic implications and depending on the site can result in impairment of function.  
 
b) Oral Mucosa 
Acute radiation toxicity in the oral and pharyngeal mucosa is a significant complication in 
treatment for head and neck cancer. As with radiation dermatitis, mucositis also results 
from loss of functional cells from the mucous membrane lining of the oral cavity and 
pharynx. Severe confluent mucositis is painful and can lead to diminished oral intake often 
requiring hospital admission for enteral feeding. Temporary treatment interruption may be 
required. 
 
c) GI tract 
In the treatment of pelvic and abdominal cancers substantial parts of the GI tract are often 
included in the irradiated volume. Acute toxicity is due to depletion of mucosal pre-cursor 
ells such as the intestinal crypt cells and lack of replacement of functional intestinal villus 
cells. Clinical symptoms may include diarrhoea, tenesmus, increased passage of mucus per 
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rectum, nausea and gastritis. If severe, treatment may have to be temporarily interrupted 
and can occasionally be life-threatening.  
 
The resulting breakdown in the mucosal barrier in the GI tract results in inflammation 
which may subside rapidly once treatment is completed, or give rise to waves of ongoing 
inflammation with induction of necrosis, vascular sclerosis and fibrosis (Hauer-Jensen, 
Richter et al. 1998). Late effects may be consequential to this on-going inflammation and 
vascular damage and include fibrosis and ischaemia in the submucosa and muscle wall of 
the bowel, along with development of telangiectasia and other vascular abnormalities. 
Clinical symptoms of late bowel toxicity include increased stool frequency, urgency, 
spotting of blood and faecal leakage. Occasionally mucosal ulceration, severe bleeding, 
pain, fistulation, stricture formation and severe incontinence can occur (O'Brien 2001) 
 
d) Brain 
Cerebral oedema with increased intracranial pressure and accompanying headache and 
nausea can occur during radiotherapy. The most important and potentially devastating 
consequences of normal tissue damage in the brain tend to occur a few months to several 
years after radiotherapy. Transient demyelination in the CNS can occur in the first 6 
months causing “somnolence syndrome” characterised by  drowsiness, lethargy and 
anorexia (Faithfull and Brada 1998). Transient memory impairment has also been reported 
as an delayed acute effect of cranial irradiation (Armstrong, Ruffer et al. 1995; Vigliani, 
Sichez et al. 1996). Features of late radiation damage to the brain occurring 6 months to 
several years following treatment are demyelination and necrosis leading to permanent and 
sometimes progressive neurological and cognitive deficit. In the first year after 
radiotherapy histological changes are mostly limited to the white matter, with increasing 
grey matter changes and pronounced vascular lesions developing later. Histological 
changes include necrosis, glial atrophy and vasculopathies with telangiectasia and 
haemorrhage (Van der Kogel 1991).  
 
e) Spinal cord 
Radiation toxicity to the spinal cord is similar to that seen in the brain in terms of timing 
and histology. Early transient demyelination results in Lhermitte’s syndrome which occurs 
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several months following treatment and can last several months. Clinical features are of 
shock-like sensations radiating to the hands and feet when the neck is flexed.  
 
Late radiation damage includes a permanent demyelination and necrosis of white matter 
which can begin 6-18 months post-treatment. A later manifestation with a latent period of 
1-4 years is progressive vascular damage with telangiectasia, haemorrhages and on-going 
necrosis. The clinical features of both of these processes are neural dysfunction with 
severe functional loss and permanent paraplegia 
 
f) Lung 
The lung is very sensitive to radiation damage. It is frequently irradiated as part of 
treatment for lung, breast and oesophageal cancers and lymphoma.  
 
Acute radiation toxicity becomes apparent 1-3 months post-treatment as “pneumonitis” 
manifested by cough, breathlessness, fever and occasionally chest pain. Histological 
changes are of inflammation with oedema and  inflammatory cell infiltrate including 
alveolar macrophages (McDonald, Rubin et al. 1995). Type II pneumocytes are increased 
and there are a reduced number of parenchymal cells. The alveoli fill with fibrinous 
exudates and gas exchange is impaired. Radiological changes are of pulmonary infiltrates 
within the irradiated volume.  
 
Pneumonitis resolves but may then be followed by late radiation toxicity consisting of 
chronic inflammation and fibrosis that may continue to develop for many years after 
radiotherapy. Histologically there is evidence of vascular damage and collagen deposition 
(McDonald, Rubin et al. 1995). The patient may experience no symptoms if the irradiated 
volume was small, but if a large lung volume has been damaged they may be permanently 
and severely breathless due to diminished gas exchange.  
 
1.3.2 Grading systems 
Evaluation of treatment outcome following radiotherapy must not only assess tumour 
control, but also the frequency and severity of side effects resulting from treatment. 
Thorough and standardised documentation of normal tissue effects is vital, both in day to 
day assessment of patients in the clinic, and in the research setting when evaluating new 
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radiotherapy regimens. Several attempts have been made to devise systems for accurate 
reporting and grading of radiation normal tissue toxicity, none of which has gained general 
acceptance as the “gold standard”.  
 
The ideal toxicity scoring system should be  
• comprehensive – it should be possible to score any relevant adverse effect  
• reproducible – intra- and inter- observer variation in scoring should be low 
• sensitive – the system should be able to detect small increases or decreases in rates 
of adverse effects  
 
 In addition the ideal system should be easy to use, clinically relevant and ensure that 
information is of sufficient quality to be of use to both clinicians and radiobiologists 
wishing to assess treatment outcomes. A number of systems have been devised and are in 
clinical use. These include: 
 
• RTOG/EORTC Acute Radiation Morbidity Scoring criteria and Late Morbidity 
scoring criteria (Cox, Stetz et al. 1995). 
• LENT/SOMA (Late Effects on Normal Tissues/ Subjective Objective Management 
Analytic) scales (Rubin, Constine et al. 1995; Rubin, Constine et al. 1995; 
Denekamp, Bartelink et al. 1996; Denekamp, Bartelink et al. 1996; Dorr and 
Hendry 2001)  
• NCI CTC (Common Toxicity Criteria) system (Trotti, Byhardt et al. 2000; Trotti 
2002; Trotti, Colevas et al. 2003; Trotti and Bentzen 2004)  
• UCLA index  
• Franco-Italian Glossary.  
 
Many centres have devised their own scoring systems or modified those above.  
 
1.4 What determines the radiation dose prescribed in today’s clinical practice? 
 
The aim of radiotherapy is to achieve the clinically desired effect, whether it be tumour 
cure or palliation of symptoms, without causing treatment related complications. There is 
evidence of a dose response relationship for tumour control probability in experimental 
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animal tumour systems and in clinical practice (Fletcher 1972; Suit 1982; Steel and 
Peacock 1989; Withers 1992; Okunieff, Morgan et al. 1995; Zelefsky, Leibel et al. 1998; 
Kuban, Pollack et al. 2003; Bradley, Graham et al. 2005; Belderbos, Heemsbergen et al. 
2006). Equally increasing radiation dose also increases the probability of normal tissue 
complications (Bentzen 1994; Bentzen 2002). The radiotherapy schedules in clinical 
practice have been developed to balance tumour control probability with normal tissue 
complication probability to try to maximise tumour control whilst keeping the risk of 
severe normal tissue toxicity in the treated population at an acceptable level. What 
constitutes an “acceptable” level of risk depends on the specific toxicity and its effect on 
the functioning of the patient. Spinal cord damage has a potentially devastating effect on 
the patient and so even a small risk is unacceptable, whilst a slightly higher risk of damage 
that is primarily cosmetic may be tolerated.  
 
Few prospective dose-escalation studies have been performed to determine the maximum 
tolerated radiation dose (MTD) in any given tissue and there is little quantitative data on 
normal tissue tolerance, particularly for those tissues where damage can lead to a 
catastrophic functional outcome, such as the spinal cord. MTD-finding studies are difficult 
to conduct as it is the late irreversible and severe effects on normal tissues rather than 
acute reversible toxicities that are generally dose limiting. A number of dose escalation 
studies aiming to define MTD in the modern radiotherapy era do exist, but in general the 
dose- effect relationships for toxicity of individual normal tissues have been derived 
empirically from clinical observation, retrospective data and consensus opinion. (Emami, 
Lyman et al. 1991). This has led to the development of parameters attempting to define the 
risk of normal tissue toxicity for a given radiotherapy schedule such as the TD5/5 i.e. the 
dose that results in a 5% chance of a specific normal tissue toxicity within 5 years of 
radiotherapy delivery (Emami, Lyman et al. 1991)., and the normalised dose-response 
gradient i.e. the percentage of increase in toxicity for a 1% increase in dose (Brahme 1984; 
Bentzen and Tucker 1997). These population-based assessments of risk of normal tissue 
toxicity with dose form the basis for prescribing radiotherapy in clinical practice. 
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1.4.1 Factors influencing the risk of and severity of radiation toxicity 
The risk of normal tissue toxicity is not only defined by the prescribed radiation dose. 
There are other features of the treatment itself and patient-related factors that are known 
influence the risk of developing normal tissue complications due to radiotherapy.  
 
1.4.1.1 Treatment-related factors 
 
Dose per fraction 
It is recognised that delivering the total radiation dose in multiple small fractions rather 
than fewer larger fractions results in a reduction in severity of late effects. Late effects are 
more sensitive to changes in fraction size than acute effects (Thames, Withers et al. 1982).  
 
Overall treatment time 
Acute effects are sensitive to changes in the overall treatment time but late effects less so – 
it has been demonstrated that a reduction in the overall treatment time in head and neck 
cancer by treating with two or three fractions of radiotherapy per day (accelerated 
fractionation) increases the risk and severity of acute effects, with a decrease in some late 
toxicity end-points(Dische, Saunders et al. 1997; Bourhis, Calais et al. 2004).  
 
Volume of irradiated tissue 
The risk of organ dysfunction and symptomatic toxicity is related to the volume of tissue 
receiving a high radiation dose (Withers, Taylor et al. 1988). The functional structure of 
the organ and its functional reserve determines its susceptibility to this volume effect.  An 
organ with serial organisation of functional subunits will fail if even a small section is 
damaged – an above-tolerance dose of radiation to even a small volume of the spinal cord 
can result in overall organ dysfunction and paralysis. An organ with parallel arrangement 
of functional subunits, such as the lung, can tolerate radiation damage to a small volume. 
For example, lung tissue has a low radiation tolerance but a high dose of radiation to a 
small volume of lung can be tolerated as the larger volume of independently functioning 
undamaged lung can compensate. However, a low dose of radiation to a large volume of 
lung can reduce overall gas exchange significantly resulting in potentially fatal respiratory 
failure.  
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Dose homogeneity 
Despite careful attention to beam modification and arrangement patient outline and tumour 
position may mean that there are unavoidable “hot-spots” within the irradiated volume 
which will receive a higher dose and dose per fraction than other areas. As a consequence 
this tissue will be at a higher risk of complications. 
 
Concurrent chemotherapy 
The concurrent administration of chemotherapy with radiotherapy has been shown in 
randomised controlled trials and large meta-analyses to improve local control and survival 
in some tumour types, particularly in cervical and head and neck cancer (Pignon, Bourhis 
et al. 2000; Green, Kirwan et al. 2005). There is also clear randomised controlled evidence 
that concurrent chemotherapy increases the risk and severity of acute radiation reactions 
although the effect on late toxicity is less clear (Bourhis, Calais et al. 2004; Denis, Garaud 
et al. 2004; Green, Kirwan et al. 2005).  
 
1.4.1.2 Patient-related factors 
 
Co-morbidity 
Patient comorbidities can influence the development of radiation normal tissue toxicity. 
Co-morbidities that affect the vascular system especially diabetes and uncontrolled 
hypertension appear to increase the risk of radiation toxicity (Turesson, Nyman et al. 1996; 
Herold, Hanlon et al. 1999). A systematic review has identified that connective tissue 
disease is associated with an increased risk of late radiation toxicity (Holscher, Bentzen et 
al. 2006) 
 
Smoking 
Smoking during therapy can increase the risk and severity of both acute and late normal 
tissue radiation toxicity (Johansson, Bjermer et al. 1998; van der Voet, Keus et al. 1998; 
Eifel, Jhingran et al. 2002; Twardella, Popanda et al. 2003; Wells, Macmillan et al. 2004) 
 
Body Mass Index 
Wells et al (2004) found that a high body mass index was predictive of increased skin 
toxicity in patients treated for breast and head and neck cancer 
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Haemoglobin 
Haemoglobin level during radiotherapy may influence the development of normal tissue 
toxicity. There is some evidence suggesting that a low haemoglobin during treatment is 
associated with a lower risk of normal tissue toxicity but this has not been a consistent 
finding by all groups (Bentzen and Overgaard 1994; Henke, Bechtold et al. 2000; Daly, 
Poulsen et al. 2003). 
 
Genetic syndromes 
Some groups of patients may have a genetic susceptibility to radiation normal tissue 
damage – rare but recognised genetic syndromes associated with increased normal tissue 
radiosensitivity include Ataxia-telangiectasia, Blooms’, Fanconi’s anaemia and Nijmegen 
Breakage syndrome. (Rogers, Plowman et al. 2000; Gatti 2001; Alter 2002; McMillan 
2002) 
 
1.5 Individual intrinsic normal tissue radiosensitivity 
 
Patients who are apparently matched in terms of the factors known to  influence 
radiotherapy toxicity will exhibit a wide spectrum of incidence and severity of normal 
tissue toxicity for a given radiotherapy dose and fractionation regimen.(Turesson 1989; 
Turesson 1990; Withers 1992). Some patients will exhibit greater than average normal 
tissue reaction whilst others will exhibit less toxicity for the same given dose. The 
frequency of differing severities of normal tissue toxicity forms an approximate Gaussian 
distribution (Burnet, Johansen et al. 1998). Analysis of the clinical radiotherapy 
fractionation studies performed in Gothenburg has estimated that approximately 80% of 
the inter-individual variation in observed normal tissue reactions is due to differences in 
individual intrinsic normal tissue radiosensitivity rather than extrinsic factors such as 
differences in delivered dose, co-morbidities, smoking or other confounding factors. 
(Turesson 1989; Turesson and Thames 1989; Turesson 1990; Turesson, Nyman et al. 
1996). Intra-patient correlation in severity of normal tissue toxicity in separately treated 
areas is further evidence that individuals possess an intrinsic level of normal tissue 
radiosensitivity (Tucker, Turesson et al. 1992; Bentzen, Overgaard et al. 1993) and 
suggests this may be genetically determined. Further weight to the idea that intrinsic tissue 
radiosensitivity is genetically determined comes from the existence of the inherited 
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syndromes mentioned above, a component of which is enhanced radiation sensitivity of 
normal tissue  
If the biological determinants of intrinsic normal tissue radiosensitivity could be identified 
they could potentially form the basis of a diagnostic test or “predictive assay” to identify 
individuals at risk of severe normal tissue damage. 
 
1.6 Predictive assays for normal tissue radiosensitivity 
 
1.6.1 Clinical value of a predictive assay of normal tissue radiosensitivity 
If a high precision assay of normal tissue radiosensitivity existed which could accurately 
and reliably predict an individual’s risk of developing severe normal tissue radiation 
toxicity, how could its results be incorporated into clinical practice and used to improve 
the therapeutic index of radiotherapy? 
 
As discussed above, an apparently similar group of patients treated with the same dose of 
radiotherapy will experience a wide range of severity of normal tissue toxicity due to a 
presumed spectrum of intrinsic normal tissue sensitivity (Figure 1.3). In clinical 
radiotherapy the radiation dose delivered in standard treatment regimens is limited in order 
to maintain the population risk of unacceptable normal tissue toxicity at approximately 5% 
or less. The population risk of toxicity is determined by the minority of patients whose 
tissues are particularly radiosensitive (Group A in Figure 1.3).  This minority who form the 
tail of the Gaussian distribution of radiation sensitivity therefore define the tolerance dose 
for the whole population. The “normally” radiation sensitive majority and the “radiation-
resistant” minority could potentially tolerate a higher dose of radiation than is delivered in 
standard radiotherapy regimens before developing toxicity. They will therefore effectively 
be “under-dosed” in order to try to prevent damage to the sensitive minority. 
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Figure 1.3 Frequency distribution of normal tissue response amongst patients treated with 
an identical radiotherapy schedule 
If it were possible to measure an individual’s propensity to develop normal tissue damage 
prior to starting radiotherapy then theoretically their radiation treatment could be modified 
with the aim of preventing serious toxicity in those who are radiosensitive. A strategy 
using normal tissue radiosensitivity testing and prospective prediction of normal tissue 
response might also permit safe dose escalation in appropriate “non-sensitive” individuals 
which should result in improved rates of tumour control. In this way treatment could be 
“biologically” individualised and the therapeutic ratio of radiotherapy could be improved. 
The results from a predictive assay of normal tissue radiosensitivity could therefore 
potentially be used to: 
 
a) Screen for the minority of individuals with very high normal tissue radiosensitivity 
and treat these with a reduced radiation dose or offer an alternative to radiotherapy 
such as surgical resection.  
 
b) Screen out the radiosensitive minority and escalate the dose in the remainder.  
 
c) Completely individualise the dose prescription so that patients are treated with 
different radiotherapy doses according to their individually quantified normal tissue 
tolerance – this should result in the same level of normal tissue complications in all 
patients 
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A number of authors have modelled the potential impact of normal tissue radiosensitivity 
testing on outcome after radiotherapy (Norman, Kagan et al. 1988; West and Hendry 1992; 
Tucker, Geara et al. 1996; Bentzen 1997; MacKay, Niemierko et al. 1998; Mackay and 
Hendry 1999) . In most cases a clinically useful improvement in tumour control 
probability without a corresponding increase in normal tissue radiation toxicity has been 
predicted. 
 
Tucker et al (Tucker, Geara et al. 1996)  have estimated the potential for individualising 
dose prescription in order to attain a uniform 15% risk of severe late damage to mucous 
membrane and bone, based on results from a study correlating fibroblast radiosensitivity in 
vitro and late normal tissue complications. They estimate that for the 8 patients in the 
study who were sensitive to radiation, an average dose reduction of 13.1Gy would have 
been necessary to reduce the Normal Tissue Complication Probability (NTCP) to 15%. In 
20 of the 21 remaining cases, a dose escalation averaging 7.7Gy could be tolerated whilst 
still maintaining the risk of severe late damage at 15% for each individual. The resulting 
effect on tumour control probability is not modelled but the authors assume that these dose 
modifications would result in higher Tumour Control Probability (TCP) than observed in 
reality as there would have been twice as many dose increases as decreases.  
 
If a precise and accurate predictive assay was available with high positive predictive power 
MacKay et al have estimated that by selecting an appropriate assay cut-off point that it 
would be possible to increase the dose to 95% of patients (MacKay, Niemierko et al. 
1998). Recognising that such an idealised highly precise assay is potentially unachievable, 
that in vitro assays do not necessarily account for in vivo factors that may modify normal 
tissue response and that the relationship between normal tissue and tumour radiosensitivity 
is unresolved, MacKay et al then went on to re-model the potential impact of normal tissue 
radiosensitivity testing incorporating these inherent sources of imprecision (Mackay and 
Hendry 1999).  This model was again based on the radiosensitivity of fibroblasts. 
Modelling was performed using a hypothetical population of 10 000 patients with a log 
normal distribution of fibroblast radiosensitivities created by a random number generator. 
An idealised perfect correlation between predictive assay result and clinical outcome was 
assumed and then the inherent variability and uncertainties likely in clinical practice fitted 
into the model to assess how they impacted clinical utility of the assay. 
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In the context of an ideal predictive assay, the predicted gain in population TCP resulting 
from tailoring individual patient dose to attain a NTCP of 5% is 30% and is predicted to be 
highest when individuals have a higher sensitivity and the distribution of radiosensitivity 
in the population is greatest. When the distribution of radiosensitivity in the population is 
high, the spread of doses required to achieve the isoeffect of 5% NTCP is wide, with a 
small tail of very high doses achievable of up to 200Gy. In reality, the inherent 
inaccuracies in the fibroblast radiosensitivity data used to generate the model have 
probably resulted in an overestimate of the spread of intrinsic radiosensitivity in the 
population. If radiosensitivity is modelled with a narrower distribution within the 
population, possibly more reflective of reality, the range of doses predicted to give a 
NTCP of 5% is narrower and the high dose tail much smaller.  
 
In reality results of predictive assays measuring a biological endpoint such as normal tissue 
radiosensitivity are likely to possess an inherent variability or “noise” – i.e. the same test 
performed on repeated occasions on the same individual may give differing results. 
MacKay and Hendry demonstrated that when assay noise is fitted into their model no gain 
in TCP could be achieved if the assay coefficient of variation was greater than 50% of the 
inter-individual biological variation. They conclude that a crucial factor in gaining a 
therapeutic advantage by individualisation of radiotherapy dose is the development of an 
accurate and reliable assay.  
 
In another study modelling the potential effect of individualising dose prescription 
according to normal tissue radiosensitivity Bentzen comes to a different conclusion 
(Bentzen 1997).  He also bases his model on published results of in vitro assays of 
fibroblast radiosensitivity and argues that the low prevalence of highly radiosensitive 
individuals in the population reduces the positive predictive value of any screening test. 
Even if successfully identified, the removal of this radiosensitive minority, who form the 
left hand tail of the Gaussian distribution of normal tissue radiosensitivity, is unlikely to 
allow a significant dose increase to the remaining patients because of the sigmoid shape of 
the dose-response curve for normal tissue toxicity. In his model, individualisation of dose 
based on information about normal tissue radiosensitivity without simultaneous 
information about tumour sensitivity leads to a virtually symmetrical distribution of dose 
changes in his simulation that could lead to a reduction rather than an increase in tumour 
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control probability. In the simulation the individualisation of dose increased the average 
dose received by the population as a whole by 1.4Gy, but tumour control dropped by 3%. 
Because of the non-linearity of the dose response curve for TCP, a positive dose increment 
of a given size will increase the TCP by a smaller amount than the same dose decrement 
would decrease TCP. These conclusions have been criticised by other authors who feel 
that some of the assumptions used in Bentzen’s model are based on too small a data set 
and are therefore inaccurate (MacKay, Niemierko et al. 1998; Mackay and Hendry 1999). 
  
An alternative to complete individualisation of dose prescription is to use predictive testing 
of normal tissue radiosensitivity to split the population into three groups – high, average 
and low radiosensitivity - and to treat each group differently (Mackay and Hendry 1999) – 
(Table 1). This would avoid the potential problems likely to be encountered whilst trying 
to individualise dose prescriptions using an assay that is less than completely reliable.  
 
Table 1.1 Theoretical division of population into 3 groups according to normal tissue 
radiosensitivity and the dose to which each group could be treated to maintain NTCP<5% 
 CV = 0.2 CV = 0.1 
Radiosensitivity High Average Low High  Average Low 
% Population 12 43 45 18 42 40 
Prescribed dose (Gy) 56 66 78 64 70 78 
 
Results are shown for 2 different populations with log normal distribution of SF2=0.36 and 
CV (coefficient of variation) of assay results across the population of 0.2 and 0.1. Before 
splitting into groups the whole population would have been treated with 60Gy (CV = 0.2) 
or 66Gy (CV = 0.1) in order to keep the population NTCP <5%. (Mackay and Hendry 
1999) 
 
MacKay and Hendry calculate that by splitting into groups and dosing as in Table 1.1, the 
overall population TCP increases by 22% if the assay CV is 0.2. As assay reliability 
decreases, the NTCP increases for the population as patients are placed in the wrong 
group. To compensate for this misclassification and to reduce the NTCP to an acceptable 
level the dose prescribed must also be reduced with a consequential reduction in TCP. 
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When the assay CV is 50% of the biological variation within the population it is still 
possible, however, to have a potential gain in TCP of 27%. This contrasts to the effect of 
assay unreliability on complete individualisation of dose prescription where no gain in 
TCP was expected with this level of assay unreliability. In fact, by dividing the population 
into groups in this way it is predicted that an increase in TCP of 11% is still possible even 
if the assay CV is the same as the biological CV. Tripartite separation of the population 
would therefore seem to be less sensitive to assay uncertainty than complete 
individualisation of radiotherapy dosing. 
 
If tumour radiosensitivity is correlated with normal tissue radiosensitivity then the 
potential clinical gains resulting from normal tissue radiosensitivity testing are even 
greater (MacKay, Niemierko et al. 1998). However, whether such a relationship exists is 
debatable and if present is likely to be weak. (West and Hendry 1992; Geara, Peters et al. 
1996; Bernier, Thames et al. 1998; West, Davidson et al. 1998). 
 
Mathematical models are provisional and require appropriate caveats (Jones and Dale 
1999) – their output is dependent on the quality of the data entered into the model and so 
results cannot be assumed to be generalisable, and they must be re-tested when new 
clinical data is available. They do however provide a useful tool for estimating possible 
outcomes of changes in therapy without conducting clinical trials which, in the case of 
normal tissue radiosensitivity testing, would not only be costly and time-consuming, but 
potentially dangerous with a concomitant risk of loss of tumour control and increased 
radiation toxicity. Mathematical modeling so far would seem to support the concept that 
normal tissue radiosensitivity testing could potentially improve the therapeutic index of 
radiation therapy if incorporated into clinical practice. 
 
1.6.2 Development of a predictive assay of normal tissue radiosensitivity 
 
The principles underpinning the development of any diagnostic test apply to the 
development of predictive assays of normal tissue radiosensitivity. The assay must be 
reliable and not subject to repeated assay failures. It must also be precise and accurate. 
Precision is a measure of assay reproducibility – an assay which is precise will give a 
similar result each time when repeated on the same sample or same individual. Diagnostic 
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accuracy is the ability of an assay to correctly diagnose the condition in question and is 
measured by assay sensitivity and specificity. Ideally an assay should be generalisable to a 
large population and could be performed in different laboratories with reproducible results. 
The results of a diagnostic assay should influence clinical decisions - to do this it must not 
only be reliable, precise and accurate, it must be able to produce results quickly in a 
clinically relevant time-frame. It must also be affordable and acceptable to patient and 
clinician without the need for unpleasant or dangerous invasive procedures otherwise it 
will not be adopted in routine clinical practice no matter how efficiently it performs. 
 
A fundamental issue in the development of any diagnostic assay is determining which 
parameter should be measured and how to measure it reliably. One of the main problems 
in the development of a biological assay to predicate normal tissue toxicity has been the 
relative lack of knowledge of the molecular, cellular and tissue pathophysiology 
underlying acute and late radiation toxicity. Strategies tested so far have had mixed 
outcomes. 
 
1.6.2.1 Functional cell-based assays 
 
Assays that are based on sampling of living cells from an individual and examining their 
response to ex-vivo irradiation have until recently been the main focus of most work on 
predictive testing. The fundamental principle underlying these assays is that there is a 
relationship between in vitro cellular response to irradiation and normal tissue toxicity and 
that it is possible to test for this relationship using a single cell type sampled from an 
individual as a surrogate for the normal tissue in question. Assay end-points examined 
have included clonogenic cell survival, assays of radiation-induced DNA damage, 
apoptosis, and differentiation. Fibroblasts derived from skin biopsy and peripheral blood 
lymphocytes have been the most frequently tested surrogate tissue 
 
Clonogenic cell survival. 
Normal tissue toxicity may be a result of loss of proliferative capacity of crucial stem cells 
within the normal tissue due to death or permanent growth arrest induced by radiation. One 
of the first indications that there may be a relationship between in vitro cell response to 
radiation and normal tissue toxicity came when Burnet et al demonstrated a correlation 
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between fibroblast radiosensitivity as measured by a clonogenic cell survival assay and 
late skin toxicity in 6 patients treated with post-mastectomy chest wall radiation(Burnet, 
Nyman et al. 1992; Burnet, Nyman et al. 1994) . Subsequent studies confirmed this 
relationship (Geara, Peters et al. 1993; Brock, Tucker et al. 1995; Johansen, Bentzen et al. 
1996) whilst others did not (Russell, Grummels et al. 1998; Peacock, Ashton et al. 2000; 
Oppitz, Baier et al. 2001). Fibroblast radiosensitivity correlated with the development of 
late central nervous system complications after stereotactic radiosurgery for arterio-venous 
malformations in a small group of Canadian patients (Raaphorst, Malone et al. 2002) Late 
radiation effects after head and neck radiotherapy, however,  did not correlate with 
fibroblast SF2 in a prospective study of 25 patients (Rudat, Dietz et al. 1999) 
 
Similarly studies examining the relationship between acute radiotherapy toxicity and the 
clonogenic survival of skin fibroblasts have revealed conflicting results (Begg, Russell et 
al. 1993; Rudat, Dietz et al. 1997; Oppitz, Baier et al. 2001; El-Awady, Mahmoud et al. 
2005) 
 
Lymphocyte radiosensitivity measured by clonogenic survival has been correlated with the 
development of late effects after pelvic radiotherapy (West, Davidson et al. 2001) 
 
Assays of radiation-induced DNA damage 
Clonogenic survival assays are time consuming to perform. Fibroblast assays do not 
deliver results for at least 6 weeks post biopsy and even lymphocyte clonogenic survival 
assays can take 2-3 weeks to perform. In order to try to develop assays that deliver results 
within a shorter, clinically useful time frame several groups have examined the 
relationship between in vitro radiation-induced DNA damage and normal tissue damage. 
There is a substantial body of evidence that suggests that DNA damage is a crucial type of 
cellular damage that can lead to cell death following irradiation (McMillan 2002). 
Microbeam irradiation of the nucleus results in much higher cell death than irradiation of 
the cytoplasm. The incorporation of radionucleotides with short-range emissions into DNA 
causes cell killing at much lower absorbed doses than when the same radionucleotides are 
incorporated into the cytoplasm. The number of chromosome or chromatid aberrations and 
the number of unrepaired DNA double-strand breaks following ionising radiation exposure 
both correlate well with cell death rates in cell culture. Cell death correlates best with the 
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level of DNA double-strand breaks (DSBs) rather than with other types of DNA damage. 
Cells are very sensitive to formation of DNA DSBs and even a single DSB can trigger the 
damage sensing process (Huang, Clarkin et al. 1996) and can lead to cell death if 
unrepaired (Bennett, Lewis et al. 1993). Maintaining the integrity of DNA therefore seems 
to be very important biologically, and the ability to detect and repair DNA damage appears 
to determine whether a cell will survive following radiation.  
 
It follows then that an individual’s ability to detect, process and repair DNA damage may 
in part determine their intrinsic normal tissue radiosensitivity and radiation tolerance and 
several studies have studied the relationship between in vitro DNA damage and repair and 
clinical radiosensitivity using assays of DNA damage such as the comet assay or pulsed-
field gel electrophoresis (PFGE) or cytogenetic endpoints of DNA double-strand breaks 
such as the micronucleus assay, G2 chromatid radiosensitivity or studies of chromosome 
re-arrangements 
 
A positive correlation has been found between cellular radiosensitivity as measured by the 
micronucleus assay and both early (Widel, Jedrus et al. 2003) and late radiotherapy 
toxicity (Nachtrab, Oppitz et al. 1998; Barber, Burrill et al. 2000; Lee, Allison et al. 2003; 
Widel, Jedrus et al. 2003). Rached et al however found no such relationship between 
micronucleus yield and acute radiotherapy toxicity (Rached, Schindler et al. 1998) 
 
Chromosome aberrations or G2 chromatid damage  induced by in vitro irradiation have 
been found to correlate with acute (Kearsley, Fang et al. 1998) and late  radiation toxicity  
(Borgmann, Roper et al. 2002)( Borgmann, Roper et al. 2000; (Neubauer, Dunst et al. 
1997; Barber, Burrill et al. 2000)  
 
Ability to repair radiation-induced DNA damage in vitro  as measured by the alkaline 
comet assay has been found by some groups to correlate with acute and late toxicity 
(Oppitz, Denzinger et al. 1999) whilst others have not demonstrated such a relationship 
(Popanda, Ebbeler et al. 2003; Twardella, Popanda et al. 2003) . Similar inconsistency of 
results has been found with assays of  DNA DSB formation and repair measured by 
electrophoresis (Kiltie, Barber et al. 1999; Kiltie, Ryan et al. 1999; Dikomey, Brammer et 
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al. 2000; Dickson, Magee et al. 2002; El-Awady, Mahmoud et al. 2005; Lopez, Guerrero 
et al. 2005; Wang, Chen et al. 2005; Pinar, Lara et al. 2007) 
 
Radiation-induced apoptosis 
Crompton et al have demonstrated that the lymphocytes in blood samples from patients 
with high levels of both acute and late radiation toxicity undergo less radiation-induced 
apoptosis in vitro as measured by flow cytometry than those from patients with average 
levels of normal tissue toxicity (Crompton, Miralbell et al. 1999). The same group 
confirmed this finding  in a prospective study demonstrating a relationship between 
increased late radiation toxicity and lower levels lymphocyte apoptosis after in vitro 
irradiation of peripheral blood samples (Ozsahin, Crompton et al. 2005). Another group 
however, could not correlate apoptotic rate in human peripheral blood lymphocytes after in 
vitro irradiation with rates of breast fibrosis, telangiectasia or breast retraction after 
radiotherapy for breast cancer (Barber, West et al. 2000) 
 
1.6.2.2   Other strategies in development of predictive assays of normal tissue 
radiosensitivity: 
As shown above, the results from functional cell-based assays of normal tissue 
radiosensitivity have been inconsistent. Authors have raised concerns that the assays lack 
reliability due to confounding external influences (West, Davidson et al. 2001). Even when 
a statistically significant relationship between an assay result and normal tissue toxicity 
has been demonstrated considerable overlap in assay results between patients with high 
and low normal tissue toxicity has led authors to conclude  that cell based assays are not 
sufficiently discriminatory to be of any use in the clinic (West, McKay et al. 2005; Burnet, 
Elliott et al. 2006). 
  
Given that intrinsic normal tissue radiosensitivity is thought to have a genetic basis 
attention has focussed instead on developing assays based on genotyping to measure an 
individual’s risk of developing severe normal tissue toxicity – so called “radiogenomics”. 
A cell’s genetic code is fixed and assay results should not be susceptible to the 
confounding environmental or biological confounders that might interfere with functional 
assays.  Modern technology allows high throughput genotyping and it is hoped that by 
indentifying high risk single nucleotide polymorphisms (SNPs) in candidate genes, such as 
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those involved in DNA repair, free radical scavenging, cell cycle control and cytokine 
release,  it may be possible to predict radiation sensitivity(Andreassen, Alsner et al. 2002) 
A tissue bank with linked data regarding patients demographics, comorbidity, tumour, and 
precise radiotherapy details and dosimetry has been set up in the EU to  enable this process 
(GENEPI)(West, McKay et al. 2005) . Initial results from genotyping assays have been 
promising but positive results have so far not been confirmed in appropriate validation 
studies (Andreassen, Alsner et al. 2003; Andreassen, Alsner et al. 2005; Andreassen, 
Alsner et al. 2006).   
 
Other assays based on serum cytokine measurements during radiotherapy have shown a 
correlation between increased TGF-β at the end of radiotherapy and interleukin 6  levels 
during radiotherapy for lung cancer and the development of subsequent radiation 
pneumonitis (Anscher, Kong et al. 1997; Chen, Hyrien et al. 2005). These assays have 
already been tested to see if  radiation dose can safely  be escalated in those patients 
identified as having a low susceptibility to pneumonitis (Anscher, Marks et al. 2003). This 
study confirmed the principle that TGF-β could predict those at risk of pneumonitis – 
unfortunately whilst patients who were dose escalated had acceptable rates of pneumonitis 
they did suffer severe complications in other normal tissues which had not been predicted 
by the assay. 
 
1.6.3  Have functional cell-based assays been proven to be of no clinical utility? 
Although potentially susceptible to confounding external influences and of no proven 
clinical utility so far, functional cell-based assays do theoretically hold advantages over 
assays based on genotyping. Assays based on genotyping alone do not give information 
about epigenetic phenomena such as control of gene expression, post-translational 
modification and interaction of gene products themselves that ultimately determine the 
cellular and tissue response to radiation. Genotyping can only be performed in selected 
genes and not the whole genome. We have only limited knowledge of the molecular 
pathology underlying normal tissue radiation reactions, so selection of the genes for 
examination is limited to those that we believe are important such as those involved in 
DNA repair, ROS scavenging, cell cycle control and induction of fibrotic reactions. We 
know from gene expression studies using microarray technology that the expression of 
thousands of genes is altered by in vitro irradiation and the sequence and function of them 
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all is not yet known (Rodningen, Overgaard et al. 2005). It remains to be seen whether 
SNPs in a few of these candidate genes can reliably predict a highly radiosensitive 
phenotype.  
 
In the meantime, functional assays have the advantage of not relying on an in depth 
knowledge of the molecular machinery governing radiation response. In effect the cell is a 
“black box” – we can put in a signal (the test dose of radiation) and measure the output 
signal (the assay result) without knowledge of the circuitry and wiring within. Is there 
sufficient evidence to be sure that function cell based assays have no role in predictive 
testing of normal tissue radiosensitivity? 
 
As described above many groups have tried to develop functional cell-based assays of 
intrinsic normal tissue sensitivity based on study designs which correlate in vitro cellular 
radiosensitivity with severity of normal tissue reaction. These studies must collect 
standardised information on radiotherapy toxicity as well as radiation exposure and factors 
other than intrinsic normal tissue radiosensitivity known to modify normal tissue response 
so allowing potential confounding factors to be taken into account during data analysis. 
Twardella et al performed a systematic review of studies examining the relationship 
between cell based assays and normal tissue toxicity in patients receiving radiotherapy for 
breast cancer (Twardella and Chang-Claude 2002) . They found that of the 25 studies 
identified limitations in study design were frequently found, with potential sources of bias 
arising from misclassification of patients due to non-standardisation of assessment of 
treatment related side effects, selection bias by studying convenient patient groups rather 
than truly representative groups and confounding due to failure to adjust analysis for 
important factors influencing normal tissue reaction. An estimate of assay sensitivity and 
specificity was performed in only one of the studies identified. Given the methodological 
problems in assay design and testing reported by Twardella et al it is possible that the 
assumption that functional cell based assays are unhelpful in predictive testing of normal 
tissue sensitivity may be premature. 
 
Similar concerns about study design and statistical analysis have also been raised about 
prognostic tumour marker studies. In this field, despite years of research and numerous 
published reports, very few clinically useful prognostic tumour markers have been 
27 
 
identified – as with predictive testing of normal tissue sensitivity studies looking at similar 
assay end points have yielded inconsistent results with methodological differences, poor 
study design, small sample sizes, non-standardised or non-reproducible assays, and 
inappropriate statistical analyses being thought to account for these inconsistencies 
(Fielding, Fenoglio-Preiser et al. 1992; Simon and Altman 1994; Hayes, Bast et al. 1996; 
Hall and Going 1999; Schilsky and Taube 2002). 
 
A joint initiative between the National Cancer Institute (NCI) and European Organisation 
for the Research and Treatment of Cancer (EORTC) has identified poor study design and 
analysis, assay variability and inadequate reporting of studies as some of the major barriers 
to progress in this field. Following this the reporting recommendations for tumour marker 
prognostic studies have been published (REMARK) (McShane, Altman et al. 2005). These 
recommendations suggest the systematic reporting of key study features including quality 
control assessment procedures for the prevention of bias in assay and clinical 
measurement, statistical analysis and appropriate reporting of findings which should allow 
transparent and complete reporting with relevant information so that the usefulness of the 
data can be judged clearly by others. The same reporting standards are transferable to 
predictive assays of normal tissue radiosensitivity. 
 
1.7 H2AX phosphorlyation in human peripheral blood lymphocytes – a potential 
predictive assay of normal tissue sensitivity. 
 
Predictive assays based on measuring DNA damage in cells irradiated in vitro using 
standard techniques have yielded inconsistent results as discussed. Recently much has 
been discovered about the molecular processes involved in the recognition of DSBs within 
a cell and the subsequent signalling processes leading to repair of DNA damage or to cell 
death. The question arises as to whether this greater understanding can lead to the 
discovery of molecular markers of DNA damage and repair that might be quantified and 
may result in the development of more sensitive and reliable assays of DNA damage and 
repair than previously used cell-based techniques.  
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1.7.1 DNA DSBs and γH2AX induction  
When a DSB is introduced into DNA the histone protein H2AX becomes rapidly 
phosphorylated at serine 139 within its COOH-terminal region involving hundreds to 
thousands of H2AX molecules in  a megabase region on either side of the DSB (Rogakou, 
Pilch et al. 1998; Stiff, O'Driscoll et al. 2004) . A commercially available monoclonal 
antibody to the phosphorylated form of H2AX (γH2AX) has been developed and using 
immunocytochemistry it is possible to visualise these DNA DSBs as large foci within the 
cell nucleus (Rogakou, Boon et al. 1999). A single DSB is sufficient for the formation of a 
γH2AX focus and there appears to be a 1:1 correspondence between the number of DSBs 
and  γH2AX foci after DNA damage induction (Sedelnikova, Rogakou et al. 2002). 
Immunofluorescent staining for γH2AX foci can detect DSB induction at much lower 
doses than established DNA DSB assays and has been reported to be sensitive enough to 
detect DSBs in cells after doses as low as 0.001Gy (Rothkamm and Lobrich 2003). 
 
The phosphorylation of H2AX is thought to recruit DNA repair factors to the site of the 
DNA DSB (Paull, Rogakou et al. 2000) and may also be involved in the amplification of 
DNA damage signals that activate the G2/M checkpoint to prevent damaged cells from 
entering mitosis (Fernandez-Capetillo, Chen et al. 2002). Inability to form γH2AX foci has 
been correlated to radiosensitivity, genomic instability and other repair defects (Bassing, 
Chua et al. 2002; Celeste, Petersen et al. 2002; Kuhne, Riballo et al. 2004; Taneja, Davis et 
al. 2004).  The mechanism by which γH2AX is removed following DNA repair is 
incompletely understood. In some studies the kinetics of γH2AX loss mirrors the kinetics 
of DNA DSB rejoining (Rothkamm and Lobrich 2003) whilst others have found that 
although the number of γH2AX foci formed after irradiation correlates with the number of 
double strand breaks formed the kinetics of foci development and loss differ from those 
characteristic of double-strand break re-joining, and loss of γH2AX may therefore be 
indicative of more than simple DSB re-joining..(MacPhail, Banath et al. 2003). 
 
Clinically relevant ionizing radiation doses induce similar patterns of γH2AX focus 
formation in radiosensitive and radioresistant human tumour cell lines and xenografted 
tumours, but radiosensitive tumour cells and xenografts retain γH2AX for a greater 
duration than radioresistant cells and tumours (MacPhail, Banath et al. 2003; Taneja, Davis 
et al. 2004). There is evidence that the rate of loss of γH2AX after irradiation of  cells in 
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culture  correlates with clonogenic survival at 2Gy (MacPhail, Banath et al. 2003) and the 
rate of γH2AX disappearance is  slower in radiosensitive tumour cells and radiosensitive 
murine normal tissue than radioresistant cell lines or normal tissue (Olive and Banath 
2004). The techniques for immunofluorescent staining and γH2AX quantification in 
cultured cells are quick and yield results in a number of days rather than many weeks. 
Quantification of γH2AX induction and the kinetics of γH2AX loss in normal human cells 
or tissues after a test dose of radiation could therefore potentially form the basis of a 
predictive assay of human normal tissue radiosensitivity. 
 
Normal cells sampled from patients and utilised for predictive testing should be plentiful 
and easily and rapidly accessible by non-invasive means. For γH2AX quantification the 
cells would ideally be non-cycling as γH2AX foci are also induced at collision of 
replication forks during DNA replication (Furuta, Takemura et al. 2003). Human 
peripheral blood lymphocytes (PBLs) obtained by venepuncture in the clinic fulfil both 
these criteria and could be used as a surrogate tissue to test if there is a relationship 
between cellular γH2AX induction and loss in vitro after irradiation and normal tissue 
radiosensitivity. 
 
1.8 Aims 
 
The aims of this project were therefore: 
 
• To conduct a systematic review of the literature regarding functional cell-based 
assays in the predictive testing of normal tissue radiosensitivity to ascertain 
whether studies so far  have been performed with sufficiently rigorous approach to 
assay quality control, avoidance of bias in study design, and statistical analysis of 
results, and to determine if the perception that cell-based assays are not helpful in 
predicting normal tissue radiosensitivity is really valid based on current literature. 
 
• To develop a rapid, reliable cell-based assay measuring γH2AX kinetics in human 
PBLs in a methodical and systematic fashion with appropriate attention to issues of 
precision and quality control, which might have a potential role as a predictive 
assay for normal tissue radiosensitivity in the clinic 
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2. Materials and methods 
 
2.1 Materials 
A list of the laboratory equipment, consumables, chemicals and reagents, kits and 
antibodies used can be found in Appendix 1. 
 
2.2 Methods 
 
The methods for the systematic review are described in Chapter 3. 
 
2.2.1 Collection of peripheral blood samples from healthy volunteers 
The School of Medicine did not have an active research ethics committee scrutinising 
research involving staff and students when this study commenced. Healthy volunteer 
subjects were recruited from within the department. The purpose of the study was 
explained to volunteers, and it was made clear that samples collected would not be used 
for any other purpose other than the research described. All subjects agreed to give at least 
3 samples of peripheral blood on 3 separate occasions. Volunteers were informed that 
blood samples and data derived from samples would be anonomised and individual 
volunteers would not be made aware of their assay results. Samples would not be stored 
and would be destroyed after the completion of the study. Basic demographic details 
regarding sex, age and smoking status at the time of blood sampling were taken from 
volunteers but no information regarding medical history or current medication was sought. 
Details of the volunteers recruited are given in Table 6.1 (page 140). 
 
Blood collection 
Peripheral blood samples were collected from volunteer subjects by medically qualified 
staff using the BD Vacutainer system for venous blood collection. Samples for analysis by 
microscopy were collected into 5ml Lithium heparin tubes, whilst those for analysis by 
flow cytometry were collected into 8ml sodium citrate CPT tubes (Cell Preparation tubes, 
BD Biosciences).  
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2.2.2 Gamma source operation and dosimetry 
In vitro irradiation was performed in a self-contained 137Caesium gamma irradiator 
(IBL437C Cis Bio International, High Wycombe, UK).  
 
Dosimetry 
Calibration was performed using the Fricke-Frankenberg procedure for ferrous sulphate 
dosimetry (Frankenberg 1969). The dosimetry solution was prepared by diluting Fricke 
stock solution 1:10 with deionised water (sterilised). 4x15ml Polypropylene tubes were 
"conditioned" by filling with 10ml solution and irradiating for 600 seconds within the 
gamma source. The tubes were emptied and rinsed with deionised sterilised water. Each 
was then filled with 6 ml solution and irradiated for 300 seconds. During irradiation each 
was tube positioned within the 4-tube rack which used for irradiation in the subsequent 
γH2AX experiments. The rack was rotated automatically within the chamber during 
irradiation to achieve equal distribution of dose to all tubes. A sample from each tube was 
then transferred to a quartz cuvette and extinction was measured using a UV 
spectrophotometer (304nm). The spectrophotometer was zeroed between each sample 
using the quartz cuvette filled with non-irradiated solution. 
 
Dose (D) was calculated by D = Extinction at 304nm x 281/0.97 Gy (0.97 = correction 
factor for temperature 22oC)    
  
This was repeated for 600, 900 and 1200 seconds. The mean value for each time point was 
plotted against expected dose using half life based on the manufacturer’s dosimetry on 
manufacture. The mean measured dose rate in Gray/minute was calculated and the 
projected dose rate over the next 12 months tabulated  assuming decrease in dose rate over 
time due to decay of the source calculated. For calculations the half-life of 137caesium was 
assumed to be 30.6 years. 
 
The measured dose rate was 3.297Gy/minute on 25/1/2005. See Appendix 2 for results and 
theoretical isodose distribution within the irradiation chamber. 
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Sample irradiation 
Muntjac fibroblasts were grown on coverslips in Petri dishes and irradiated by placing the 
Petri dish in a custom made Perspex rack in the centre of the irradiation chamber. For 
irradiation of lymphocytes in suspension, 15ml sample tubes were placed in the custom 
built Perspex rack in the irradiation chamber. The cells were exposed to the gamma source 
for the appropriate number of seconds required to achieve the desired total dose. Control 
samples were mock-irradiated by taking them from the incubator at the same time as the 
cells to be irradiated and transporting them to the gamma source together. Control samples 
were left outside the irradiator on the bench whilst irradiation took place.  
 
2.2.3 Immunomagnetic isolation of CD4 and CD8 positive peripheral blood 
lymphocytes  
Human peripheral blood lymphocytes were isolated using a CD4 and a CD8 positive 
isolation kit in combination (Dynal, Oslo, Norway). Each kit contains Dynabeads, 
4.5micrometre magnetisable polystyrene beads coated with primary monoclonal antibody 
specific for either the CD4 or CD8 membrane antigen on human peripheral blood 
lymphocyte subsets. Each kit also contains either DETACHaBEAD CD4 or 
DETACHaBEAD CD8 as appropriate. DETACHaBEAD is a polyclonal anti-Fab antibody 
specific for either the CD4 or CD8 antibody on the Dynabeads and when added to bead-
bound cells competes with the antibody/antigen at the cell surface and releases the 
antibody and bead from the cell. The manufacturers confirmed that it was possible to mix 
reagents from both kits together and isolate both CD4 positive and CD8 positive cells 
simultaneously in the same sample tube. The magnetic separation device used throughout 
was Dynal Magnetic Particle Concentrator (MPC) MPC –L (Dynal, Oslo, Norway). Cell 
isolation technique was performed as per the manufacturer’s instructions.  
 
Dynabeads washing procedure 
The Dynabeads were resuspended in the vial. 180 microlitres each of the CD4 and CD8 
beads were transferred to a 15ml polypropylene tube (36 microlitres of each per ml whole 
blood to be processed – 5ml blood sample). 1ml PBS/1%FCS added and thoroughly mixed 
with beads. The tube was placed in the magnet for 30 seconds and supernatant pipetted off 
and discarded. The washed beads were then resuspended in 360 microlitres of 
PBS/2%FCS. 
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Separation of CD4 and CD8 positive cells 
5ml of whole blood was added to the pre-washed beads and mixed by inversion of the tube 
three times. The tube was then incubated at 4oC for 30 minutes on a rotary mixer. The CD4 
and CD8 positive cells were isolated by placing the tube in the MPC for 3 minutes. The 
supernatant was discarded whilst the bead/cell rosettes were still attached to the test tube 
wall by the MPC. The rosettes were then washed 4-5 times in PBS/2%FCS using the MPC 
and then resuspended in 250 microlitres RPMI1640/1%FCS. 
 
 
Bead detachment 
25 microlitres each of DETACHaBEAD CD4 and DETACHaBEAD CD8 were added to 
the prepared cell suspension and incubated at room temperature for 60 minutes. The tube 
was then placed in the MPC for 2 minutes and the supernatant containing the released cells 
was transferred to a fresh tube. To obtain residual cells the Dynabeads were washed 3 
times in 500 microlitres RPMI/1% FCS and the supernatant collected each time. The 
detached cells were then washed to remove DETACHaBEAD by re-suspending in 10ml 
RPMI/1%FCS and then centrifuging at 300g for 8 minutes. The cells were then counted 
using the pre-calibrated Coulter counter (Beckman Coulter) and resuspended in 
RPMI/1%FCS at a concentration of 1x105/ml for use in the γH2AX immunofluorescence 
staining procedures 
 
2.2.4 Immunostaining procedure for focus analysis by microscopy 
Peripheral blood lymphocyte suspensions or Muntjac fibroblasts on coverslips were 
irradiated or “mock-irradiated” and then returned to the 37oC incubator for the pre-
determined interval to allow formation of γH2AX. 0.4ml of the lymphocyte suspension 
was then placed in the chamber of a cytospin funnel and cyto-centrifuged onto a clean 
glass slide at 800rpm for 10 minutes. The slides were not allowed to dry but were 
immediately immersed in freshly prepared 4% paraformaldehyde (PFA) for 10 minutes. 
For the Muntjac fibroblasts, culture medium was removed from the Petri dish after 
incubation, and the coverslips were washed in PBS x1 before fixation. 
 
After fixation in PFA, the slides were washed twice in PBS for 5 minutes before 
immersion in 0.2% Triton in PBS for 10 minutes. After two more 5 minute washes in PBS 
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slides were placed in blocking solution (0.1M glycine/1% donkey serum in PBS) and 
stored at 4oC overnight. 
 
The following day the blocking solution was removed and slides were placed on a tray in a 
humidified chamber. 100 microlitres of a 1:500 dilution of mouse anti-γH2AX antibody in 
0.5% donkey serum/PBS (Upstate, USA) was pipetted carefully onto the cell layer. 
Laboratory film was carefully laid over each slide to ensure even distribution of the 
antibody solution over the cell layer and to prevent drying during incubation. The slides 
were incubated at room temperature for 1 hour. The film was removed and the slides 
placed in a rack and washed in 0.5% donkey serum/PBS for 15 minutes x 4 over 1 hour. 
Slides were then placed in the humidified chamber and, in the dark-room, 100 microlitres 
of a 1:500 dilution of FITC-tagged donkey anti-mouse secondary antibody (Jackson 
Immunoresearch) in 0.5% donkey serum/PBS was pipetted over each cell layer and a piece 
of laboratory film placed over each as before. The slides were incubated at room 
temperature in the dark for 1 hour before being uncovered and washed in PBS for 15 
minutes x 4 over 1 hour in the dark. Without allowing the cells to dry and working in the 
dark, the slides were mounted with coverslips and 12 microlitres of MOWIOL-DAPI and 
left to dry in the dark at 4oC overnight before microscopy. 
 
2.2.5 Fluorescence microscopy, digital image capture and image analysis 
For image acquisition, an upright fluorescence microscope (Zeiss Axioplan) with a CCD 
digital camera interfaced with the Cytovision System (Applied Imaging, Sunderland, Tyne 
& Wear, UK) was used. Control of the camera, image acquisition, and image analysis were 
performed by the system software. 
Throughout the study the same control settings for exposure, brightness/darkness and z-
stack and image thresholding were utilised for each image during image capture using the 
FITC filter: Brightness 100, darkness 111, exposure 5 seconds, z-stack 5 x 1.5micrometres, 
threshold 180. 
 
2.2.6 Cell separation procedure using CPT tubes 
The cell isolation procedure for blood samples collected in CPT tubes was performed 
according to the manufacturer’s recommendations. CPT tubes were kept upright after 
blood collection. Prior to centrifugation the tubes were remixed by gentle inversion 5 
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times. The tubes were then centrifuged at room temperature in a horizontal rotor (Heraeus) 
for 20 minutes at 1500 x g 
After centrifugation the monocyte layer was resuspended in plasma by inversion of the 
unopened container 5 times. The CPT tube was then opened and the entire contents of the 
tube above the gel layer were pipetted into a sterile 15ml polypropylene tube.  
Sterile PBS at room temperature was added to bring the volume up to 15ml. The tube 
contents were mixed by inversion of the capped tube and then centrifuged at 1500 x g for 
15 minutes. The supernatant was aspirated and the cell pellet was resuspended by tapping 
the tube. Sterile PBS was added to bring the volume up to 10ml and the contents were 
mixed by inversion of the capped tube. The tube was centrifuged for 10 minutes at 300 x g. 
The supernatant was aspirated, the cell pellet resuspended in 5ml RPMI/1% FCS. The cells 
were then counted using the pre-calibrated Coulter counter (Beckman Coulter) and then 
finally resuspended at a concentration of 1x106cell/ml in RPMI/1% FCS. 2ml of cell 
suspension was pipetted into individual 15ml sterile polypropylene tubes and RPMI/1% 
FCS added to make up a total volume of 7ml. Each tube was gassed with 5% CO2 in air 
and then placed in the incubator at 37oC prior to irradiation and γH2AX quantification.  
 
2.2.7 Immunofluorescent staining of PBLs for flow cytometric analysis 
Following irradiation or mock-irradiation and the appropriate incubation period, tubes 
were removed from the incubator, cooled on ice and centrifuged at 1oC at 300 x g for 5 
minutes. The supernatant was discarded and the pellet resuspended by tapping the tube 
before  adding 2ml ice cold 70% ethanol. After thorough mixing by pipetting the sample 
was divided between 2 pre-labelled 1.5ml plastic safe-lock tubes (Eppendorf) and stored at 
-20oC for up to 15 days before immunostaining. One tube from each pair served as the 
negative control for flow cytometry to correct for autofluorescence and non-specific 
binding of the secondary antibody. 
 
For immunostaining and analysis the samples were removed from the freezer and 
centrifuged at 300 x g for 5 minutes. The supernatant was discarded and the pellet 
resuspended in 1ml PBS before centrifugation, removal of the supernatant and re-
suspension of the cell pellet in 1ml cold PBS/1% donkey serum/0.1% Triton X-100 (PST 
solution). The tubes were placed on ice for 30 minutes to allow cell rehydration and 
permeabilisation and blocking. Tubes were centrifuged at 300 x g for 5 minutes and the 
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supernatant discarded. For the negative controls the cell pellet was resuspended in 200 
microlitres of PST, whilst the other cell pellet from the other member of the pair was 
resuspended in 200 microlitres of anti-γH2AX mouse monoclonal antibody diluted to 
1:500 in PST. The cells were incubated at room temperature for 2 hours before being 
washed twice in 1 ml PBS/0.5% donkey serum. The cell pellets were then resuspended in 
200 microlitres of FITC-labelled donkey anti-mouse secondary antibody diluted to 1:500 
in PST and incubated at room temperature for 1 hour in the dark. Cells were rinsed twice 
in PBS and then resuspended in 1ml PBS and transferred to pre-labelled 5ml polystyrene 
tubes for flow cytometric analysis  
 
2.2.8 Flow cytometric analysis of γH2AX staining 
The cell sample was introduced though the sample injection port. Using Cell Quest 
software (Version 3, Becton Dickinson) a dot plot of FSC (forward scatter) vs. SSC side 
scatter was generated (Figure 2.1 A) and the FSC and SSC gains altered to produce a 
clearly discernable cell population corresponding to the lymphocytes within the sample. 
This population was gated and the mean fluorescence intensity of 10 000 cells was 
measured on the FL-1 channel and plotted on a log scale (Figure 2.1 B). FL-1 
photomultiplier tube settings were kept at 500 throughout the study. For each sample the 
mean fluorescence intensity for the negative control corresponding to autofluorescence and 
non-specific binding of the secondary antibody were subtracted from the results from the 
corresponding fully stained irradiated or non-irradiated sample. γH2AX levels were then 
calculated as the normalised fluorescence ratio (NFR) i.e. the ratio of mean fluorescence 
intensity in irradiated cells to that of non-irradiated controls with both values having been 
corrected for autofluorescence.  
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Figure 2.1 Flow cytometric analysis of γH2AX stained PBLs 
A. Dot plot of FSC vs. SSC showing a clearly defined cell population with has been gated 
(circle). B. Histogram of the fluorescence intensity of 10 000 cells in the gated population. 
Cell Quest software calculated the mean fluorescence intensity for the gated population 
and this value was used for subsequent calculations of γH2AX induction. 
 
2.2.9 Cell phenotyping  
In order to confirm that the gated population did consist of human peripheral blood 
lymphocytes, cell immunophenotyping was performed. Different white blood cells can be 
identified by the expression of differing cell surface markers. All white blood cells are 
CD45 positive and monocytes are CD14 positive. Given that the cell separation procedure 
during centrifugation of the CPT tubes should have removed granulocytes, the remaining 
white cell population in the supernatant layer that underwent irradiation and γH2AX 
staining procedure should contain a mixture of lymphocytes and monocytes. The gating 
procedure was designed to exclude monocytes from analysis so the gated population, if 
lymphocytes, should be CD45 positive confirming leucocyte origin and CD14 negative 
confirming that it does not contain monocytes. In addition the gated population should be 
CD3 and CD19 positive confirming a mix of T- and B-lymphocytes.  
 
For the fixed sample phenotyping, peripheral blood was collected in a sodium citrate CPT 
tube and the mononuclear cell fraction separated and washed. 1x105 cells were transferred 
into each of 6 x 15ml sterile polypropylene tubes and fixed in 70% ethanol for 10 minutes. 
Following fixation the cells were washed in PBS, centrifuged at 300 x g and the cell pellet 
resuspended in 100 microlitres of PBS alone. To each was added: 
BA 
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Tube 1: nil – unstained control 
Tube 2: 20 microlitres of FITC-conjugated mouse IgG1 isotype control 
Tube 3: 20 microlitres of FITC- conjugated mouse anti-human CD3 antibody 
Tube 4: 20 microlitres of PE-conjugated mouse anti-human CD19 antibody 
Tube 5: 20 microlitres each of both anti CD3 and CD19 antibodies 
Tube 6: 20 microlitres of Simultest LeucoGATE (FITC-labelled anti CD45 and PE-
labelled anti-CD14). 
 
Each tube was incubated for 30 minutes at room temperature in the dark before the 
addition of 1ml PBS, mixing, centrifugation at 300 x g for 5 minutes, aspiration of 
supernatant and re-suspension in 1 ml of PBS. This washing procedure was repeated 
before analysing the samples on the flow cytometer. For each sample the presumed 
lymphocyte population was gated and the green (FITC) fluorescence measured on the FL-
1 channel and plotted against similar measurement of red (PE) fluorescence on the Fl-2 
channel to confirm leucocyte phenotyping. See Appendix 3 for results.  
 
2.2.10 Flow cytometer performance monitoring with CaliBrite beads 
BD CaliBrite beads are designed for use with FACSComp software to adjust instrument 
settings, set fluorescence compensation, and check instrument sensitivity. Using the 2 
colour kit, two sample tubes were prepared. Tube A contained 1 drop of unlabelled bead 
suspension in 1ml sheath fluid. Tube B contained 1 drop each of unlabelled, FITC-labelled 
and PE-labelled beads in 3ml sheath fluid. Both tubes were stored on ice in the dark before 
use. The initial adjustment of instrument setting was performed with the Becton Dickson 
engineer – following the instructions accompanying the FACSComp software Tube A was 
used to adjust the photomultiplier tube settings and Tube B was used to adjust fluorescence 
compensation to   optimise discrimination between green and red fluorescent signals using 
the FL-1 and FL-2 channels and to perform a sensitivity test for all channels. The beads 
were used again after 6 months to repeat the sensitivity test but a further adjustment of 
compensation was not performed. 
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2.2.11 Measurement of DNA double-strand break re-joining in human peripheral 
blood lymphocytes  
Mononuclear cells were separated from whole blood, washed and resuspended in 10 ml 
RPMI/1% FCS as per the protocol in Section 2.2.6.  The cell suspension was transferred 
into a 25cm2 tissue culture flask and incubated at 37oC for 1 hour to allow the monocytes 
to attach to the culture flask and therefore remove them from the analysed cell population. 
The cells were then transferred to a 15ml polypropylene tube, centrifuged, resuspended in 
RPMI/1%FCS, and counted, adjusting the final concentration of cells to 1.5x105 per ml. 
1ml of cell suspension was transferred to each of the required number of 15ml 
polypropylene tubes. The tubes were gassed with 5% CO2 in air and incubated at 37oC for 
30 minutes. The cells were then cooled on ice and irradiated on ice. Samples for dose-
response experiments were then kept on ice. Samples for measurement of DNA DSB 
repair quantification were transferred to a water bath at 37oC for the required repair time 
before being transferred to ice again for rapid cooling before lysis. 
 
Once all samples were ready and cooled on ice, the tubes were centrifuged at 0oC and the 
medium aspirated. 80 microlitres of 0.8% low melting point agarose (LMP) in PBS at 
37oC was added to each cell pellet and rapidly mixed and transferred to a gel plug mould 
and allowed to set on ice for 10 minutes. Plugs of agarose containing the cells were then 
expelled into ice-cold lysis solution and held for 30 minutes on ice before incubation at 
37oC for 18 hours. 
 
Plugs were recovered from the lysis solution and placed in comb wells in a 200ml 0.8% 
Ultrapure agarose gel in TAE (Tris/Acetic acid/EDTA buffer) which contained ethidium 
bromide (0.5 micrograms/ml) in a Bio-Rad Sub-Cell horizontal electrophoresis apparatus. 
Wells were sealed using 0.8% LMP agarose in PBS and the gel run in 0.5 TAE at 
0.6V/cm, 8V, constant current, for 96 hours. 
 
The gel was imaged and the image analysed using a gel documentation and analysis 
system (SynGene, Synoptics, Cambridge, UK). The fraction of DNA released from the 
wells during electrophoresis was used as a measure of the induced-double-strand breakage. 
DNA was quantified by ethidium bromide fluorescence, analysed using Syngene 
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Genetools software. The fraction of DNA released (FDR) was calculated from the 
relationship: 
 
FDR=DRi/(DRi + DWi)-DRc/(DRc + DWc) 
Where: 
DRi = DNA released (irradiated sample) 
DWi = DNA remaining in well (irradiated sample) 
DRc = DNA released (unirradiated control sample) 
DWc = DNA remaining in well (unirradiated control sample) 
 
2.2.12 Detection of apoptosis in human peripheral blood lymphocytes after 
irradiation 
The Annexin V-FITC apoptosis detection kit (BD Pharmingen) utilises FITC conjugated 
Annexin V as a highly sensitive probe for identifying apoptotic cells and when used with 
flow cytometry can quantitatively determine the population of cells within a population 
that are undergoing apoptosis. It binds to phosphatidylserine (PS) which is a membrane 
phospholipid translocated from the inner to the outer leaflet of the plasma membrane 
during apoptosis. Propidium iodide (PI) is a standard flow cytometric viability probe that 
can be used to distinguish viable from non-viable cells. Viable cells with intact membranes 
exclude PI whereas the membranes of dead and damaged cells are permeable to PI. Cells 
that stain positive for Annexin V-FITC but are negative for PI are undergoing apoptosis. 
Cells that are positive for both Annexin V-FITC and PI are in the end-stage of apoptosis, 
necrotic or dead. Cells that are negative for both are alive and not undergoing measureable 
apoptosis.  
Peripheral blood was collected in a CPT tube and peripheral blood mononuclear cells were 
isolated, resuspended in RPMI/1% FCS, irradiated and incubated at 37oC for the specified 
time. The cells were then washed twice in cold PBS and resuspended in 1x binding buffer 
(supplied as x10 concentrate in kit) at a concentration of 1x106/ml. 100 microlitres was 
transferred to a 5ml polystyrene tube. 5 microlitres each of Annexin V-FITC and PI were 
added and gently mixed. The cells were then incubated at room temperature in the dark for 
15 minutes. 400 microlitres of x1 binding buffer was added to the tube and the sample was 
analysed by flow cytometry. After gating the lymphocyte population FITC fluorescence 
(FL-1) was plotted against PI fluorescence (FL-2) and a density dot plot generated. The dot 
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plot was divided into quadrants and the proportion of cells in each quadrant compared. 
This was performed for irradiated and non-irradiated cells.  
 
2.2.13 Statistical analysis 
Statistical analyses and graph drawing were performed using GraphPad Prism version 5.00 
for Windows, GraphPad Software, San Diego California USA, www.graphpad.com.  
 
ROC curve construction and analysis and forest plot construction were performed using 
Stats Direct software version 2.6.6 (StatsDirect Ltd, Altrincham, UK). 
Details of the statistical tests used are reported within each chapter. 
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3. Systematic review of the current evidence base relating to functional 
cell-based predictive assays of normal tissue radiosensitivity. 
 
3.1 Methodology of diagnostic test development and assessment of clinical utility 
 
How do the normal processes involved in the development of a diagnostic test relate to 
predictive assays of normal tissue radiosensitivity? 
 
A diagnostic test has two purposes – to provide reliable information about a patient’s 
condition and to influence the health care provider’s plan for managing the patient. A test 
can only serve this purpose if the health care provider knows how to interpret it. This 
information is acquired through an assessment of the test’s precision and diagnostic 
accuracy, which is simply the test's ability to discriminate between different states of 
health. Often the clinical question can be dichotomised - the presence or absence of high 
normal tissue radiosensitivity in the case of predictive testing for normal tissue 
radiosensitivity. If the test result does not differ in the two health states the test has 
negligible accuracy and if the test results do not overlap for the two health states the test 
has perfect accuracy. Most test accuracies fall between these extremes.  
 
Fryback and Thornbury 1991 describe a working model for assessing the efficacy of 
diagnostic tests in clinical medicine and propose a six-level hierarchical model: 
 
Level 1: Technical Efficiency  
Optimisation of assay parameters within the laboratory and examination of assay precision 
measured by features such as within-  and between-sample reproducibility. 
 
Level 2: Diagnostic accuracy efficacy 
The test's sensitivity, specificity i.e. it's ability to discriminate between radiosensitive and 
non-radiosensitive individuals. 
 
Level 3: Diagnostic thinking efficacy 
The difference in the clinician’s estimated probabilities of a diagnosis (high normal tissue 
radiosensitivity) before versus after the test results are known.  
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Level 4: Therapeutic efficacy 
The percentage of time that therapy planned before the diagnostic test is altered by the 
result of the test, e.g. radiotherapy is not given or dose reduced for those with a positive 
test, or dose-escalated for those with a negative test. 
 
Level 5: Patient outcome efficacy 
 e.g. the improvement in an individual's quality of life gained by avoiding radiation 
toxicity in a radiosensitive patient or the control of a tumour achieved by dose-escalation 
in a patient with a negative test. 
 
Level 6: Societal efficacy 
The cost-effectiveness of the test from society’s point of view e.g. improved population 
control rate of cancer or reduced cost of treating radiation toxicity. 
 
In this model a key feature is that for a diagnostic test to be efficacious at a higher level it 
must be efficacious at all lower levels. Equally, if the test is efficacious at one level it does 
not follow that it will be efficacious at all higher levels. Strategies for developing an 
efficacious diagnostic test must therefore start at level 1 and test efficacy at each level 
before working up to the next. Levels 1 to 2 are important in the pre-clinical testing of 
assay performance. No predictive assay of normal tissue radiosensitivity has so far been 
tested at level 3 or above. 
 
3.1.1 Technical efficacy 
Level 1 testing of technical efficacy requires a measurement of assay precision or 
reproducibility once the technical parameters of the assay have been optimised. The 
technical performance of the assay can be estimated by the measurement of intra-sample 
and inter-sample reproducibility using samples from the same individual. For assays with 
subjective endpoints such as scoring of chromosomal aberrations an assessment of inter-
scorer reproducibility is also necessary. Whether sample handling, such as storage of 
samples before testing, affects assay results should also be assessed and handling 
conditions optimised to avoid adding an uncontrolled source of assay variation into 
subsequent studies. 
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3.1.2 Diagnostic accuracy 
To determine diagnostic accuracy (Level 2), the ability of the assay to discriminate 
between health conditions must be compared with the gold standard assay already in 
clinical use. No “gold standard” predictive test for normal tissue radiosensitivity currently 
exists so the gold standard must be a clinical assessment of normal tissue radiosensitivity. 
This is achieved by measuring normal tissue toxicity using a standardised tool such as one 
of the grading systems (e.g. RTOG/EORTC) described in Chapter 1. This must then be 
adjusted to account for those factors other than intrinsic normal tissue radiosensitivity 
known to influence the development of normal tissue toxicity. These confounding factors 
include the treatment related factors and patient related factors described in Section 1.4.1.  
 
As the development of late toxicities increases over time following radiotherapy, the time 
elapsed between the completion of radiotherapy and the measurement of late toxicity must 
also be taken into account otherwise differing severities of late toxicity between 
individuals may simply be due to one individual having had more time to manifest side 
effects rather than a difference in intrinsic normal tissue radiosensitivity. Only after 
adjustment for these confounders of normal tissue reaction can an estimation of an 
individual’s normal tissue radiosensitivity be made with any degree of certainty and even 
then it is difficult to account for imprecision in radiation dose homogeneity caused by 
variations in shape and size of individual patients and other currently unknown factors 
(other than intrinsic normal tissue radiosensitivity) which may influence normal tissue 
radiation reaction.  
 
3.1.3 Ideal study design in assessment of diagnostic accuracy of predictive assays of 
normal tissue radiosensitivity 
The choice of study design is of primary importance in reducing bias in diagnostic test 
research. In a prospective cohort study the predictive assay is performed before 
radiotherapy, thus ensuring that radiotherapy itself does not influence the assay result. The 
researcher can strictly define the eligibility criteria for the study, the type of data to be 
collected and by whom, the method of data collection and the analysis techniques. With 
appropriate design, the study therefore includes an unselected group of homogenous 
patients receiving a homogenous radiotherapy regimen with standardised collection of 
information on toxicity by direct inspection by the researcher and prospective collection of 
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information on possible confounding factors. Statistical techniques such as multiple 
regression analysis can be used to correct for the influence of other recognised 
confounders and determine if assay result is an independent prognosticator of normal 
tissue reaction and therefore radiosensitivity. The quality of data from a prospective cohort 
study of radiosensitivity is high but the power of this study design to achieve statistically 
significant results in normal tissue radiosensitivity testing is limited by the low frequency 
of severe radiation toxicity amongst unselected patients, unless very large numbers of 
patients are recruited to the study. Although it is straightforward to collect data regarding 
acute toxicity rapidly, prospective cohort studies have limited potential when examining 
assays which predict late normal tissue damage which may take many years to manifest. 
Firstly it would take many years to obtain results from the study, and secondly the attrition 
of patients due to disease progression or other factors during this time means that the 
cohort size needs to be even larger than for studies using acute tissue toxicity as an end-
point in order to generate sufficient data to potentially achieve meaningful results. 
 
By performing the assay and measuring late toxicity in patients previously treated with 
radiotherapy in the past, retrospective cohort studies may help overcome the problems 
associated with assessing predictive assays of late normal tissue radiosensitivity in a 
prospective study. Collecting accurate information about patients and treatment 
retrospectively can be difficult, but if patients were treated as part of a clinical trial of 
radiotherapy they will usually form a relatively homogenous group with respect to tumour 
type and radiotherapy schedule and technique, and information about other confounding 
factors such as concurrent chemotherapy or comorbidity may already have been collected 
or built into the trial inclusion and exclusion criteria. The generalisability of assays 
assessed in retrospective studies may be limited by the fact that a selection process 
unavoidably occurs with time so that the patients available for study many years after 
radiotherapy delivery may not be truly representative of the original cohort and therefore 
the population as a whole. 
 
Retrospective case control studies dichotomise the patient population and seek to compare 
assay results in a group of patients with known high clinical radiosensitivity (cases) and 
those known low or average clinical radiosensitivity (controls). In order to correct for the 
influence of confounding factors other than intrinsic normal tissue radiosensitivity on the 
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development of radiation toxicity the cases and controls must be matched with respect to 
known confounders and both cases and controls must be drawn from the same population 
(i.e. same group of patients treated within the same centre during the same specified time 
period). Failure to match cases and controls or drawing cases and controls from separate 
populations will introduce bias and make the results of the study difficult to interpret. 
 
Scoring of toxicity should be standardised throughout the study with specification of 
scoring system used, the individual/s responsible for grading toxicity and an assessment of 
inter-scorer reproducibility performed, if relevant. As different cell-based assays may 
predict specific radiation responses in different tissues, homogeneity in toxicity assessment 
should be employed measuring specific early and late end-points in specific tissues 
separately for separate analysis rather than heterogeneous endpoints in a variety of 
different tissues which may lead to masking of a relationship between the assay result and 
a specific tissue endpoint. 
 
Blinding of the laboratory researchers performing the assay to the normal tissue responses 
of the patients, and of the clinical researchers scoring toxicity to the assay result may also 
reduce potential sources of bias. 
 
3.1.4 Statistical methods employed in assessment of diagnostic accuracy. 
Whilst it is important to determine if there is a statistically significant correlation between 
assay result and normal tissue response after adjusting for confounders or if there is a 
statistically significant difference in mean or median assay results from cases and controls, 
it is the power of the assay to discriminate between radiosensitive and non-radiosensitive 
individuals that is important in diagnostic accuracy assessment. Outcome measures used in 
determining diagnostic test accuracy are: 
 
• Sensitivity: the rate of correct identification of patients with high normal tissue 
radiosensitivity by the predictive assay 
 
• Specificity: the rate of correct identification of patients with normal or low normal 
tissue radiosensitivity by the predictive assay. 
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In order to calculate these parameters radiosensitivity data has to be dichotomised which 
does lead to a loss of information and statistical power. It also requires a definition of a 
cut-point in toxicity grading to divide clinically highly radiosensitive from non-clinically 
radiosensitive individuals – given that clinical radiosensitivity is most likely a 
continuously varying characteristic the choice of cut-point is arbitrary. Nevertheless the 
sensitivity and specificity of a diagnostic assay are valuable measurements of its clinical 
utility and are the accepted methods for defining the discriminatory power of a diagnostic 
test. 
 
In order to calculate sensitivity and specificity each individual needs to be classified as a 
true positive (radiosensitive) or true negative (not radiosensitive) according to the “gold 
standard” (in this case clinical assessment of normal tissue toxicity after adjustment for 
confounders) and then classified as positive or negative according to the predictive assay 
under investigation. 
 
A diagnostic test 2 by 2 table is then constructed: 
 
 Clinically 
radiosensitive 
Clinically non-
radiosensitive 
Predictive assay 
positive 
a  
(true positive) 
b  
(false positive) 
Predictive assay 
negative 
c 
 (false negative) 
d 
 (true negative) 
 
Sensitivity = a/(a+c) 
Specificity = d/(b+d) 
 
In order to calculate sensitivity and specificity, a cut off for the assay results must be 
chosen to define what constitutes a positive and what constitutes a negative test. Receiver 
Operator Characteristic (ROC) curves have been used since the 1970s as a way of 
assessing whether or not a diagnostic test has useful discriminatory power and can be used 
to help define appropriate cut-offs for positive and negative tests and to compare the 
discriminatory power of different tests (Zweig and Campbell 1993). 
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To construct a ROC curve all cut-off points that give a unique pair of values for sensitivity 
and specificity are considered, sensitivity versus 1-specificity are plotted and the data 
points connected by lines to generate the curve (Figure 3.1). If a test has any 
discriminatory power the curve will lie to the left of the diagonal of the graph. The area 
under the curve gives an estimate of the discriminatory power of a test. If the tests has 
perfect discriminatory power and possessed a cut off that would result in 100% sensitivity 
and 100% specificity then the ROC curve would go across the top of the grid area and the 
AUC would be 1. If the test posses no discriminatory power then 100% sensitivity can 
only be achieved with 0% specificity and vice versa – the ROC curve would follow the 
diagonal on the grid and the AUC would be 0.5. The closer the AUC for the ROC curve is 
to 1 the better the assay performance.  
 
The ROC curve can also be used to choose optimal cut-offs values for a test depending on 
the clinical implications of false positive and false negative results and therefore the 
relative requirements for sensitivity versus specificity. 
 
The diagnostic odds ratio (ad/bc) is a summary statistic of diagnostic assay performance 
often used when combining studies of diagnostic accuracy in a systematic review. Its value 
is often reasonably constant no matter the choice of cut-off values for the diagnostic 
threshold, although a single diagnostic odds ratio corresponds to a single set of sensitivities 
and specificities chosen from the ROC curve. In the case of predictive assays of normal 
tissue radiosensitivity it describes the odds of a positive test in participants with high 
normal tissue radiosensitivity versus the odds of a positive test in those with normal tissue 
radiosensitivity. The value of this statistic in systematic reviews is that it combines both 
the positive and negative predictive capabilities of an assay in one value, but its meaning is 
difficult to apply directly to clinical practice (Deeks 2001) . 
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Figure 3.1 ROC curve for % reduction in Binucleated index after radiation in human 
fibroblasts and risk of wound healing complications after post-operative radiotherapy for 
soft-tissue sarcoma. AUC is 0.805 (95% CI 0.432-1) (Data for analysis extracted from 
(Akudugu, Bell et al. 2006) 
 
3.1.5 Hypothesis generating and validation data sets 
If a study establishes a relationship between a particular predictive assay result and an 
individual’s normal tissue radiosensitivity, then this relationship should be validated by 
testing the assay's discriminatory ability on a separate independent data set to avoid 
recursive reasoning. 
 
3.1.6 Rationale for a systematic review of the current literature pertaining to 
functional cell-based assays in the predictive testing of normal tissue radiosensitivity.  
Many researchers have tried to develop a predictive assay of normal tissue radiosensitivity 
based on the measurement of the response of cells sampled from an individual to a test 
dose of radiation in vitro. As discussed in section 1.6 the results from these studies have 
been inconsistent leading to the opinion of many researchers that their ongoing 
investigation is not worthwhile and a move towards other strategies. Problems with the 
methodology of the studies involving patients with breast cancer have been identified 
(Twardella and Chang-Claude, 2002) and the question arises as to whether or not the 
current evidence base is sufficient to disregard cell-based assays entirely or whether there 
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is evidence that difficulties in study design and reporting may have resulted in bias and 
masked their potential clinical utility. A systematic review of the literature was therefore 
performed in an attempt to answer the following questions: 
 
• Is there evidence from the literature that intrinsic radiosensitivity of normal tissue 
and consequent increased susceptibility to radiotherapy side effects can be 
predicted by functional cell-based laboratory assays?  
 
• Have clinical studies assessing potential assays of normal tissue radiosensitivity 
been performed   and reported with a sufficiently rigorous approach to assay 
feasibility and quality control and been reported in sufficient detail to allow 
adequate assessment of study quality and generalisability of results?  
 
• Is the generally held belief that cell-based assays are not helpful in predicting 
normal tissue radiosensitivity justified based on current literature? 
 
3.2 Method 
 
3.2.1 Identification of relevant studies 
The literature was searched according to the following strategy: 
• Medline/EMBASE search - 1966-present (including articles published online 
before 28th February 2008). Search Strategy –“ radiotherapy AND radiation effect/s 
or radiation injury or radiation tolerance” (NB  MeSH headings such as “assay” 
“test” “diagnostic test” “predictive” etc do not reliably pick up all of the predictive 
assay studies) 
• Reference lists from papers 
• Hand searching of “Radiotherapy and Oncology” and "International Journal of 
Radiation Oncology Biology and Physics” journals. 
• Reverse citation tracking for electronic resources (“cited by” links) 
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Inclusion criteria 
• Any study comparing cellular radiosensitivity as measured by the assay under 
investigation with severity of acute and/or late normal tissue toxicity following 
radiotherapy. 
• All potential functional cell-based assays (i.e. measures response of a living cell 
after test dose of radiation in vitro) and assay techniques 
• All types of tissue sample (e.g. skin, blood et c) 
• Patients may have received radiotherapy (with or without synchronous 
chemotherapy) at any site, for any type of malignancy 
 
Exclusion criteria 
• Studies published in abstract form only 
• Papers reporting data presented already elsewhere, or reports of pilot studies where 
the full data is presented in another later publication. 
• Any study of a non- functional cell-based assay (e.g. genotyping) 
• Studies comparing highly radiosensitive patients to healthy “controls” who have 
not had radiotherapy and are therefore of unknown radiosensitivity 
• Studies comparing assays of radiosensitivity in cultured cell lines only without 
direct link to clinical data 
• Case reports of assay results in individual unusually radiosensitive patients  
 
3.2.2 Data Extraction 
All studies that fulfilled the inclusion criteria were analysed according to the data 
extraction protocol in Appendix 4.2.which is based on  REMARK recommendations 
(McShane, Altman et al. 2005). 
 
3.2.3 Development of a scoring system for study “quality” 
In order to help filter the available data and determine if there is any evidence of potential 
assay efficacy in the literature, an assessment of quality of study design and conduct was 
made in order to allow appropriate weighting to higher quality studies. 
 
The scoring system is described in Appendix 4.3. A potential total score of 100 was 
possible. The heaviest weighting in the scoring system is given to appropriate study design 
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(ensuring homogeneity of patients and treatment), techniques for dealing with confounding 
factors, and appropriate choice and reporting of statistical methods. Clearly this scoring 
system is crude and has not been validated in other studies of diagnostic assays but does 
allow some objective measurement of how “convincing” the result of a particular study 
might be. 
 
3.2.4 Extraction of individual patient data, construction of ROC curves and 
calculation of diagnostic odds ratio. 
In an attempt to generate homogeneity of statistical analysis of the reviewed studies and a 
more meaningful comparison of the clinical utility of the assays under investigation, assay 
results for individual patients along with information about their normal tissue toxicity 
were extracted from the study reports where possible. Data was extracted directly from 
tables within the study report or, where individual patient data was presented as points on a 
scatter-plot, the assay result was estimated by measurements performed on a digital image 
of the relevant plot after digital calibration using the Mouseyes image digitisation program 
version 3.1 http://www.hop.man.ac.uk/staff/rtaylor . If the study in question had not been 
performed as a case-control study, a cut-off in normal tissue toxicity grading was chosen in 
order to divide patients into a radiosensitive group and a non-radiosensitive group for the 
purpose of ROC construction e.g. the majority of studies used the CTC or RTOG/EORTC 
grading systems and for the purpose of this analysis patients were divided into grades 0-2 
toxicity (normal radiosensitivity) and grade 3-4 toxicity (high radiosensitivity).  ROC 
curves were constructed for each assay using StatsDirect statistical software. Assay cut-
offs (i.e. defining a positive versus a negative test) were chosen to try to optimise 
sensitivity and specificity with a 1:1 weighting of sensitivity: specificity.  Once cut-off 
were chosen, assay sensitivity and specificity and corresponding diagnostic odds ratios and 
their 95% confidence intervals were calculated and presented graphically in Forest plots.  
Funnel plots of Sample size and quality index score against the log diagnostic odds ratio 
were constructed and visually inspected for asymmetry to assess for evidence of bias in 
results arising from publication bias or low quality of study design. 
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3.3 Results 
64 studies were identified which fulfilled the inclusion criteria, published between 1993 
and 2007 and are listed in Appendix.4.1. In many papers several assays or different assay 
end-points were compared with different toxicity end-points. In total 98 comparisons 
between assay results and specific normal tissue toxicity endpoints were reported. 47 
comparisons were reported as showing a positive relationship between the assay result and 
normal tissue radiosensitivity, whilst in 51 no such relationship could be detected. 
 
3.3.1 Assay under investigation and cell types used. 
The majority of the assays investigated can broadly be divided into assays of clonogenic 
cell survival or assays of DNA damage whether measured by cytogenetic damage or direct 
assessment of DNA breaks (Table 3.1). A smaller number of studies reported assays of 
radiation-induced apoptosis, cell cycle arrest, gene expression profiling and spontaneous 
differentiation. One study examined DNA damage in keratinocytes and all other studies 
used skin derived fibroblasts or peripheral blood lymphocytes as the surrogate tissue for 
investigation. 
 
3.3.2 Study design. 
The majority of studies employed a case-control design (Table 3.2). There were an equal 
number of prospective and retrospective cohort studies. Five studies employed a mixed 
prospective and retrospective cohort design. Four of these examined acute toxicity 
prospectively and late toxicity in a different population retrospectively (Geara, Peters et al. 
1993; Barber, Burrill et al. 2000; Slonina, Klimek et al. 2000; Alsbeih, El-Sebaie et al. 
2004). The fifth began as a prospective cohort study but recruited patients retrospectively 
due to the low rates of toxicity apparent in the prospective cohort (Oppitz, Schulte et al. 
2002). 
 
Prospective cohort studies recruited the largest number of patients with a median sample 
size of 82. In retrospective studies the sample size tended to be small with the exception of 
9 studies which included 50 or more patients.(Peacock, Eady et al. 1989; Russell, 
Grummels et al. 1998; West, Davidson et al. 1998; Crompton, Miralbell et al. 1999; 
Russell, Lara et al. 2000; Oppitz, Baier et al. 2001; Dickson, Magee et al. 2002; Hoeller, 
Borgmann et al. 2003; De Ruyck, Van Eijkeren et al. 2005)  
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Table 3.1 Categories of predictive assays and cell types investigated 
Broad assay 
category 
Assay  Number of 
papers 
reporting 
Cell type (number 
of   papers) 
Survival Clonogenic survival 24 Fibroblast (19), 
lymphocyte (5) 
 
MTT 1 Lymphocyte (1) 
DNA damage Cytogenetic - 
micronucleus 
7 Fibroblast (2), 
lymphocyte (4), 
both (1) 
 
Cytogenetic – 
chromosomal  
6 Lymphocyte (6) 
 
Alkaline comet (repair) 6 Lymphocyte (4), 
fibroblast (1), both 
(1) 
 
DSB repair (CF or PF gel 
electrophoresis) 
6 Fibroblast (5), 
keratinocyte (1) 
 
DSB induction (CF or PF 
gel electrophoresis) 
4 Lymphocyte (4) 
 
Radiation induced repair-
related foci formation 
1 Fibroblast (1) 
Apoptosis Radiation-induced 
apoptosis 
4 Lymphocyte (4) 
Cell cycle  Radiation-induced cell 
cycle arrest 
3 Lymphocyte (3) 
Differentiation Spontaneous in vitro 
fibroblast differentiation 
2 Fibroblast (2) 
Gene expression Microarray, Western 
blotting, reverse 
transcription PCR 
5 Lymphocytes (5) 
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Table 3.2 Study design and sample size for identified studies of predictive assays of 
normal tissue radiosensitivity 
Study design Number  Median sample size (range) 
Prospective cohort 15 83     (24-393) 
Retrospective cohort 14 31.5  (6-93) 
Retrospective case/control 30 29     (7-96) 
Mixed 
prospective/retrospective 
cohort 
5 27     (11-123) 
 
 
3.3.3  Reporting of tumour and patient characteristics.  
46 studies included patients in whom a solitary tumour site had been irradiated, whilst the 
remaining 18 included patients in who had received treatment for tumours in multiple 
difference sites. The majority of studies (45%) examined normal tissue toxicity following 
breast or chest wall radiotherapy. 
 
Table 3.3 Tumour sites irradiated in predictive assay studies 
Tumour site Number of studies (%) 
Breast 29 (45.3%) 
Cervix/endometrium 5  (7.8%) 
Head and Neck 5  (7.8%) 
Prostate 4  (6.3%) 
Soft tissue sarcoma (site not specified) 2  (3.1%) 
Brain (arteriovenous malformation) 1  (1.5%) 
Mixed 18 (28.1%) 
 
Tumour staging was reported in only 25 (39%) of studies. 
 
 35 studies (55%) did not report patient demographics. In those studies where some 
demographics were reported these tended to be restricted to age and gender. Only 6 studies 
reported smoking status (Kiltie, Barber et al. 1999; Kiltie, Ryan et al. 1999; Rudat, Dietz et 
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al. 1999; Widel, Jedrus et al. 2003; Wiebalk, Schmezer et al. 2007), 2 reported body mass 
index (Popanda, Ebbeler et al. 2003; Wiebalk, Schmezer et al. 2007) and 1 reported 
haemoglobin level (Rudat, Dietz et al. 1999), all of which are thought to influence the 
severity of radiation morbidity (see section 1.4.1). 
 
Only 18 studies (28%) either clearly excluded patients or documented the proportion of 
patients who were receiving or had received chemotherapy or other systemic therapy, or 
accounted for the confounding effect of chemotherapy by case-control matching.  
 
3.3.4 Reporting of radiotherapy details. 
The majority of, but not all, studies reported the total radiation dose and fractionation used 
in the treatment of the study subjects.  Only half of the studies reported beam quality 
including energy and just above a quarter reported radiotherapy planning technique. The 
skin dose during radiotherapy was recorded in two studies of skin toxicity (Begg, Russell 
et al. 1993; Burnet, Nyman et al. 1994). 
 
Table 3.4 Reporting of radiotherapy details 
 Number reporting (%) 
Radiotherapy dose 54 (84%) 
Radiotherapy fractionation 47 (73%) 
Beam quality 32 (50%) 
Planning technique 18 (28%) 
 
 
3.3.5 Recording and reporting of radiotherapy toxicity. 
37 studies recorded acute radiotherapy toxicities, 38 late toxicity and 16 recorded both. 
The most frequently used toxicity grading system was the RTOG/EORTC system for both 
acute and late toxicity. Some studies examining both acute and late effects used different 
systems for different end-points. A number of studies used scoring systems that had been 
developed locally in that particular department, or a system that had been developed for 
the purposes of a previous clinical trial rather than an internationally recognised system 
e.g. the scoring system used by Peacock et al, 2000 which had been developed for the 
START trial comparing cosmetic results from different radiotherapy schedules in breast 
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cancer. In 3 studies grading of late fibrosis was adjusted to account for radiation dose, dose 
per fraction and follow-up time to give a score for “excess risk of fibrosis” which was then 
used as the toxicity end-point for analysis (Johansen, Bentzen et al. 1994; Johansen, 
Bentzen et al. 1996; Herskind, Bentzen et al. 1998; Dikomey, Brammer et al. 2000). In 3 
studies toxicity was recorded as severe or not severe depending on clinical judgement with 
no further details given and 5 studies did not report how toxicity was graded at all. 
 
Table 3.5 Radiotherapy toxicity grading systems utilised in the identified studies. 
Toxicity grading system Number of studies  
RTOG/EORTC 19 
CTC (NCI) 8 
LENTSOMA 7 
Franco-Italian Glossary 2 
“Excess risk of fibrosis” 4 
Reflectance spectrography 3 
Burnet's modification of RTOG 3 
START 1 
WHO 1 
Readmission for wound packing 2 
Departmental scoring system 7 
“Clinical judgement” 3 
Not reported 5 
 
 
The median follow-up time between radiotherapy and scoring of late toxicity was not 
reported in 9 of the 45 studies which examined late toxicity. In 5 studies it was clear that 
duration of follow up had been accounted for in the analysis (Johansen, Bentzen et al. 
1994; Johansen, Bentzen et al. 1996; Herskind, Bentzen et al. 1998; Russell, Grummels et 
al. 1998; Dikomey, Brammer et al. 2000; Peacock, Ashton et al. 2000) whilst in the 
remaining studies it was not clear if varying duration of follow up in the cohort or between 
cases and controls  may have confounded the study outcome. 
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In 13 studies only one clinician was responsible for scoring of toxicity. In 17 studies there 
was more than one toxicity scorer. In only 8 of these studies had an assessment of inter-
scorer reproducibility been undertaken. The number of persons responsible for scoring 
toxicity was not reported in 34 studies. 
In 13 studies the person scoring toxicity was blinded to the laboratory assay result. 
Whether or not toxicity scorers were blinded was not reported for the other studies. 
 
3.3.6 Details of the laboratory assay under investigation. 
All studies reported assay technique in detail or referenced the protocol in another 
publication.  
 
Biological sample 
In 24 studies a skin biopsy was required to obtain cells for investigation. 32 studies 
isolated lymphocytes from a sample of peripheral blood and 4 studies used both. No more 
invasive techniques to obtain tissue were utilised. 
 
Sample handling 
15 studies commented on whether the biological sample had been stored before analysis 
and for how long. 8 of these reported the cryopreservation of lymphocytes, 1 commented 
that samples had been sent to the laboratory in the post and the others recorded maximum 
duration of sample storage at room temperature before analysis. It was not clear from any 
report as to whether samples from the whole cohort had received similar treatment and if 
cases and control samples had been treated identically. 
 
Time to obtain results 
To be of any clinical utility a laboratory assay must be able to generate results within 2 
weeks of tissue sampling, ideally faster. Although no study specifically reported the time 
taken between sampling and generation of results in the laboratory this information could 
be derived from the protocol in most studies. In 30 studies results were not available for at 
least 2 weeks following sampling (usually 4-6 weeks in the case of skin biopsies requiring 
fibroblast culture). In 32 studies results were available within 2 weeks, often within one 
week. In 2 studies it was not possible to derive this information. 
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Assay failure rate. 
The assay failure rate (the percentage of biological samples from which no assay result 
could be generated) was reported or could be derived in only 16 studies (25%). The 
median assay failure rate was 18.5% (range 1.5-71%). Most failures were associated with 
failure to obtain viable lymphocytes for testing after cryopreservation. 
 
Quality control and assay reproducibility. 
No study reported on day to day laboratory quality control procedures. In 14 studies, all 
utilising fibroblasts from skin biopsies, intra-sample reproducibility was assessed. The 
coefficient of variation (CV) was not reported for 3 studies. For the remaining 11 studies 
the median reported intra-sample CV was 13% (range 4.4-53). Inter-sample reproducibility 
(repeating the assay using repeated samples from the same individual) was reported for 20 
studies. For 7 of these studies the CV was not reported.  Where figures are given the 
median CV is 15% (range 2.5-40%). In 5 studies references are given for previous reports 
from the same laboratory where intra- and inter-sample reproducibility had already been 
assessed (West, Elyan et al. 1995; West, Davidson et al. 1998; Barber, Burrill et al. 2000; 
West, Davidson et al. 2001; Lopez, Guerrero et al. 2005) 
 
Scoring of subjective assay end-points 
Laboratory assays had subjective endpoints in 50 of the studies reported. No study 
reported an assessment of intra-scorer reproducibility. In 46 studies there was no comment 
as to whether the scoring was performed by more than one individual and whether inter-
scorer reproducibility had been assessed. In 4 studies inter-scorer comparisons were 
performed but not reported. 
In 4 studies the scorer was blinded to the toxicity data pertaining to the relevant patient. In 
41 studies there was no comment on blinding of the assay scorer. 
 
3.3.7 Treatment of confounding factors and statistical analysis 
In only 17 studies a deliberate strategy had been employed to control for at least some of 
the confounding factors other than intrinsic normal tissue radiosensitivity that might 
influence the development of normal tissue radiation toxicity in a given individual. In 5 
studies matching of cases and controls was performed (Peacock, Eady et al. 1989; 
Borgmann, Roper et al. 2002; Leong, Chao et al. 2003; Tell, Edgren et al. 2003; Rieger, 
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Hong et al. 2004) with differing levels of stringency and therefore effectiveness. Peacock 
et al matched cases and controls stringently according to radiation dose, year of follow-up, 
width of radiation field, thickness of lung in field, breast size, radiotherapy boost, treating 
centre, radiotherapy field separation, axillary radiotherapy, tamoxifen, adjuvant 
chemotherapy and timing of chemotherapy in relation to the radiotherapy. On the other 
hand Leong et al matched only for gender, age, tumour site, tumour stage and concurrent 
medication, and not all cases were matched with appropriate controls.  
 
Kiltie et al used multiple regression analysis including those patient and treatment related 
factors known to influence toxicity (but not specifying which ones) to determine if the 
predictive assay result was an independent prognostic factor for the development of 
radiation toxicity (Kiltie, Ryan et al. 1999; Twardella, Popanda et al. 2003). Twardella et 
al (2003) performed Cox proportional hazards analysis to determine which patient- and 
treatment-related factors influenced radiation toxicity but analysed assay result separately 
and did not incorporate it into the model with the potential confounders. Univariate 
analysis examining whether or not toxicity was influenced by chemotherapy, age and beam 
quality as well as the predictive assay result was utilised by Hoeller et al, 2003, analysing 
each separately and not in one combined multivariate model.  
 
Other groups incorporated a correction factor for at least some confounders into their 
radiation morbidity scoring system  - the system for measuring excess risk of fibrosis 
developed in Aarhus accounts for radiation dose, fraction size and duration of follow up 
(Johansen, Bentzen et al. 1994; Johansen, Bentzen et al. 1996; Herskind, Bentzen et al. 
1998; Dikomey, Brammer et al. 2000) as does the system used for grading risk of fibrosis 
utilised by Russell et al, (1998 and 2000). 
 
In 2 studies ROC curves were constructed from assay results and assay sensitivity and 
specificity calculated (Mariano Ruiz de Almodovar, Guirado et al. 2002; Wang, Chen et al. 
2005). For an assay of DNA DSB induction in peripheral blood lymphocytes The Spanish 
group calculated a sensitivity of 33% and specificity of 95% for predicting acute skin 
toxicity in breast radiotherapy with a ROC AUC of 0.675 (95% CI 0.534-0.817) Wang et 
al calculated a sensitivity of 51%, specificity 94% and ROC AUC 0.715 (95% CI0.557-
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0.835) for an assay predicting acute toxicity in head and neck cancer patients again by the 
measurement DSB induction in lymphocytes.   
 
For case control studies comparison of means or medians was the most commonly used 
statistical method to establish whether the assay result differed between radiosensitive and 
non-radiosensitive patients and was reported in 25 studies using either a the student’s t-
test, Mann-Whitney U-test or ANOVA to look for statistically significant differences 
between groups. In cohort studies, non-parametric correlation (usually Spearman) was 
used to test for a relationship between assay result and grade of radiation toxicity (16 
studies), although linear regression was used in 3. Actuarial analysis with calculation of 
Kaplan-Meier survival curves, stratification by assay result and log-rank test to examine 
for a statistically significant difference in risk of developing toxicity was used in 5 studies. 
Statistical methods and results were not reported in 8 studies. 
 
3.3.8 Hypothesis generating and validation data sets 
One of the two studies of gene expression profiling (Svensson, Stalpers et al, 2006) 
included details of attempted validation of the trained classifier on a separate very small 
cohort of patients with limited success. The other study reported details of the training set 
only (Rieger, Hong et al 2004).  
 
Four other studies were validation studies from previously published hypothesis generating 
data sets. Peacock et al 2000 were attempting to validate the initial report of a correlation 
between fibroblast cell survival and late effects of radiation in breast cancer patients 
published by Burnet et al. The study by Dickson et al, 2002 was an attempt to validate the 
previous report from the same group of a relationship between DNA DSB repair and late 
radiation toxicity in breast cancer patients (Kiltie, Ryan et al, 1999). Both of these 
validation studies could not confirm the findings of the initial studies. West et al confirmed 
their initial reports that lymphocyte radiosensitivity correlated with radiation toxicity in a 
prospective study (West, Davidson et al, 2001). The prospective study by Ozsahin et al 
was performed to validate the previous retrospective study proposing a relationship 
between radiation-induced lymphocyte apoptosis and radiation toxicity, and seem to 
confirm the initial findings (Ozsahin, Crompton et al, 2005). 
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One group reported three prospective studies of lymphocyte DNA damage assays in the 
prediction of toxicity following breast radiotherapy. It was difficult to determine from the 
reports whether the patient groups in these studies overlapped or formed early hypothesis-
generating and later validation sets. (Lopez, E., R. Guerrero, et al. 2005; Mariano Ruiz de 
Almodovar, J., D. Guirado, et al., 2002; Pinar, B., P. C. Lara, et al. ,2007). 
 
The other reports of a positive relationship between assay result and toxicity have not so 
far been followed by confirmatory validation studies from the same group. 
 
3.3.9 Summary of the results from identified studies 
There is clearly significant heterogeneity in the identified studies with respect to assay 
type, surrogate tissue analysed, tumour sites irradiated, radiotherapy scheduling, treatment 
of confounding factors and statistical analysis, with some studies better designed and 
reported than others. The majority involve the study of clonogenic cell survival or DNA 
damage in fibroblasts or lymphocytes. In order to try to ascertain if there is any clear 
pattern of positive and negative studies to suggest clinical utility or lack of it in the 
prediction of normal tissue radiosensitivity with any particular type of assay or cell type, 
individual comparisons between assay end-point and a particular toxicity end-point were 
extracted from each paper. These comparisons were broadly divided into two categories – 
those involving assays of clonogenic cell survival and those involving assays of DNA 
damage. The DNA damage category was not subdivided further. Each category was then 
subdivided into those studies based on fibroblasts versus those based on lymphocytes and 
then further into those examining acute versus late toxicity. The proportion of positive 
versus negative studies (based on the reported p-values) for each category was then 
calculated and an estimation of the influence of quality of study design and conduct was 
made by comparing the median quality index score for positive and negative studies within 
each subgroup.  
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Table 3.6 Assays of clonogenic cell survival – Fibroblasts and acute radiation toxicity 
Negative result 
Reference Assay end-
point 
Quality 
score 
Toxicity 
Akudugu, 2006 SF2.4  35 wound healing complication 
Alsbeih, 2004 SF2 17 any 
Begg, 1993 SF2, D10 45 skin erythema 
Brock, 1995 SF2 39 skin erythema  
Burnet, 1994 D0.01 35 skin erythema  
Djuzenova 2004 SF2  21 skin 
El-Adawy,2005 SF2  38 skin 
Geara, 1993 SF2 20 skin/mucosa 
Johansen, 1996 SF3.5 60 skin erythema 
Loeffler, 1990 D0, D, D10, n 31 skin 
Oppitz, 2001 SF2 23 any 
Oppitz, 2002 SF2  47 skin 
Rudat, 1997 SF2 43 skin and mucosa 
Rudat, 1999 SF2 55 skin and mucosa 
Median quality score                                        36.5 
 
Positive result 
Reference Assay end-
point 
Quality 
score 
Toxicity 
Akudugu, 2006 %BNI 35 wound healing complication 
Loeffler, 1990 D0, D, D10, n 31 skin 
Oppitz, 2001 SF2 23 any 
Median quality score                                         31 
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Table 3.7 Assays of clonogenic cell survival – Fibroblasts and late radiation toxicity 
Negative result 
Reference Assay end-
point 
Quality 
score 
Toxicity 
Borgmann, 2002 D0.01 58 skin,mucosa,salivary glands, 
subcut 
Brock, 1995 SF2 39 telangiectasia 
Johansen, 1996 SF3.5 60  telangiectasia 
Peacock, 2000 D0.01 77 skin, subcut 
Rudat, 1999 SF2 55 laryngeal 
oedema/fibrosis/bone 
Russell, 1998 SF2 70 fibrosis 
Median quality score                                        59 
 
Positive result 
Reference Assay end-
point 
Quality 
score 
Toxicity 
Alsbeih, 2000 SF2 11 any 
Alsbeih, 2004 SF2 17 any 
Burnet, 1994 D0.01 35 telangiectasia 
Geara, 1993 SF2 20 skin/fibrosis/mucosa/ 
bone/laryngeal oedema 
Johansen, 1994 SF3.5 56 fibrosis 
Johansen, 1996 SF3.5 60 fibrosis 
Oppitz, 2001 SF2 23 any 
Raaphorst,2002 SF2 41 radiation necrosis 
Median quality score                                        29 
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Table 3.8 Assays of clonogenic cell survival – Lymphocytes and acute radiation toxicity 
Negative result 
Reference Assay end-point Quality 
score 
Toxicity 
Geara, 1993 SF2 20 skin/mucosa 
Oppitz, 2002 SF2  47 skin 
West 1995 SF2 and LDR 
sparing 
23 skin 
Median quality score                                         23 
 
No positive results 
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Table 3.9 Assays of clonogenic cell survival – Lymphocytes and late radiation toxicity 
Negative result 
Reference Assay end-point Quality 
score 
Toxicity 
Geara, 1993 SF2 20 skin/subcut/mucosa/bone/larynx 
West 1995 SF2 and LDR sparing 23 any affected tissue  
Median quality score                                  21.5 
 
Positive result 
Reference Assay end-point Quality 
score 
Toxicity 
West 1998 SF2 35 any affected tissue  
West 2001 SF2 53 most severe toxicity in any 
tissue 
Ramsay, 1995 SF2 (MTT) 25 skin subcutaneous 
Median quality score                                    35 
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Table 3.10 Assays of DNA damage – Fibroblasts and acute radiation toxicity 
Negative result 
Reference Assay end-point Quality 
score 
Toxicity 
Djuzenova 
2004 
%MRE11pos nuclei 21 skin 
Djuzenova 
2004 
%Rad51 pos nuclei 21 skin 
Oppitz, 2002 DNA repair - alkaline comet 
assay 
47 skin 
El-
Adawy,2005 
DNA repair - residual DSBs 
(CFGE) 
38 skin 
Akudugu, 
2004 
micronucleus 45 wound healing 
complication 
Slonina, 
2000 
micronucleus 11 mucosa /skin 
Median quality score                                          29.5 
 
Positive result 
Reference Assay end-point Quality 
score 
Toxicity 
Djuzenova, 
2004 
%Rad50 pos nuclei 21 skin 
Nachtrab, 
1998 
micronucleus 5 mixed 
Oppitz, 1999 DNA repair - alkaline comet 
assay 
15 mixed 
Median quality score                                          15 
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Table 3.11  Assays of DNA damage – Fibroblasts and late radiation toxicity 
Negative result 
Reference Assay end-point Quality 
score 
Toxicity 
Slonina, 
2000 
micronucleus 11 rectum/bladder 
Borgmann, 
2002 
DNA repair - residual DNA 
damage (CFGE) 
58 skin,mucosa,salivary 
glands, subcut 
Dikomey, 
2000 
DNA repair - residual DNA 
damage (CFGE) 
55 fibrosis 
Dickson, 
2002 
DNA repair - residual DNA 
damage (PFGE) 
61 fibrosis and SOMA score 
Median quality score                                          56.5 
 
 
Positive result 
Reference Assay end-point Quality 
score 
Toxicity 
Kiltie 
1999 (1) 
DNA repair - residual DNA  
damage (PFGE ) 
50 fibrosis , LENT score 
Nachtrab, 
1998 
micronucleus 5 mixed 
Oppitz, 
1999 
DNA repair - alkaline  
comet assay 
15 mixed 
Median quality score                                           15 
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Table 3.12 Assays of DNA damage – Lymphocytes and acute radiation toxicity 
Negative result 
Reference Assay end-point Quality score Toxicity 
Lopez, 2005 DNA DSB induction 
(PFGE) 
53 skin 
Twardella, 
2003 
DNA repair - alkaline comet 
assay 
53 skin  
Wang, 2005 
(2) 
DNA repair - alkaline comet 
assay 
32 skin 
Popanda, 
2003 
DNA repair - alkaline comet 
assay 
28 skin 
Rached, 
1998 
micronucleus 13 skin/mucosa/bowel 
Slonina, 
2000 
micronucleus 11 mucosa /skin 
Median quality score                                       30 
 
Positive result 
Reference Assay end-point Quality 
score 
Toxicity 
Kearsley, 
1998 Chromosome aberrations 1 mucosa /skin 
Neubauer, 
1997 chromosome rearrangements 16 mixed 
Wang, 2005 
(1) DNA DSB induction (PFGE) 52 skin  
Ruiz de 
Almodovar 
2002 DNA DSB induction (PFGE) 52 skin  
Alapetite, 
1999 
DNA repair - alkaline comet 
assay 22 skin, oesophagus 
Oppitz, 
2002 
DNA repair - alkaline comet 
assay 47 skin 
Barber, 
2000 (1) G2 assay  65 skin 
 
Widel, 2003 micronucleus 33 any 
Median quality score                                        40 
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Table 3.13 Assays of DNA damage – Lymphocytes and late radiation toxicity 
Negative result 
 
Reference 
Assay end-point Quality 
score 
Toxicity 
Lopez, 
2005 
DNA DSB induction 
(PFGE) 
53 skin 
Hoeller, 
2003 
lethal chromosome 
aberrations 
63 time to fibrosis and 
fibrosis 
Slonina, 
2000 
micronucleus 11 rectum/bladder 
Median quality score                                 53 
 
Positive result 
Reference Assay end-point 
Quality 
score Toxicity 
Neubauer, 
1997 
complex chromosome 
rearrangements 
16 mixed 
Pinar, 2007 DNA DSB induction 
(PFGE) 
50 skin subcutaneous 
Alapetite, 
1999 
DNA repair - alkaline 
comet assay 
22 fibrosis, telangiectasia, 
lung dysfunction, 
cardiac disease 
Deeley, 
1989 
DNA repair - nuclear 
lysate sedimentation 
12 bowel or bladder 
Borgmann, 
2002 
DNA repair - residual 
DNA damage (CFGE) 
58 skin,mucosa,salivary 
glands, subcutaneous 
De 
Ruyck,2005 
G2 assay  39 any 
Widel, 
2003 
micronucleus 33 any 
Barber, 
2000 (1) 
micronucleus 65 fib,telang, retraction, 
pain 
Lee, 2003 micronucleus 67 GI/GU 
Median quality score                                 39 
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Table 3.14 Summary of outcome and quality score for assays other than those examining clonogenic cell survival or DNA damage and repair 
Reference Assay category Assay end-point Cell type Outcome Quality score Toxicity assessed 
Barber 2000 (2) Apoptosis % apoptosis lymphocyte neg 42 Late 
Ozsahin, 2005 Apoptosis % apoptosis lymphocyte neg 44 Acute 
Ozsahin, 2005 Apoptosis % apoptosis lymphocyte pos 44 Late 
Kilzilian-
Martel, 2003 
Apoptosis Apoptotic fraction leucocytes pos 5 Mixed 
Crompton, 1999 Apoptosis % apoptosis lymphocyte pos 25 Mixed 
Perez, 2007 Cell cycle % cells in G2/M arrest lymphocyte pos 1 Late - bladder, bone, 
skin 
Lavin 1994 Cell cycle % G2 18 hours post 
3Gy 
lymphocyte pos 15 mixed acute and late 
Tell, 2003 Cell cycle % cells in G2 after 
8Gy 
lymphocyte neg 36 acute - pulmonary 
injury 
Svensson, 2006 Gene expression 
profiling 
gene expression 
classifier 
lymphocyte pos 32 late - bladder rectum 
Hummerlich, 
2006 
Gene expression 
profiling 
increased or decreased 
gene expression 
lymphocyte neg 32 Acute - Bone 
marrow,GI,GU 
Reiger, 2004 Gene expression 
profiling 
gene expression 
classifier 
lymphocyte  pos 51 acute - any 
Leong, 2003 DNA repair protein 
expression levels 
western blot 
quantification 
lymphocyte neg 16 mixed acute and late 
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Table 3.15 summarises the percentage of positive versus negative study results for assays 
of clonogenic cell survival and DNA damage and repair in fibroblast and lymphocytes for 
prediction of acute and late radiation toxicity. 
 
The heterogeneity of design and statistical analysis of the studies used to compile this table 
means it is not possible to make firm conclusions about the relative efficacy of clonogenic 
cell survival and DNA damage assays in these cell types. There are two features worth 
noting. The majority (82%) of studies examining the role of fibroblast survival assays in 
the prediction of acute radiation toxicity were negative. In contrast, the majority (75%) of 
studies examining the role of DNA damage and repair assay in lymphocytes in the 
prediction of late radiation toxicity were positive. The low quality of the studies means it is 
not possible to conclude that this means that clonogenic cell survival assays in fibroblast 
have no role in the prediction of acute radiotherapy toxicity and conversely that 
lymphocyte DNA damage-based assay do have a role in the prediction of late toxicity - 
this asymmetry in positive and negative studies in these two groups may simply be due to 
chance or even publication bias in the case of lymphocyte assays, with positive studies 
more likely to be published than ones with negative findings. 
 
For other assays, end-points and cell type, positive and negative studies appeared to be 
equally distributed. 
 
The quality scores for all groups were low, the highest scoring group being the studies of 
fibroblast clonogenic cell-survival and late radiation toxicity which contained the two 
highest scoring studies (Peacock et al, 2000, and Russell et al 1998). Negative studies 
examining fibroblast clonogenic cell survival in the prediction of late radiation toxicity had 
a significantly higher quality score than studies with positive results. Although it is not 
possible to form definite conclusions on the basis of a non-validated quality index score 
this finding suggest that better quality studies with more robust conclusions are more 
likely to show no relationship between fibroblast clonogenic survival and late radiotherapy 
toxicity and raises the possibility that such a relationship may not exist. 
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Table 3.15 Summary of positive versus negative outcomes for studies of cell-based predictive assays of normal tissue radiosensitivity and 
comparison of quality scores for positive and negative studies. 
 
Assay Cell Toxicity % of studies 
positive 
% studies 
negative 
Significant difference in 
quality scores (QS) between 
positive and negative studies? 
 
p-value for QS 
difference 
(Mann-
Whitney U) 
Clonogenic cell 
survival 
Fibroblast Acute 18 (3/17) 82 (14/17) No 0.41 
 
 
Fibroblast Late 53 (8/15) 47 (7/15) Yes – quality score in 
negative studies higher then 
positive (median diff = 25, 
96% CI 44-4) 
0.02 
 
 
Lymphocyte Acute 0 (0/3) 100 (3/3) No N/A 
 
 
Lymphocyte Late 60 (3/5) 40 (2/5) No 0.2 
DNA 
damage/repair 
Fibroblast Acute 33 (3/9) 67 (6/9) No 0.15 
 
 
Fibroblast Late 37.5 (3/8) 62.5 (5/8) No 0.25 
 
 
Lymphocyte Acute 57 (8/14) 43 (6/14) No 0.83 
 
 
Lymphocyte Late 75 (9/12) 25 (3/12) No >0.99 
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3.3.10  Extraction of individual patient data, ROC curve construction and 
calculation of diagnostic odds ratios 
 
It was possible to extract individual patient data, construct ROC curves and calculate 
diagnostic odds ratios for a total of 67 comparisons of assay result and specific normal 
tissue toxicity end-points. For each a ROC curve was constructed and assay cut-off points 
chosen to maximise assay sensitivity and specificity (sensitivity: specificity weighting = 
1:1). Once these cut offs were chosen, a diagnostic 2 by 2 table was constructed for each 
comparison and the diagnostic odds ratio along with 95% confidence intervals calculated.  
 
No attempt at pooling data by meta-analysis was made. As in systematic reviews of 
randomised controlled trials meta-analysis should only be considered when studies have 
recruited patients from similar populations, have used comparable experimental 
procedures and are unlikely to be biased in order to avoid generating a misleading pooled 
estimate (Deeks, 2001). As is clear from earlier sections none of these three criteria were 
fulfilled by the studies included in this systematic review. 
 
For some studies several separate assay techniques were compared with a single or 
multiple toxicity end-points e.g. Djuzenova compared MRE11, Rad 50 and Rad 51 focus 
formation with acute toxicity in three separate analyses and a diagnostic odds ratio and 
data point has been generated for each of these comparisons. The data are presented on 
forest plots in Figures 3.2 (acute toxicity) and 3.3 (late toxicity). The area of each data 
point on the chart represents the overall quality index for each study, with the data points 
with the largest areas representing the higher quality studies. Funnel plots (log odds ratio 
versus quality score and sample size) were constructed and inspected to assess for the 
impact of bias (publication and study design) on study outcome (Egger et al, 1997). Bias 
due to publication bias or poor study design should result in asymmetry of the inverted 
funnel generated by these plots.  
 
The score for appropriate statistical analysis was not included in the final quality score for 
the forest plot or funnel plot as the relevance of this parameter in study quality had been 
negated by the separate analysis of individual patient data. 
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Figure 3.2 Forest plot of diagnostic odds ratio +/- 95% confidence intervals for individual 
comparisons of assay result and acute radiation toxicity end-points. 
Area of data point corresponds to quality index value. 
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Johansen,1996 4.29 (0.52, 52.53)
Johansen, 1996 6.75 (0.95, 75.45)
Geara, 1993 56.00 (2.11, 2821.95)
Alsbeih, 2004 1.88 (0.13, 108.13)
Alsbieh, 2000 30.00 (1.00, 1645.48)
 
Figure 3.3 Forest plot of diagnostic odds ratio +/- 95% confidence intervals for individual 
comparisons of assay result and late radiation toxicity end-points.  
Area of data point corresponds to quality index value. 
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Figure 3.4 Funnel plot of effect (log DOR) vs. quality index (A) and sample size (B) to 
test for presence of bias in systematic review. 
The dotted line represents the mean log of the diagnostic odds ratio. Asymmetry of the 
"funnel" is indicative of bias.  
 
Results 
For prediction of acute and late radiation toxicity the diagnostic odds ratios calculated have 
very wide confidence intervals most of which cross the value of 1. This means that for 
these assays a positive result could be just as likely in a non-radiosensitive as a 
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radiosensitive individual and therefore these assays had no discriminatory value within the 
studies in which they were investigated. 
 
Assays showing at least some sign of discriminatory power are those where the 95% 
confidence intervals do not cross 1. The most promising of these will have a high odds 
ratio with narrow confidence intervals. In the prediction of acute toxicity five comparisons 
generated DOR where the lower 95% confidence limit was more than 1. One of these was 
an assay of lymphocyte clonogenic cell survival (West, 1995), another was for a measure 
of fibroblast clonogenic potential (binucleated index, Akudugu, 2006) whilst the other 
three were assays of DNA damage. The narrowest confidence limits and the higher quality 
scores were for 2 assays of DNA damage in lymphocytes - the G2 assay of chromosomal 
sensitivity and acute skin toxicity with a DOR of 6.3 (1.11-63.98) (Barber, 2000 (1)) and 
DNA damage induction and acute toxicity in head and neck radiotherapy with a DOR of 
18.29 (6.78-49.57) (Wang et al 2005, 1), and for the cytokinesis-blocked binucleated index 
assay in fibroblasts (DOR 16.88, 3.48-90.56, Akudugu, 2006) 
 
For late toxicity there were 8 assays whose lower 95% confidence limit was greater than 1. 
Two were assays of fibroblast clonogenic survival, and included the study which attained 
the highest quality rating (Peacock et al. 2000). The other studies examined assays of 
lymphocyte clonogenic survival (West, 1995), fibroblast DNA damage (Dickson et al, 
2002; Kiltie et al, 1999), and lymphocyte DNA damage (Deeley et al, 1999; Widel et al, 
2003). The narrowest confidence intervals and best quality scores were for the study of 
Peacock et al and for the comparison of DNA damage repair in fibroblasts and the 
modified LENTSOMA score (Dickson et al, 2002). 
 
The DORs calculated from these studies must be interpreted with caution - the overall low 
quality of design and reporting of the studies from which they were derived means that 
their validity is uncertain and that they cannot be generalised to the wider population.  
 
Inspection of the funnel plots in Figure 3.4 shows no obvious asymmetry suggesting no 
major effect of study design, sample size or publication bias on results. 
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3.4 Conclusion 
• The studies of functional cell-based assays identified from the literature in this 
systematic review are heterogeneous with respect to basic study design, the assay 
parameters investigated, toxicity end-point and scoring, treatment of confounding 
factors and statistical analysis. There is poor reporting of assay reproducibility and 
treatment of potential sources of bias such as blinding of scorers and inter-scorer 
comparisons. The factors other than normal tissue radiosensitivity known to 
influence normal tissue toxicity that might confound the study results are in general 
poorly reported.  
 
• This poor reporting and often inadequate study design makes it difficult to draw 
any conclusions about the presence or absence of potential clinical utility of 
functional cell-based assays in the predictive testing of normal tissue 
radiosensitivity. 
 
• Comparison of relative diagnostic efficacy for different assays is difficult - some 
information is gained from the comparison of diagnostic odds ratios from 
individual patient data, but limited by the quality of the studies from which the data 
is drawn. 
 
• In the current evidence base the assay which is most informative with a diagnostic 
odds ratio of 18.29  and narrow 95% confidence interval is an assay of DNA 
damage induction in lymphocytes in the prediction of acute toxicity in head and 
neck cancer (Wang et al, 2005 (1)). The hypothesis-generating study from which 
these figures were derived, however, has not been validated in a follow up study. 
 
• Certainly no assay has emerged from studies so far that has proven its precision 
and diagnostic accuracy to be sufficiently robust to be used in clinical decision-
making 
 
• It is possible that heterogeneous study design and insufficient control of 
confounding factors have led to potentially useful cell based assays have been 
overlooked. 
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4. γH2AX induction and loss as a potential assay of normal tissue 
radiosensitivity - quantification of γH2AX foci by microscopy 
 
The heterogeneity and poor quality of the majority of the studies included in the systematic 
review means that it is not possible to come to any firm conclusions about the potential 
discriminatory power and clinical utility of functional cell-based assays in the 
identification of individuals with high normal tissue radiosensitivity, and it is entirely 
possible that the potential discriminatory power of some assays may have been masked. 
The highest diagnostic odds ratio was derived for an assay of DNA DSB induction in 
lymphocytes. Although this result has not been validated it justifies the investigation of the 
diagnostic potential of a novel cell-based assay which utilises recent progress in the 
understanding of the molecular processes of the cellular response to DNA damage.  
 
The rate of loss of γH2AX after irradiation of 10 cell lines correlates with clonogenic 
survival at 2Gy with the most radiosensitive cell lines demonstrating slower rates of loss. 
(MacPhail, Banath et al. 2003). The rate of γH2AX disappearance is slower in 
radiosensitive tumour cells both in culture and tumour xenografts as well as  radiosensitive 
murine normal tissue (Olive and Banath 2004; Taneja, Davis et al. 2004). The 
quantification of γH2AX induction and kinetics of γH2AX formation and loss in human 
peripheral blood lymphocytes after a test dose of radiation could therefore potentially form 
the basis of a predictive assay of human normal tissue radiosensitivity. 
 
Two methods for the quantification of γH2AX foci in cultured cell lines have been 
published in the literature – direct visualisation and quantification of foci by microscopy 
and indirect quantification by flow cytometry. Both techniques could potentially be 
applied to isolated human peripheral blood lymphocytes (PBLs). 
 
Counting of γH2AX foci by direct visualisation by microscopy has been the most 
frequently  reported technique for the quantitative evaluation of γH2AX induction and loss 
by various cytotoxic agents, including ionising radiation (Sedelnikova, Rogakou et al. 
2002; Rothkamm and Lobrich 2003). Whilst this technique has been applied to cell 
cultures grown in an adherent monolayer it had not been described as a technique for 
quantifying γH2AX in cells in suspension such as human peripheral blood lymphocytes. In 
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order to explore the potential of γH2AX quantification by microscopy in human PBLs as a 
predictive assay of normal tissue sensitivity, a technique for the immunostaining of 
isolated human PBLs using the commercially available monoclonal antibody was 
developed. The optimal method for quantification of foci was then investigated and the 
precision of the assay assessed - as in any diagnostic test, assay development must start at 
Level 1 of Fryback and Thornbury's model with assessment of the technical efficacy. 
  
4.1 Quantification of γH2AX foci by microscopy in irradiated mammalian 
fibroblasts 
A standard immuno-fluorescent staining technique was firstly used to confirm that it was 
possible to induce and detect discrete foci of γH2AX in mammalian cells (Muntjac 
fibroblast) in cell culture in our laboratory. Muntjac fibroblasts were selected due to their 
tendency to enter growth arrest when grown to confluence in culture so reducing 
background γH2AX staining due to DNA breaks during replication fork collision. Cells 
were cultured on glass cover slips in MEM supplemented with 10% FCS, and allowed to 
grow to confluence at which point they entered growth arrest (G0). The cover slips were 
irradiated (0.5Gy) in their growing medium at room temperature whilst the controls were 
“mock-irradiated”. Cover slips were then incubated at 37oC for 15 minutes to allow 
formation of γH2AX before being washed and fixed in paraformaldehyde. The 
immunostaining procedure for γH2AX described in section 2.2.4 was then performed. 
 
Cover slips were mounted on glass slides and viewed on a Zeiss fluorescence microscope 
at x40 magnification. The number of discrete FITC-tagged foci in 100 nuclei was counted 
using a hand-held counter, and the mean number of discrete foci per cell calculated. The 
experiment was repeated four times. 
 
Discrete foci were clearly visible in both irradiated and non-irradiated G0 Muntjac cells 
presumed to correspond to foci of γH2AX. The foci were clearly separated and easily 
quantifiable by eye. There was a clear and statistically significant increase in the mean 
number of foci per cell in the irradiated cells (p= 0.0286, Mann-Whitney U test) (Figure 
4.1). 
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Figure 4.1 Irradiated Muntjac fibroblast after 0.5Gy γ-rays showing discrete, easily 
visualised and quantifiable foci of γH2AX.  
There was a statistically significant increase in the mean number of foci per cell in the 
irradiated compared to non-irradiated cells. 
 
4.1.1 Immunofluorescent detection of γH2AX in human peripheral blood 
lymphocytes. 
Immunostaining and direct visualisation of γH2AX foci seemed a feasible method for the 
quantification of in cultured mammalian cells grown on cover slips. The next step was to 
adapt this technique for use in human peripheral blood lymphocytes.  
 
Human peripheral blood contains a mixed cell population of erythrocytes, lymphocytes, 
granulocytes, monocytes and platelets. In adults lymphocytes represent 35% of the total 
circulating blood leucocyte population and are present at a concentration of 2.5x109/L. 
60% of the total circulating lymphocyte pool are T cells and 20% B-cells. 5% of total body 
pool of lymphocytes are circulating at any one time (Turgeon 2004).  
 
In order to obtain sufficient numbers of human PBLs for immunostaining PBLs had to be 
isolated and concentrated from samples of whole blood. The cell separation method had to 
be quick and result in a reliably consistent pure population of non-activated (and therefore 
G0) PBLs. Contamination by erythrocytes which are subject to autofluorescence (Bidlack 
and Tappel 1973; el-Rahman, Hammouda et al. 1995) would hinder focus quantification.   
 
There is some evidence that B-cells and T-cell populations may differ in radiosensitivity 
especially at low radiation dose (Prosser 1976; Louagie, Van Eijkeren et al. 1999; Vral, 
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Thierens et al. 2001; Schmitz, Bayer et al. 2003). In order to minimise any confounding 
influence on the assay results that might result from differing proportions of B and T cells 
in different individuals or within the same individual over time it was decided that a pure 
T-cell population should be used for investigation. In order to achieve a consistently pure 
population of human peripheral blood T-lymphocytes an immunomagnetic bead separation 
technique (Dynal) was employed using immunomagnetic beads to isolate a pure CD4 and 
CD8 positive T-cell population. The immunomagnetic bead separation process should 
result in an isolated cell population that is pure (>99%), with >90% of cells in G0 phase of 
the cell cycle, with no up regulation of activation markers or detectable proliferation 
(Friedl, Noble et al. 1995; Dynal 2000) 
 
Once isolated the T lymphocytes were resuspended in RPMI/1%FCS, placed in 15ml 
polypropylene tubes, gassed with 5% CO2/air and incubated at 37oC for 30 minutes. 
Samples were then irradiated with increasing radiation doses (0Gy, 0.2Gy, 0.4Gy, 0.6Gy, 
0.8Gy and 1.0Gy) before being incubated at 37oC for 30 minutes to allow γH2AX 
formation to take place. The PBLs were attached to glass slides by cytocentrifugation 
before being fixed and stained using the same technique as for the Muntjac fibroblasts. 
Slides were examined and photographed (Figure 4.2). Foci of γH2AX were visible in 
irradiated cells only and appeared on inspection to increase in number as radiation dose 
increased, in a dose dependent fashion confirming that the immunostaining procedure was 
indeed detecting a radiation-induced phenomenon in keeping with DNA DSB formation. 
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Figure 4.2 Cytospin preparations of human peripheral blood CD4 and CD8 T-
lymphocytes fixed and stained for γH2AX 30 minutes after irradiation and viewed at x100 
magnification. 
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4.2 Techniques for quantification of γH2AX foci in human PBLs by microscopy 
 
Having demonstrated that it was possible to detect radiation-induced foci of γH2AX in 
PBLs by immunocytochemistry, a robust and reliable method of quantifying γH2AX had 
to be developed. Whilst direct “real-time” inspection and manual counting of foci in 
Muntjac fibroblasts had been relatively straightforward, a number of problems were 
encountered when attempting the same technique in human PBLs.  
 
Human PBLs are significantly smaller than fibroblasts and need to be viewed at a higher 
power of magnification. Their nuclei are spherical and, despite cytocentrifugation at 
increased speed and times (data not shown), still retained a significant “depth” on the slide 
compared to fibroblast nuclei. This resulted in overlap of foci in the x and y planes making 
it difficult to distinguish between different foci. To avoid missing foci lying at different 
depths within the nucleus, each nucleus also had to be examined whilst focussing in and 
out through the z plane. 
 
As a result analysis of each nucleus took considerably longer than with  fibroblasts and 
consequently problems with the recognised phenomenon of “bleaching” of the FITC signal 
due to prolonged incident light exposure were then encountered (Longin, Souchier et al. 
1993). Frequently the FITC signal from γH2AX foci had completely disappeared after 
only 10-20 cells had been analysed, making further analysis impossible and casting doubt 
over the validity of the results from those nuclei already examined. This problem was not 
overcome by changing the anti-fading agent in the mounting medium from MOWIOL to 
Vectashield. 
 
In order to circumvent this problem, digital images of 100 cells from each slide were 
obtained so that “data” could be captured more rapidly before bleaching had time to occur. 
Analysis of the digital images was then performed. To overcome the problem of the 
“rounding up” of the PBL nuclei on the slide, images were obtained through several slices 
of the nucleus using the Z-stack facility on the motorised microscope stage. Five slices 
were taken through each nucleus images taken at 5 micrometre intervals. Digital capture 
software (CytoVision, Applied Imaging) superimposed the images to create a 2-
dimensional image of a 3-dimensional structure. A threshold level was selected for the 
images by visual inspection which resulted in the best discrimination of foci from 
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background and the images saved for later analysis. The threshold level was noted and 
used at the same setting for all further experiments. 
 
4.2.1 Analysis of digital images 
A reproducible and objective method of quantifying γH2AX foci on each digitally 
captured image was required. Using the available equipment and software within the 
department a number of options were available: 
 
a) Direct visual quantification 
b)  Automatic slide scanning and digital image analysis using CytoVision “SPOT” 
software 
c) Semi-automated “computer” quantification 
 
a) Direct visual quantification 
This consisted of counting the number of foci per cell using a hand-held counter by 
inspecting the images by eye. The advantages of this technique are that obvious non-
specific background staining can be disregarded and a judgement can be made about the 
number of foci actually present when several foci overlap on the images. The 
disadvantages are that visual inspection is time-consuming and labour-intensive, and 
subjective assessment of what does and does not constitute a focus could lead to inter-
observer variation in results if the technique is utilised by a number of workers in more 
than one laboratory. 
 
b) Automatic slide scanning and digital image analysis using CytoVision “SPOT” 
software.  
The Spot AX system (CytoVision, Applied Imaging) had already been installed in the 
department for use in the scanning, re-location, capture and analysis of FISH signals 
during chromosome analysis. The system consists of a fully motorised, automated 
microscope stage on a fluorescence microscope, with a motorised focus and fluorescent 
filter changer. The Spot AX software allows fully automated scanning and digital image 
capture with data being transferred to an analysis program (Review, Applied Imaging) 
which identifies and quantifies fluorescent FISH signals. During a visit by a product 
specialist from Applied Imaging, the possibility of adapting this system to capture and 
quantify γH2AX foci was explored.   
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Figure 4.3 “SPOT” image analysis 
The SPOT program has successfully identified 
and marked with a green square all foci within 
a muntjac fibroblast nucleus. The program 
recognises the DAPI mask and outlines a 
solitary nucleus for focus quantification 
Figure 4.4 “SPOT” image analysis 
Human lymphocyte nucleus – SPOT 
programme has failed to identify several 
obvious foci (arrowed) 
Various parameters in the Review programme can be altered to determine the level of 
sensitivity of focus detection, ability to discriminate between real signal and background 
“noise” and ability to discriminate between two separate foci lying close together. By 
altering the parameters which determine the minimum and maximum thresholds for spot 
area, distance between spots, and spot intensity, and the thresholds for recognising 
background debris, it was possible to adapt the program for automatic scanning and 
γH2AX foci quantification in Muntjac fibroblast cells. (Figure 4.3). Unfortunately attempts 
to with human PBLs were less successful. Despite altering the thresholding for spot 
intensity, area, and separation the system regularly failed to count several foci per cell 
(Figure 4.4), failed to discriminate between overlapping foci (Figure 4.5) and often failed 
to distinguish between nuclei lying close to each other and counted all foci within a group 
of nuclei as belonging to one cell. (Figure 4.6). It was concluded that whilst the system 
could be adapted for foci quantification in large well separated nuclei it did not have 
sufficient discriminatory capacity or sensitivity for similar use in small, often clumped 
human PBLs. 
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Figure 4.5 “SPOT” image analysis 
Human lymphocyte nucleus – several partially 
overlapping but obviously discrete foci have 
been counted as one single focus (arrowed) 
Figure 4.6 “SPOT” image analysis 
The program has not discriminated between 
several close lying nuclei. They have been 
outlined as one cell and all foci within them 
counted together. 
 
 
 
c) Semi-automated “computer” quantification 
As a compromise between the time consuming and subjective manual focus quantification 
and the fully automated but less sensitive and less discriminatory “Spot” analysis a 
technique was developed that combined features of each.  
 
The CytoVision software includes a facility that automatically outlines all discrete areas of 
FITC staining on a digital image (Figure 4.7). For each image a summary statistic 
containing the total number of regions outlined on the image and mean area of outlined 
regions (in pixels) is generated. The outlining facility is very sensitive and outlines all 
discrete FITC staining regions on the image, even very small areas of only a few pixels 
diameter, barely visible to the eye.  This means that areas of obvious background staining 
between nuclei are outlined i.e. the outlining tool is very sensitive but not specific. It is 
possible to visually inspect the image after automatic outlining and to delete the foci 
between cells that are obviously background staining erroneously outlined by the software, 
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Figure 4.7 Semi-automated focus 
quantification 
Cytovision software automatically 
outlines areas of FITC staining on the 
image (pink boxes).Any area of 
background staining between nuclei or 
areas outline in partial images of cells 
(arrowed) can be deleted by clicking the 
cursor over them, They will then not be 
included in the statistics regarding focus 
number and area generated for the image 
 
and to delete the foci outlined on partial images of cells. This can be repeated for a number 
of images so that a total of 100 complete cells have been analysed. It is then possible to 
calculate the total number of foci seen per 100 cells and therefore the mean number of foci 
per cell. The program also calculates the mean focus area for per image in pixels. If the 
results from non-irradiated control samples are subtracted then any erroneously included 
background staining overlying the DAPI stained nuclei should be accounted for.  
 
 
  
 
The advantage of this method over manual scoring is that the use of the computer to 
identify foci removes subjectivity and increases sensitivity. Confounding effects of non-
specific background speckling difficult to quantify by eye can theoretically be accounted 
for by subtracting the results from the non-irradiated control. Although it is time 
consuming removing the background staining between the cells, the final count is fully 
automated and information about focus size is also retrieved.  
Using this hybrid technique it is therefore possible to generate data on: 
• Mean number foci per cell 
• Mean focus area 
• Mean FITC coverage per cell by multiplying the mean focus area by the mean 
number of foci per cell – multiple foci overlapping result in one apparent large 
focus. A simple count of number of foci will not take this into account and may 
confound the results i.e. produce an erroneously low value for a cell with multiple 
foci that appear to merge into one. Calculating the mean FITC coverage per cell 
may correct for this. 
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4.3  Determination of the most precise technique for focus quantification. 
 
For an assay to have any utility as a diagnostic test to guide clinical practice it must be 
reliable and precise. Reliability means that one can expect to obtain a result each time the 
assay is performed. If precise, an assay will generate reproducible results when performed 
on the same sample within the same “run” and on the same individual on multiple 
occasions over time. 
In order to estimate assay precision for the various focus quantification techniques 
described above, an assay endpoint needed to be chosen and the ability of each technique 
to produce reproducible results for this end point assessed. The end point chosen was the 
quantification of γH2AX at a specific time point in isolated PBLs after a test dose of 
radiation in vitro. The most appropriate radiation dose and time point were determined by 
measuring radiation dose response and kinetics of radiation-induced γH2AX formation and 
loss. 
 
4.3.1 Dose response of γH2AX induction in human peripheral blood lymphocytes 
Human peripheral blood lymphocytes were isolated from a venous blood sample freshly 
drawn from a healthy volunteer (Subject 6). After re-suspension in RPMI/1% FCS cells at 
2x105 cells per ml, cells were divided between each of 6 15ml polypropylene tubes, gassed 
with 5%CO2/air and incubated at 37oC for 30 minutes before irradiation. Each tube 
received 0, 0.2, 0.4, 0.6, 0.8, or 1Gy.  The cells were then incubated at 37oC for 30 minutes 
before being fixed. Immunostaining and digital image capture and analysis were 
performed as previously described. The experiment was repeated 5 times on different days, 
on each occasion using a fresh blood sample from the same volunteer.  
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Results: 
Computer focus quantification
0.0 0.2 0.4 0.6 0.8 1.0
0
5
10
15
r=1.0, p=0.002
Radiation dose (Gy)
M
ea
n
 
n
u
m
be
r
γγ γγH
2A
X
fo
ci
 
pe
r 
ce
ll
Mean focus area
0.0 0.2 0.4 0.6 0.8 1.0
0
20
40
60
80
r=0.94, p=0.02
Radiation dose (Gy)
M
ea
n
γγ γγH
2A
X
fo
cu
s 
a
re
a
Mean FITC coverage/cell
0.0 0.2 0.4 0.6 0.8 1.0
0
200
400
600
r=0.94, p=0.02
Radiation dose (Gy)
M
ea
n
 
FI
TC
 
co
v
er
ag
e 
pe
r
 
ce
ll
(p
ix
el
s)
Manual focus quantification
0.0 0.2 0.4 0.6 0.8 1.0
0
5
10
15
r=0.94, p=0.02
Radiation dose (Gy)
M
ea
n
 
n
u
m
be
r
γγ γγH
2A
X
fo
ci
 
pe
r 
ce
ll
 
 
Figure 4.8 Dose-response of γH2AX focus induction after irradiation (microscopy). 
For each data point the mean and standard deviation from 5 separate experiments are 
shown along with the best fit line (linear regression), correlation coefficient (Spearman) 
and p-value for each method of γH2AX focus quantification 
 
The number and size of foci increased linearly with dose up to 0.8Gy. With the exception 
of the computer count technique there was a suggestion of a “plateauing” effect between 
0.8Gy and 1.0Gy most evident in the manual scoring, probably due to significant overlap 
of foci resulting in a saturation of ability to discriminate visually between foci and 
masking any increase in focus size. The slope of the linear regression line was shallowest 
for mean focus size suggesting this parameter has the lowest ability to discriminate 
between different quantities of γH2AX. There was considerable inter-experimental 
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variability in results as demonstrated by the large standard deviation particularly for mean 
focus area and consequently mean FITC coverage per cell. 
A radiation dose of 0.4Gy was chosen as the test dose for further assay development - this 
resulted in significantly increased levels of γH2AX compared to baseline when measured 
by all 4 potential methods of γH2AX quantification but was still within the linear increase 
section of the dose response curve, well below any plateau effect. 
 
4.3.2 Optimisation of time between radiation and γH2AX quantification. 
In order to determine the most appropriate time point at which to quantify γH2AX after 
test irradiation the kinetics of γH2AX induction and disappearance after 0.4Gy were 
examined. PBLs were isolated from a freshly drawn venous blood sample and resuspended 
at 2x105 cells per ml in RPMI/1%FCS, divided into two 15ml Polypropylene tubes. The 
tubes were gassed with 5%CO2/air and incubated at 37oC for 30 minutes. A sample was 
taken from each, centrifuged onto glass slides, fixed and used as a baseline control. The 
tubes were then gassed again and one tube was then exposed to 0.4Gy gamma irradiation 
whilst the other was mock irradiated. Both tubes were then returned to the incubator and 
retained at 37oC. Samples taken from each at 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 
and 24 hours. At each sampling point the tubes were re-gassed with 5% CO2/air. The 
samples were centrifuged onto glass slides and fixed. Immunocytochemical staining for 
γH2AX was performed and foci quantification carried out. The experiment was repeated 
three times on 3 separate occasions each time using freshly drawn blood from the same 
healthy volunteer (Subject 2). At each time point the results from the non-irradiated 
controls were subtracted from the results from irradiated samples to account for any 
increase in background γH2AX formation that may have occurred as a result of cell 
separation and with time in PBLs once isolated from whole blood and stored in vitro. 
 
Results: 
The results for all 4 quantification techniques are shown in Figure 4.9. Significant non-
specific background staining made quantification of γH2AX foci difficult both by manual 
counting and using the modified computer count. In one experiment the non-specific 
background staining was so severe that image analysis was abandoned and no data was 
obtained. For the other two experiments, the results from the foci counting both manually 
(A) and using the computer method (B) were extremely variable.  The computer count was 
especially variable as very small “speckles” of background staining were automatically 
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counted and varied between different slides. This problem was resolved to some degree by 
incorporating mean focus area (C) into the modified computer method – the speckled 
“foci” which were due to non-specific background staining tended to be small whilst the 
irradiated cells on visualisation clearly contained larger foci presumed to be true γH2AX 
foci. By plotting the mean FITC coverage per cell against time a clearer picture of the 
kinetics of γH2AX emerges (D) but must still be interpreted with caution due to the 
paucity of available data points. 
 
The mean FITC coverage per cell increases rapidly after irradiation with 0.4Gy, peaks at 1 
hour and falls following this, returning to background level by 6 hours post radiation dose. 
Non-linear best fit modelling using the method of least squares (GraphPad Prism software)  
of the kinetics of loss γH2AX as measured by mean FITC coverage per cell suggests that 
γH2AX loss fits with the kinetics of one phase exponential decay (Figure 4.10.)  Half life 
of γH2AX loss according to this model is 1.74hours (95% CI 1.11 to 3.99 hours).  
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Figure 4.9 Kinetics of γH2AX focus induction and loss in human PBLs following 0.4Gy 
γ-irradiation in vitro (microscopy). 
Each experiment was repeated three times. No data was available from the third repeat due 
to extremely inconsistent staining and severe background staining so that analysis not 
possible. Mean +/- SD from 2 experiments shown in graphs. 
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Figure 4.10 Modelling of the kinetics of γH2AX loss 
Non-linear modelling of the kinetics of γH2AX loss - the loss fits with a model of one 
phase exponential decay (R2=goodness of fit value).  
 
4.3.3 Determination of the most precise method for focus quantification by 
microscopy - intra-sample precision 
A certain amount of variability in results of any assay will naturally occur when a sample 
is tested repeatedly. Variability is affected by operator technique, environmental 
conditions, and the performance characteristics of the assay method. The degree of 
fluctuation in the measurements is indicative of the “precision” of the assay. A high 
performance assay should be precise with concordance of results from repeated assays on 
the same blood sample (intra-sample precision) and from repeated assays on different 
samples from the same individual if the characteristic being measured by the assay is fixed 
(inter-sample precision). 
 
It was clear that technical difficulties were resulting in inconsistent staining for γH2AX 
and high levels of background staining. In order to quantify the variation in assay results 
due to these technical problems and any other influencing factors, and to determine the 
most precise method for γH2AX focus quantification, intra-sample and inter-sample 
precision was measured for all 4 methods of focus quantification.  
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100x 
mean
SDCV =
The coefficient of variation (CV) is the standard statistical tool used for the comparison of 
variability in non-identical data sets (e.g. where the assay end points are measured in 
different units). If data sets are not identical variability must be expressed as a relative 
rather than an absolute measure in order to allow comparison. This is accomplished by 
expressing the standard deviation (SD) as a percentage of the mean – i.e. calculating the 
coefficient of variation (CV).  
     
 
In order to measure the intra-sample precision for each assay method, PBLs from the same 
blood sample were divided into 3-4 aliquots and each aliquot analysed in parallel on the 
same day.  
 
To avoid simultaneous handing of large number of samples, a single time point (30 
minutes) post irradiation was chosen as an end point for the measurement of intra-sample 
precision for all 4 methods of γH2AX focus quantification rather than a full assessment of 
γH2AX kinetics. 30 minutes was chosen because it was clear from the kinetics 
experiments that there would be a reasonable amount of γH2AX focus induction at this 
time after irradiation, but not so much as to result in the coalescence of foci that made 
manual and computer focus quantification more difficult. 
 
To try to minimise non-specific background staining both the primary and secondary 
antibodies were titrated to the lowest possible dilution that still resulted in γH2AX staining 
The same batch of both primary and secondary antibody were used throughout. All 
incubations were performed in a humidified chamber to prevent drying out of samples 
which may have unpredictably affected staining quality, and all preparation and stages 
involving the FITC-tagged secondary antibody were performed in a darkroom. The 
timings for all steps in the procedure were accurately measured. Digital images were 
captured using same exposure and brightness settings throughout and images thresholded 
at the same level.  
 
A single fresh peripheral whole blood sample was collected from a volunteer subject. CD4 
and CD8 positive PBLs were isolated using  immunomagnetic beads and cells resuspended 
in RPMI/1%FCS at 20,000 cells/ml. 1ml of cell suspension was  transferred into each of 
three pairs of 15ml Polypropylene tubes. Each tube was gassed with 5% CO2/air and 
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incubated at 37oC for 30 minutes. One tube in each pair was irradiated with 0.4Gy whilst 
the other was mock-irradiated. The tubes were then incubated at 37oC for 30 minutes 
before 0.5ml from each sample was taken for fixing, staining and analysis. 
 
This experiment was repeated 6 times using fresh blood samples from four different 
volunteers. The coefficient of variation was calculated for each experiment and the mean 
coefficient of variation for each method of focus quantification calculated (Table 4.1). 
 
Table 4.1 Coefficients of Variation (%) for intra-sample repeats – γH2AX 30 minutes 
after 0.4Gy 
Quantification 
technique 
 
 
 
Subject 
5 
(run 1) 
n=4 
Subject 
3 
(run 1) 
n=4 
Subject 
2 
(run 2) 
n=3 
Subject 
3 
(run 3) 
n=3 
Subject 
5 
(run 3) 
n=3 
Subject 
6 
(run 3) 
n=3 
Mean CV 
for each 
technique 
Manual count 
 
 
16.21 18.49 6.10 
 
4.23 7.72 5.29 9.673% 
Computer 
count 
 
15.28 15.81 7.77 10.51 4.54 6.96 10.15% 
Mean focus 
area 
 
30.24 15.93 9.45 21.34 8.56 7.89 15.57% 
Mean FITC 
area 
per cell 
43.24 26.38 4.86 25.99 13.01 15.05 21.42% 
 
 
Intra-sample precision was highest (lowest CV) for manual and computer foci counting. 
There was higher variability in the mean focus area and this variability was compounded 
in the multiplication required to calculate the mean FITC coverage per cell. 
In order to determine the extent to which operator technique may be influencing assay 
precision the CV for each technique was plotted for each of the dates when the precision 
testing was performed, operator experience increasing with each run. (Figure 4.11) 
Assay precision does appear to improve with time. Given that the same reagents and same 
techniques were employed throughout it would seem likely that assay precision improves 
with increasing operator experience.  
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Figure 4.11 Coefficient of variation (mean +/-SD) for intra-sample γH2AX quantification 
with increasing operator experience. 
 
4.3.4 Inter-sample precision. 
An individual’s normal tissue radiosensitivity is thought to genetically based and therefore 
should be constant over time. An assay purporting to measure radiosensitivity should 
therefore give a consistent result when repeated over time in the same individual i.e. there 
should be inter-sample precision. Lack of inter-sample precision would suggest that the 
assay is subject to interference by technical or environmental factors during the assay 
procedure, or confounded by interfering biological factors within the individual which 
vary over time. 
 
In order to assess inter-sample precision the assay was repeated on 5 occasions over 4 
months ( i.e. at approximately 3 weekly intervals)using freshly drawn blood samples from 
the same individual (Subject 2) and assessment of inter- sample variation in assay results 
performed. 
 
On each occasion blood samples were handled identically. The same batch of reagents and 
primary and secondary antibody were used each time, and there was strict adherence to the 
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immunostaining protocol. Images were captured on same microscope and the settings for 
image capture were the same for each assay. 
 
The individual concerned was a healthy volunteer who admitted to no regular or one off 
medications at the time of sampling or any concurrent illness over the study period. The 
subject was not fasted before blood sampling. 
 
Results. 
 
Table 4.2 Inter-sample variability in a single volunteer over 5 experimental runs  
 
 
Manual 
count 
Computer 
count 
Mean focus 
area 
(pixels) 
Mean FITC coverage 
per cell (pixels) 
Run 1 5.09 4.94 18.67 95.76 
Run 2 6.56 4.28 22.01 99.02 
Run 3 2.29 -2.52 20.13 310.61 
Run 4 8.46 8.07 29.54  237.20 
Run 5 3.94 1.71 12.52 21.37 
CV 
(%) 
45.07% 119.91% 29.88% 77.06% 
  
For all 4 assay parameters assessed there was considerable variability in assay results with 
the coefficient of variation ranging from 29.88% at best for mean focus area to 119.91% at 
worst for the computer count. 
 
To try to ascertain whether this variability was due to systematic drift in assay results (e.g. 
as might occur if any reagent was becoming degraded such as FITC-tagged secondary 
antibody fading if repeatedly exposed to light), or if variability was secondary to random 
error or lack of precision or consistency in assay technique, the values for each assay 
parameter were plotted against time with the mean value for all 5 repeats marked on the 
same graph. (Figure 4.12) 
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Interpretation is somewhat limited by the lack of data points available (in clinical 
laboratories at least 20 data points would be required for Quality Control purposes). 
However, for each assay parameter there appears to be random dispersion of values around 
the mean and no clear trend to suggest a systematic drift of assay results upwards or 
downwards with time. 
101 
 
Manual count
Ru
n 
1
Ru
n 
2
Ru
n 
3
Ru
n 
4
Ru
n 
5
0
2
4
6
8
10
Mean of all 5 runs
M
ea
n
 
n
u
m
be
r
γγ γγH
2A
X
fo
ci
 
pe
r 
ce
ll
Computer count
Ru
n 
1
Ru
n 
2
Ru
n 
3
Ru
n 
4
Ru
n 
5
-5
0
5
10
Mean of all 5 runs
M
ea
n
 
n
u
m
be
r
γγ γγH
2A
X
fo
ci
 
pe
r 
ce
ll
Mean focus area
Ru
n 
1
Ru
n 
2
Ru
n 
3
Ru
n 
4
Ru
n 
5
0
10
20
30
40
Mean of all 5 runs
M
ea
n
γγ γγH
2A
X
fo
cu
s 
a
re
a
 
(p
ix
el
s)
Mean FITC coverage per cell
Ru
n 
1
Ru
n 
2
Ru
n 
3
Ru
n 
4
Ru
n 
5
0
100
200
300
400
Mean of all 5 runs
M
ea
n
 
FI
T
C
 
co
v
er
a
ge
 
pe
r 
ce
ll
(p
ix
el
s)
 
Figure 4.12 Inter-sample variability - assay results plotted against time for 5 assay repeats 
over 4 months using fresh blood samples from the same individual to assess for systematic 
drift in results over the study period 
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4.3.5 Assay failure rate  
If any assay is to be useful in influencing clinical practice there must be a high probability 
of obtaining a result when a sample is sent to the laboratory for analysis. Clinical decisions 
regarding treatment must be made rapidly and cannot be delayed whilst repeat samples are 
re-analysed because of previous assay failure.  
 
In 3 out of 18 assay runs performed no useful data could be obtained due to high 
background staining on one occasion, and patchy and inconsistent staining on the other. 
The assay failure rate was therefore 16%.  
 
4.3.6 Time taken to obtain assay results. 
Blood sampling to collation of data from image analysis took a minimum of 3 working 
days. The kinetics experiments took considerably longer due to the larger number of 
samples and therefore images that required analysis.  
Day 1:  PBL isolation, irradiation and fixation (6 hours work, intensity dependent 
on number of samples being handled simultaneously) 
Day 2:  Immunostaining – (5 hours work, intensity again dependent on number of 
samples) 
Day 3 - 5:  Image acquisition and analysis – (image acquisition 3 hours, analysis and 
collation of data 5-20 hours depending on number of samples) 
 
4.3.7 Inter - individual variation. 
Insufficient data was generated to make any meaningful comparisons of γH2AX focus 
induction between individuals. 
 
4.4 Discussion 
The above evidence demonstrates that it is possible to induce and detect γH2AX using 
immunofluorescence staining technique in human PBLs irradiated in vitro.  
Foci number and area increased linearly with dose between 0-1 Gy in freshly isolated 
human PBLs. A linear dose response for γH2AX induction for dose below 1Gy has 
previously been reported in other experimental studies. A linear dose response between 
0.001 and 2Gy was demonstrated for the human fibroblast cell line MRC-5 when γH2AX 
foci were counted by eye (Rothkamm and Lobrich 2003). Olive and co-workers reported a 
linear dose response in various cell lines irradiated in vitro when  γH2AX induction was 
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analysed by flow cytometry (MacPhail, Banath et al. 2003; Olive and Banath 2004) 
Similar findings were reported when examining γH2AX foci number in human skin 
irradiated between 0Gy and 1Gy in vivo and then biopsied (Qvarnstrom, Simonsson et al. 
2004). 
 
Interpretation of the data regarding the kinetics of γH2AX focus induction and 
disappearance is limited due to the fact that data was only available from 2 experiments 
and there were significant difficulties in accurate focus quantification due to background 
staining. The peak of γH2AX induction appears to be at 1 hour post irradiation with rapid 
loss of γH2AX following this with a half life of between 1 and 4 hours.  
 
 Published data on γH2AX kinetics after irradiation has shown that the peak level of 
γH2AX in cell lines is observed earlier than this, at 10-30 minutes after irradiation 
(Rogakou, Pilch et al. 1998; Rogakou, Boon et al. 1999; Olive and Banath 2004) although 
high levels are still seen at 1 hour in some cell cultures, tumour xenografts and normal 
mouse tissues (Olive and Banath 2004). The half life of γH2AX loss is reported as 
between 2-7.6 hours in irradiated mouse tissue depending on tissue type, and the same 
authors report a half life of 3 hours +/-0.6hours for γH2AX loss in human lymphocytes 
when analysed by flow cytometry although further information regarding this or 
experimental details were not included in the relevant paper (Olive and Banath 2004). The 
limited data available from this study would be consistent with this figure.  
 
Limited data makes modelling of the kinetics of γH2AX loss difficult – loss may be 
exponential and computer-modelled curve fitting would fit with this. However, the lack of 
and unreliability of data points makes firm conclusions about modelling the kinetics of 
γH2AX loss impossible based on this data. 
 
Throughout the experiments significant problems were encountered with unpredictable 
non-specific background staining which made focus quantification difficult and on two 
occasions impossible. At the other extreme, in one experiment immunofluorescent staining 
was extremely patchy and only a few cells could be reliably scored and no meaningful data 
obtained. This was despite careful titration of both primary and secondary antibody to the 
lowest required concentration and strict adherence to technique. There was no clear 
evidence that complete experimental failure was more common at the beginning of the 
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study period whilst the technique was being learned and refined – 2 out of the 3 failures 
occurred towards the end of the study period. Although the exact causes of assay failure 
were not determined it is likely that they were due in part at least to operator inexperience 
and failure rate may have decreased if the study had continued. 
 
The time from tissue sampling to result of 3-5 days with this technique compares 
favourably with other techniques previously investigated as predictive assays of normal 
tissue toxicity – if γH2AX kinetics were demonstrated to predict normal tissue toxicity 
assay results could be produced within a clinical useful time frame. It should be noted, 
however, that the actual assay procedure and digital image analysis using these methods 
are very labour-intensive. 
 
There is no generally accepted definition of an acceptable CV for an assay’s intra sample 
variability but as intra-sample variation is due entirely to experimental error clearly this 
should be as small as possible. Manual count and computer count result in the lowest intra 
–sample coefficient of variation but all methods resulted in CVs of approximately 10% or 
above. Sources of intra-experimental error may be due to failure to mix reagents 
thoroughly, slight differences in incubation and washing times and possibly differential 
photo-bleaching during image capture. Only 100 cells per assay are analysed which also 
increases the chance of random error There is evidence that for all methods of focus 
quantification assay precision improved with time presumably due to increasing operator 
experience.. Whether this is due to improved consistency in the immunostaining procedure 
or more consistent analysis of foci on digital images is not clear. If microscopic 
quantification of γH2AX were to be continued ongoing repeat testing of intra-sample 
precision would be required to ensure this is a consistent improvement for quality control 
purposes. The fact that operator experience might influence assay results means that 
appropriate operator training and an assessment of inter-observer variability in digital 
image analysis scoring would be required before results from different operators could be 
comparable if the assay was to be performed by more than one operator in the same 
laboratory or in different laboratories. 
 
Inter-sample variation was high for all quantification techniques. The CV for the computer 
count was particularly high (119%) due to difficulty scoring the second experiment due to 
high background staining which actually led to a negative number once the results from 
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the control sample had been subtracted. Other cell-based assays of radiosensitivity have 
reported much lower inter-sample CVs of 2.5-40% (median 15%) as reported in Section 
3.1.6.  
 
Inter-sample variation may be due to underlying poor assay precision as well as   random 
technical factors such as unexpected changes in laboratory temperature or lighting, or 
inconsistencies in laboratory technique. Variability in results between samples may also be 
due to systematic error such as a sustained seasonal rise or fall in laboratory temperature, 
or the degradation over time of one of the assay reagents.  Examining the plot of assay 
results against time in Figure 4.12, the assay results seem to be randomly dispersed around 
the assay mean and there is no clear evidence of a systematic drift in assay results with 
time. It would be reassuring to have more data points on this graph to confirm this.  
 
Another possible source of inter-sample variability is real biological differences over time 
in the volunteer giving the blood sample. Biological factors that might affect γH2AX 
induction are unknown. They may conceivably include a change in the level of dietary 
antioxidant intake, infection, medications, alcohol and smoking. The subject in whom 
inter-sample variation was measured did not smoke or take medications and denied any 
concomitant viral infections. Dietary intake was not monitored, however. There is 
evidence that increased dietary antioxidant intake reduces in vitro oxidative DNA damage 
in isolated human PBLs  (Thompson, Heimendinger et al. 1999; Gill, Haldar et al. 2004; 
Gill, Haldar et al. 2007; Maffei, Tarozzi et al. 2007)and given that ionising radiation 
generates DNA DSB at least in part via reactive oxygen species it is possible that a 
fluctuating dietary intake of antioxidants may influence in vitro γH2AX induction in PBLs 
in an individual over time. It would be difficult to study biological effects on γH2AX 
induction in human PBLs without first improving assay precision and reducing variability 
due to any technical factors likely to be the source of inter-experimental variation. 
 
Inconsistencies in staining technique and assay throughput could be improved with the use 
of a fully automated immunostaining facility. Automated systems for 
immunocytochemistry are commercially available and have an established role in 
histopathology laboratories resulting in fully automated, rapid and reproducible staining 
with virtually no background (e.g. DAKO). An automated system therefore may play a 
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role in improving the precision of any assay of γH2AX foci and would help speed the 
throughput of multiple samples if such as assay was being tested in a patient population. 
 
Another major source of imprecision is the analysis of the digital images taken in this 
study. The sophistication of image analysis was limited by the technological capabilities of 
available software. To try to maintain consistency images were all taken using the same 
camera settings and threshold settings. To set a threshold is a way of extracting objects 
from an image where the threshold is the grey level chosen to separate the objects of 
interest from the background, resulting in a binary image. Increasing the threshold level 
when background staining was problematic would have resulted in decreased back ground 
interference on the image to be analysed, but would have potentially also reduced 
sensitivity for detecting γH2AX foci.  
 
Scoring was labour-intensive which meant that it was only realistic to score 100 cells per 
sample resulting in an increased susceptibility of results to Type 2 error.  
 
Qvarnstrom and colleagues have a more sophisticated method of digital image analysis to 
allow quantification of γH2AX foci in irradiated human skin biopsies (Qvarnstrom, 
Simonsson et al. 2004). The aim of digital image analysis was to transform the γH2AX and 
DAPI images each containing approximately 60 cells and obtained manually via a digital 
camera mounted on a fluorescence microscope, into binary images from which the number 
of foci could be counted. Qvarnstrom employed mathematical technique used in digital 
image analysis technique called “a feature-enhancing top hat transformation” before 
setting the threshold for image analysis. This step results in subtraction of background 
interference and extracts foci clearly from an uneven background. A common threshold 
can then be set which detects foci in all of the cells being examined. The top-hat 
transformation effectively increases sensitivity and specificity of γH2AX focus detection. 
The group then scored images using a fully automated system scoring 2000 cells for each 
sample with each sample being scored in 30 minutes. The group implemented their image 
analysis methods as Java TM plug-ins to pre-existing image analysis software.  
 
Bocker and Iliakis (2006) have also recognised the disadvantages of manual focus scoring 
in γH2AX focus quantification describing it as tedious, unreliably, subjective and error-
prone and requiring substantial training. They have derived a personal computer-based 
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algorithm for automated focus analysis based on immunofluorescent staining, confocal 
laser scanning microscopy and computerised image analysis. It too involves a top-hat 
transformation and operates as a utility on commercially available software can also be 
extended to images acquired on a digital camera. As well as allowing focus quantification 
to be performed in large number of cells in a consistent and reproducible manner 
uncompromised by investigator introduced biases, it can also correct for focus overlap and 
measure the integrated optical density of each focus. This increases linearly with radiation 
dose and may be a biologically significant parameter.  
 
In conclusion,  
• Quantification of γH2AX foci by microscopy in irradiated human peripheral blood 
lymphocytes is technically possible. 
• Quantification is imprecise and unreliable using the available laboratory facilities 
and software 
• The intensive labour demands, lack of reliability and imprecision would render this 
technique impractical for examining γH2AX kinetics in a large numbers of clinical 
samples without consideration of automation of staining and image analysis to 
improve assay reliability, precision and throughput.  
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5. Quantification of γH2AX in human peripheral blood lymphocytes by 
flow cytometry. 
 
Given the poor assay precision and reliability demonstrated for γH2AX quantification in 
PBLs using microscopy, an alternative technique for quantification of the signal from cells 
after immunofluorescent staining for γH2AX was sought. One of the groups who had 
shown a relationship between the kinetics of γH2AX induction and loss and cellular 
radiosensitivity had measured the signal from FITC-tagged anti-γH2AX using flow 
cytometry (MacPhail, Banath et al. 2003; Banath, Macphail et al. 2004; Olive and Banath 
2004). 
 
Flow cytometry is a system for measuring and analysing the signals that result as particles 
flow in a liquid stream through a beam of light (Givan, 2001). A flow cytometer contains: 
 
1) A light source (laser) and a means of focussing the light source. 
 
2) A fluidics system - Fluid lines and controls to direct a liquid stream containing the 
particles through the focussed light beam 
 
3) An electronic network for detecting the light signals coming from the particles as 
they pass through the light beam and then converting the signals to numbers that 
are proportional to light intensity (photodetectors, photomultiplier tubes, and 
amplifiers) 
 
4) A computer for recording the numbers derived from the electronic detectors and 
then analysing them. 
 
With appropriate permeabilisation procedures flow cytometry can provide a means of 
analysing intranuclear proteins such as γH2AX by running immunofluorescent stained 
cells through the cytometer to measure fluorescence intensity. Under good conditions 
fluorescence intensity should be related to the amount of intracellular protein present 
(Givan, 2001). The flow cytometer is useful at comparing intensity of different cells, but 
not so good at providing absolute value for light intensity it measures. Fluorescence is 
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therefore best expressed as a ratio of the fluorescence intensity of one cell population 
compared to another analysed at the same time. McPhail et al express γH2AX staining as a 
normalised fluorescence ratio i.e. the ratio of fluorescence in irradiated cells to 
fluorescence in non-irradiated controls (MacPhail, Banath et al. 2003).  
 
In flow cytometry it is possible to select out a cell population according to scatter 
characteristics and carry them forward for analysis – this is called "gating". A cell’s 
forward and side scattering of light as it passes through the cytometer is determined by its 
size and intracellular complexity. Gating employed effectively using light scattering 
profiles can isolate lymphocytes from within a mixed population of cells from peripheral 
blood being run through the cytometer. Once experienced gating can be done by eye but 
confirmed with immunofluorescent phenotyping of the gated cells to confirm that the 
correct cell type is being analysed.  Gating is one of the most powerful aspects of flow 
cytometry – it needs to be as objective as possible but there is unavoidable subjectivity in 
selecting the correct population for analysis from a forward and side scatter dot-plot 
(Givan, 2001).  
When compared to immunostaining and foci quantification by microscopy, flow cytometry 
has immediately apparent advantages and disadvantages: 
 
Advantages –  
1) Cells are analysed in suspension and therefore obviates need to fix cells to glass 
slide. 
2) Gating can select out lymphocytes from any other cell types contaminating samples 
3) Fluorescence quantification is objective  
4) Ten thousand cells can be analysed  in a few minutes 
5) After irradiation and fixation cell samples can be stored before immunostaining and 
analysis 
 
Disadvantages –  
1) Requires a flow cytometer and relevant expertise in its operation. 
2) Requires many more cells for analysis than microscopy. 
3) Cannot give information about individual foci (e.g. area) in individual cells 
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5.1 Development of basic technique for flow cytometric analysis of γH2AX 
staining in human PBLs. 
 
5.1.1 Lymphocyte isolation from whole blood 
In order to generate statistically valid results the signal from 10 000 cells per sample 
analysed is usually measured in flow cytometry. For any radiation dose or time point after 
irradiation being investigated 4 samples must be prepared – irradiated and non-irradiated 
cells stained for γH2AX, along with irradiated and non-irradiated cells stained with the 
secondary antibody only to correct for non-specific background staining of the secondary 
antibody and any differences in cellular autofluorescence. Therefore for an experiment 
examining the kinetics of γH2AX induction and loss after irradiation a minimum of 40,000 
cells are required for final analysis for each time point. To account for approximately 50% 
cell loss during staining and washing procedures at least 100,000 cells would be required 
for each time point of γH2AX kinetics experiments (7x105 – 1x106 for the 7 time point 
kinetics experiment performed for the microscopy study). 
 
The mean yield of PBLs from whole blood using the immunomagnetic bead isolation 
technique was 20-40,000 per ml. Using this technique to isolate PBLs for flow cytometry 
would require 25ml of blood per kinetics assay and a prohibitively large quantity of the 
immunomagnetic bead separation kit. Using immunomagnetic bead separation for this 
quantity of blood would also require simultaneous handling of large number of tubes and 
take a considerable length of time. A more time and cost effective and high yielding 
method of cell isolation was sought. 
 
A well known technique for mononuclear cell separation from anticoagulated whole 
peripheral blood is the centrifugation of whole blood through a liquid density gradient 
medium, the most commonly used medium being Ficoll 400 with sodium metrizonate or 
sodium diatrizoate (Boyum 1968; Fotino, Merson et al. 1971; Ting and Morris 1971).  
This technique involves dilution of the blood sample in a buffered solution, careful 
layering on top of the density gradient medium and then centrifugation, which isolates the 
mononuclear cells above the medium. The cells are harvested by carefully pipetting them 
from the above the interface with the medium.  
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BD Vacutainer Systems have used this technique to develop the BD Vacutainer Cell 
Preparation Tube (CPT). This combines a blood collection system containing citrate 
anticoagulant with a Ficoll Hypaque density fluid and a polyester gel barrier which 
separates the two liquids. Blood is collected directly into the tube during venepuncture and 
the tube is centrifuged. During centrifugation the mononuclear cells become separated 
from the denser blood components by virtue of the Ficoll gradient and the gel then moves 
to form a barrier between the mononuclear cells and other blood components to prevent re-
mixing. The tube is a convenient system for the collection of whole blood and separation 
of mononuclear cells. Samples can be transported after centrifugation without removing 
from the tube. Each tube has an 8ml draw capacity. 
 
The manufacturer reports recovery of 71% of mononuclear cells in peripheral blood using 
CPT tubes. Lymphocytes comprise 86% of the recovered cells which are 99.9% viable. 
The mean absolute mononuclear cell count from a 8ml blood sample is reported as 12.72 
x106   i.e. 1.59 x106 per ml of whole blood and 1.36 x106 lymphocytes per ml (BD 
Vacutainer Systems). Obviously the lymphocyte population will consist of mixed B and T 
cells rather than the pure CD4 and CD8 positive T cell population used in the focus 
quantification experiments. 
 
The cost and time advantages of using this system over immunomagnetic bead separation 
were felt to outweigh any potential disadvantages of using a mixed B and T cell population 
for γH2AX analysis.  
 
5.1.2 Immunostaining procedure and flow cytometric analysis 
The procedures for cell fixation and immunostaining was adapted from that of McPhail 
(MacPhail, Banath et al. 2003) and are described in Section 2.2.7.. After cell separation 
and irradiation cells were fixed in 70% ethanol and stored at -20oC for up to 15 days before 
the immunostaining procedure. 
Following immunostaining cells were analysed by flow cytometry according to the 
procedure outlined in Section 2.2.8. The mean fluorescence intensity of 10,000 cells was 
quantified for irradiated cells and their non-irradiated controls and the γH2AX induced by 
irradiation was expressed as the normalised fluorescence ratio (NFR) - the ratio of 
fluorescence intensity in irradiated compared to non-irradiated cells after correction for 
autofluorescence. 
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Prior to flow cytometric analysis the flow cytometer was checked using CaliBrite beads 
according to the procedure described in Section 2.2.10 
 
Immunophenotyping of the gated cell population confirmed that the cells analysed were 
CD45 positive confirming that they were leucocytes, andCD14 negative confirming that 
they were not monocytes. The cell population gated for γH2AX analysis contained a 
mixture of CD3 or CD19 positive cells confirming a mixed population of T and B 
lymphocytes although some cells with the FSC and SSC characteristics of lymphocytes did 
not stain for either CD3 or CD19. This may have been due to low affinity of the antibodies 
for the cell surface antigen after fixation, or to the presence of a non-B, non-T cell 
lymphocyte population, possibly natural killer cells (see Appendix 3).  
 
5.1.3 Quantification of the dose response relationship between γH2AX induction 
and increasing radiation dose by flow cytometry. 
In order to establish that a linear dose response relationship similar to that detected by 
visual quantification of γH2AX foci could also be detected by flow cytometry, and to 
determine a suitable test dose of radiation for examining γH2AX kinetics, a dose-response 
experiment was performed. PBLs were isolated from a fresh 8 ml venous blood sample 
collected from volunteer 6 and resuspended in RPMI/1%FCCS and divided between 8 x 
15ml polypropylene tubes. After 30 minutes incubation at 37oC they were irradiated with 
increasing doses of gamma rays (0, 0.2, 0.4, 0.6, 0.8, 1.0, 1.5 and 2.0Gy), returned to the 
incubator for 30 minutes, before centrifugation at 0oC and fixation and storage at -20oC. 
Samples were immunostained and analysed by flow cytometry. Following staining a 
sample from each was centrifuged onto glass slides, counterstained with DAPI and 
visualised by fluorescence microscopy to ensure than the cells had the same γH2AX foci 
staining characteristics seen previously during the focus quantification study. 
 
Results 
The  normalised fluorescence ratio (NFR) increases linearly with increasing dose between 
0 and 2 Gy corresponding to an increase in foci seen when the same cells are visualised by 
microscopy.  
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Figure 5.1 Dose response of γH2AX induction in human PBLs 30 minutes after γ-
irradiation in vitro. 
Each data point represents the mean +/- SD from 3 separate experiments using 
lymphocytes from same volunteer. Spearman rank correlation shows a statistically 
significant relationship between radiation dose and γH2AX induction as measured by the 
NFR (Normalised fluorescence ratio = fluorescence in irradiated cells/fluorescence in non-
irradiated cells) (Spearman R = 1.00, p<0.0001).  
 
0Gy          1Gy    2Gy 
Figure 5.2 Visual confirmation H2AX focus induction in samples analysed by flow 
cytometry 
The corresponding digital images of the same samples, cytospun onto glass slides after the 
immunostaining procedure, counterstained with DAPI and visualised by fluorescence 
microscopy (x100) confirm that discrete foci have been induced and detected after 
irradiation which increase in number with increasing radiation dose 
The plateau effect above 0.8Gy observed during quantification by microscopy is not 
present suggesting that quantification by flow cytometry is not saturable in the dose range 
examined. The slope of the dose response curve is shallower than that seen with direct 
114 
 
visual focus quantification suggesting that this technique is not as sensitive at detecting 
γH2AX induction after low doses of radiation e.g.<1Gy. There is a statistically significant 
difference overall in γH2AX levels observed following different radiation doses (Kruskall-
Wallis, p=0.0023) but direct comparison between different pairs of dose levels could only 
detect a statistically significant difference between non-irradiated cells and cells which had 
received 2Gy (p<0.05, Dunn’s multiple comparisons test). 2Gy was therefore used as the 
test dose of radiation for examining the kinetics of γH2AX induction and loss in 
subsequent experiments. This dose is the also the usual dose per fraction used in clinical 
radiotherapy schedules and there is therefore the potential to use a clinically relevant test 
dose of radiation in this assay.  
 
5.1.4 Kinetics of γH2AX induction and loss after 2Gy 
The kinetics of γH2AX induction and loss in irradiated human PBLs after 2Gy as 
measured by flow cytometry were examined. Potential endpoints for measuring γH2AX 
induction and loss which could be used in a predictive assay were assessed for 
reproducibility. 
 
A fresh peripheral blood sample (4x8ml CPT tubes) was taken from subject 2. The sample 
was immediately processed and isolated PBLs resuspended in RPMI/1% FCS at 1.5 x 
106/ml, divided into 13x15ml polypropylene tubes, gassed with 5% CO2/air and incubated 
at 37oC for 30 minutes. The cells in one tube were fixed to measure baseline γH2AX 
levels. 6 of the remaining tubes were irradiated (2Gy) and the other 6 were mock 
irradiated. All were then returned to the incubator and at each pre-specified time point 
irradiated and non-irradiated samples were fixed. All samples were stored at -20oC until 
immunostaining. Immunostaining of all samples from the same experiment was performed 
simultaneously and analysed by flow cytometry. The normalised fluorescence ratio was 
calculated for each time point. 
Kinetics of H2AX induction and loss were measured 11 times in subject 2. The pre-
specified time points for quantification of γH2AX were 0, 0.5,1, 2, 4, 6 and 24 hours.  
 
Results 
After the first 3 repeats of this experiment it became clear that 24 hours after irradiation it 
was not possible to gate a population of lymphocytes during flow cytometry. The 
FSC/SSC plot of the 24 hour sample consistently showed particles with a wide variability 
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in forward and side scatter characteristics and it was not possible to define a population for 
gating that gave a clearly discernable peak in green fluorescence. For the remaining 
kinetics experiments the 24 hour time point was omitted. 
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Figure 5.3 Kinetics of γH2AX induction and loss in human peripheral blood lymphocytes 
after 2Gy  
The mean and standard deviation for each time point are shown (n=11) 
 
γH2AX levels peak at 1 hour post irradiation, appear to plateau between 1 and 2 hours and 
then fall between 2 and 6 hours. Levels are still approximately 3 times greater than 
baseline at 6 hours after irradiation.  Insufficient number of time points makes it very 
difficult to ascertain the precise kinetics of γH2AX loss. The decrease in γH2AX between 
2 and 6 hours may either be occurring in a linear fashion (linear regression analysis, R2= 
0.7128, non-significant departure from linearity on runs test)   or be the early part of an 
exponential decay curve (non-linear best fit of one phase exponential decay curve, 
R2=0.7295). Assuming that γH2AX is lost in a linear fashion the half life for loss is 3.26 
hours (95% CI 2.944 to 3.582 hours). Using the exponential decay model, the half-life of 
γH2AX loss is 2.55 hours (95% CI 0.9836 to +infinity). 
 
5.1.5 Potential assay end-points for measuring γH2AX kinetics 
A diagnostic test needs a defined end-point to allow comparisons between individuals. 
Possible assay end points for describing the kinetics of γH2AX include: 
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• Area under the Curve (AUC) – this would give an integrated measurement of the 
effect of time on γH2AX levels after irradiation using data from all time points.  
• Half-life of γH2AX loss – Given the lack of time points for analysis calculating the 
half-life for γH2AX loss assuming exponential loss will be inaccurate if not 
impossible on data from individual experiments. Therefore, as a compromise, half 
life for γH2AX loss assuming a linear relationship between time and γH2AX levels 
between 2 and 6 hours and using the slope of the best fit line calculated by linear 
regression was investigated as a possible assay endpoint. The fact that this method 
of assessing γH2AX kinetics assumes a linear relationship which may not actually 
be present, and that the slope of a linear regression line is an mathematical estimate 
rather than a direct observation are both potential disadvantages of this method.  
• A more pragmatic endpoint based on direct observations and making no 
assumptions about the kinetics of γH2AX loss is the ratio of γH2AX peak levels 
compared to those at 6 hours.  
 
The half-life of γH2AX loss, peak:6 hour level of γH2AX and AUC of γH2AX kinetics, as 
well as the measured levels of γH2AXat each specified time point were assessed as 
potential assay endpoints, firstly by estimating their precision. 
 
Intra-sample precision   
Because cells isolated from a single blood sample can be stored after fixation it is possible 
to measure assay precision both within a single run and between runs of the 
immunostaining procedure for the same blood sample. 
 
It was inappropriate to take sufficient blood at one time from one individual to allow 
repeated measurement of γH2AX kinetics on a single blood sample. Therefore estimates of 
intra-sample precision were based on the ability of the assay to predictably and reliably 
quantify γH2AX levels at a single time point after radiation. The time point chosen was 1 
hour post irradiation when peak levels of γH2AX were demonstrated in subject 2. Intra-run 
and between-run precision were measured for PBLs isolated from the same blood sample. 
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a) Intra- sample precision (intra-run) 
A peripheral blood sample was taken from subject 2 (5X8ml CPT tubes). PBLs  were 
isolated and resuspended in RPMI/1% FCS at 1 million/ml. 4 million cells were  
transferred into each of 12 pairs of 15ml polypropylene tubes, gassed with 5%CO2/air and 
incubated at 37 oC for 30 minutes. One tube of each pair was irradiated with 2 Gy whilst 
the other was mock irradiated and all were incubated at 37oC for 1 hour before being 
cooled and fixed. The samples were stained for γH2AX and analysed by flow cytometry 
on the same day. The coefficient of variation was calculated as an estimate of within run 
intra- sample precision. 
 
b) Intra- sample precision (inter-run)  
A peripheral blood sample was taken from subject 2 – cells were separated and 
resuspended at a concentration of 1 million per ml in two separate 15ml polypropylene 
tubes gassed with 5%CO2/air and incubated at 37 oC for 30 minutes. One of each pair was 
irradiated and the other mock-irradiated and all were incubated at 37oC for 1 hour before 
being cooled and fixed. Fixed cells divided into 12 pairs of storage tubes (one irradiated 
and one control per pair). Three pairs of samples were analysed separately on 4 
consecutive days. 
 
Table 5.1 Intra-sample precision – mean results, standard deviation and coefficient of 
variation for flow cytometric quantification of γH2AX in human PBLs at 1 hour post 2Gy 
 Mean level γH2AX 1 hour 
post 2 Gy (NFR) 
Standard 
deviation 
Coefficient of 
variation 
Intra- run 
precision (n =12) 
8.13 0.69 8.41% 
Inter run 
precision. (n=4) 
5.872 0.66 8.74% 
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Figure 5.4 Intra-sample/inter run precision – mean and standard deviation for flow 
cytometric quantification of γH2AX in human PBLs at 1 hour post 2Gy from a single 
blood sample. 
Cells were isolated, irradiated and fixed on the same day but immunostained and analysed 
over 4 consecutive days. There was no statistically significant difference in results over the 
4 days (p= 0.0752, Kruskall-Wallis test) 
 
Inter-sample precision  
In order to measure  inter-sample precision for all potential assay end points γH2AX 
kinetics after 2Gy were measured in freshly collected human peripheral blood lymphocytes 
from the same volunteer on repeated occasions (n=11) over 12 months. The coefficient of 
variation for each potential assay endpoint was calculated. PBLs were isolated 
immediately from each blood sample with strict adherence to the protocols for irradiation, 
fixation, immunofluorescent staining and flow cytometric analysis throughout. After 
irradiation and fixation samples were stored for at -20oC for differing durations before 
analysis up to a maximum of 15 days. Subject 2 did not admit to any concurrent illness or 
taking any medication at any time over the study period. Diet was not assessed. 
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Table 5.2 Inter-sample precision for potential end-points of an assay of the kinetics of 
γH2AX induction and loss after in vitro irradiation in human PBLs. 
The mean NFR, 95% confidence intervals and coefficient of variation for 11 repeated 
measurements on the same individual over a 12 month period for each assay endpoint are 
given. 
 Mean 95% CI Coefficient of Variation 
γH2AX at 0.5 hour 7.23 6.23-8.21 20.26% 
γH2AX at 1 hour 9.91 8.88-10.95 15.55% 
γH2AX at 2 hours 9.34 7.82-10.84 24.14% 
γH2AX at 4 hours 5.46 4.53-6.39 25.32% 
γH2AX at 6 hours 3.22 2.62-3.82 27.83% 
Area Under Curve 33.44 28.41-38.47 22.39% 
Half-life of γH2AX loss (h) 3.26 2.94-3.58 14.55% 
Ratio peak:6 hour γH2AX 3.32 2.96-3.68 16.10% 
 
There was considerable inter-sample variability in results - the lowest variability, 
suggesting the best precision is for γH2AX levels at 1 hour, half-life of γH2AX loss and 
the ratio of peak levels to γH2AX at 6 hours. Inter-sample variation is higher than intra- 
sample-variation measured for γH2AX levels at 1 hour (15.55% vs. 8%). 
 
To ascertain if the inter sample imprecision of each assay end point was due to random 
error or a systematic drift in results over time, the results from each end point were plotted 
against the experiment repeat number and results examined for any evidence of a 
correlation between assay result and time.   
 
There was a statistically significant positive correlation between γH2AX levels at 2 hours 
after irradiation and the time in the study period (Spearman R 0.66, p=0.03, shown in 
Figure 5.5). For the other assay end points there appeared to be a trend towards increasing 
assay result over the sampling period, but the increase was not statistically significant. 
(Figure 5.5 and Table 5.3) 
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Figure 5.5 Change in γH2AX assay results in a single individual over the study period. 
Assay results are shown plotted against the day of the study period on which the assay was 
performed (first experimental run was performed on day 1)  
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Table 5.3  Relationship between assay results and time in a single individual over the 
study period (corresponds to Figure 5.5) 
 
Spearman rank correlation was used to test for any relationship between the assay results 
and timing of the experimental run within the study period for different end-points over 11 
repeats in a single individual over 12 months.  
 
 
 
  
Assay end-point 
γH2AX at fixed  time point after 
irradiation (hours) 
AUC Half-life 
γH2AX 
loss 
 
Ratio 
peak:6 
hour 
γH2AX 
0.5 1 2 4 6 
Spearman 
R  
0.54 0.33 0.66 
 
0.35 0.33 0.56 0.52 0.00 
p-value  
(two-tailed) 
0.09 0.33 0.03 0.30 0.33 0.07 0.10 1.00 
 
 
After cell fixation, samples for assessment of inter-sample precision were stored at -20oC 
before immunostaining and analysis. Duration of storage varied from 1-15 days. As all 
other parameters of the assay technique were standardised throughout the study period the 
possibility that duration of sample storage after fixation and before analysis may have 
affected assay results was examined. Duration of storage was plotted against assay result 
for each of the potential assay endpoints (Figure 5.6). There was no correlation between 
duration of storage and assay results for any of the end-points (Table 5.4) 
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Figure 5.6 Relationship between duration of storage of fixed samples and assay results 
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Table 5.4 Correlation (Spearman rank) between duration of sample storage at -20oC and 
assay results for potential assay end-points.(Corresponds to Figure 5.6) 
 
 
 
Assay end-point 
γH2AX at fixed  time point after 
irradiation (hours) 
AUC Half-life 
γH2AX 
loss 
 
Ratio 
peak:6 
hour 
γH2AX 
0.5 1 2 4 6 
Spearman R 0.30 0.20 0.05 0.42 0.13 0.26 -0.16 0.11 
p-value  
(two-tailed) 
0.37 0.56 0.87 0.20 0.70 0.43 0.63 0.74 
 
 
 
5.1.6 Assay practicality: 
The number of times it was not possible to determine a γH2AX level for any given pair of 
irradiated and non-irradiated samples was calculated to give an estimate of assay 
reliability. 1/86 pairs of irradiated vs. control samples over the course of the assay 
precision experiments failed, giving an assay-failure rate of 1.16% 
Assay results were available 2 working days following blood sample collection. Freezing 
of samples after irradiation and fixation meant that staining and flow cytometric analysis 
could be performed at convenient time. 
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5.1.7 Kinetics of γH2AX induction and loss in human PBLs after different radiation 
doses 
In order to determine if the kinetics of γH2AX induction and loss in isolated G0 human 
PBLs varied with applied radiation dose, γH2AX kinetics after 5, 10 and 20Gy were 
measured in freshly collected peripheral blood samples from the same volunteer 
(Volunteer 2). Each experiment was performed independently on different days and for 
each dose level was repeated between 2 and 4 times (Figure 5.7). The AUC, peak: 6 hour 
ratio and half-life were measured for each independent experiment and the presence of any 
relationship between resulting assay end-points and radiation dose was examined by 
Spearman rank correlation. The results from the previous experiments in the same 
volunteer examining the kinetics after 2 Gy were included in the analysis.  
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Figure 5.7  Kinetics of γH2AX induction and loss in isolated PBLs from a single 
volunteer following different test doses of in vitro irradiation 
Each data point represents the mean and standard deviation from between two (5Gy) and 
eleven (2Gy) independent repeats.  
 
At all of  the time points examined there was a trend to an increase in induced γH2AX 
levels with increasing radiation dose, but at no time point did this trend become 
statistically significant (Figure 5.8A and Table 5.5). A similar relationship was seen for 
AUC measurements (Figure 5.8B and Table 5.5). There was a suggestion that the dose-
response curves for these end-points was beginning to plateau at 20Gy. The end-points 
examining the kinetics of γH2AX loss (half-life and peak: 6 hour ratio) did not appear to 
correlate with increasing radiation dose (Figure 5.8A and Table 5.5). There was, however, 
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a statistically significant difference between peak: 6 hour ratio and half-life of γH2AX loss 
for different radiation doses (p=0.03, Kruskall-Wallis) with Dunn’s multiple comparisons 
test showing a significant difference between 5Gy and 10Gy but not between other 
radiation doses for both endpoints (p<0.05 for both),  
 
Table 5.5 Correlation between radiation test-dose and assay end-points.  Spearman R and 
p-values suggest that there is no relationship between radiation test dose and assay results 
for any of the assay end-points. 
 
 
 
 
Assay end-point 
γH2AX at fixed  time point after 
irradiation (hours) 
AUC Half-life 
γH2AX 
loss 
 
Ratio 
peak:6 
hour 
γH2AX 
0.5 1 2 4 6 
Spearman 
R 
1.00 1.00 1.00 1.00 1.00 1.00 0.60 -0.60 
p-value  
(two-tailed) 
0.08 0.08 0.08 0.08 0.08 0.08 0.42 0.42 
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Figure 5.8 Correlation of end-points of γH2AX kinetics experiments with in vitro test 
dose of radiation 
There was a non-significant trend for an increase in γH2AX levels at all time points (A) 
and the AUC of the kinetics curve (B). There was no clear relationship between measures 
of γH2AX loss and applied radiation dose (C) 
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5.1.8 Comparison of the kinetics of radiation-induced DNA double strand break 
repair and γH2AX induction and loss in human peripheral blood lymphocytes. 
The data presented in Section 5.1.7 illustrates that it is possible to use flow cytometry to 
measure γH2AX kinetics following a radiation dose of 20Gy. Quantification of DNA 
double-strand breaks (DSBs) by constant field electrophoresis is a relatively insensitive 
technique compared to γH2AX quantification and requires doses in excess of 10Gy to 
allow detection of DNA DSBs. Using flow cytometry to quantify γH2AX rather than foci 
therefore  allows simultaneous comparison of the kinetics of  γH2AX and DSBs in same 
cell population after the same radiation dose to test the assertion that γH2AX foci are 
equivalent to DNA DSBs and that loss of γH2AX foci equates to DNA DSB repair. 
 
Using the technique described in Section 2.2.11 DNA DSBs in isolated human peripheral 
blood lymphocytes (from Subject 2) were measured immediately after exposure to 
increasing doses of gamma irradiation (0, 10, 20 and 30Gy). This confirmed a linear dose-
response relationship with an increase in induction of DNA DSBs with rising radiation 
dose. (see Appendix 5). 
 
Peripheral blood was collected from volunteer 2 (8x8ml CPT tubes). The mononuclear cell 
fraction was isolated, washed and resuspended in RPMI/1%FCS. The cell suspension was 
transferred to a tissue culture flask and incubated at 37oC for 1 hour to remove the 
monocyte fraction. The cells were then counted and resuspended at a concentration of 
1x106 cell/ml in RPMI/1%FCS. 4 ml was transferred to each of 18 x 15ml Polypropylene 
tubes for the H2AX analysis (Set 1). 150 microlitres was transferred to another set of 18 
tubes for the DSB assay (Set 2), RPMI/1% FCS was added to all tubes to bring the volume 
up to 7ml. Each tube was gassed with 5% CO2 in air and incubated at 37oC for 30 minutes. 
The tubes were then cooled on ice. 9 tubes from each set were irradiated on ice (20Gy) 
whilst the non-irradiated controls were kept on ice. After irradiation one irradiated and one 
control tube from each set was kept on ice whilst the others were returned to the incubator. 
At the pre-specified time points one irradiated and one control sample from each set were 
cooled rapidly on ice and held on ice at 0oC until all time points had been reached. The 
tubes were then processed according to the usual protocols for each assay. The time points 
chosen were 0, 0.25, 0.5, 1, 2, 6, 18 and 24 hours following irradiation. The number of 
DNA DSBs and γH2AX as quantified by the normalised fluorescence ratio were plotted 
against time. The experiment was repeated 4 times. 
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Results 
As would be expected peak levels of DSBs were detected at 0 hours, immediately 
following irradiation and before any repair had occurred (Figure 5.9 A). The number of 
DSBs fell rapidly in the first hour after irradiation before plateauing between 2 and 6 hours 
and then rising again steadily at 18 and 24 hours after irradiation. At 24 hours the number 
of DSBs was higher than originally induced by irradiation. 
 
γH2AX levels rose rapidly following irradiation, peaking at 1 hour and then falling 
steadily in an apparent linear fashion between 1 and 6 hours. As previously experienced in 
the examination of γH2AX kinetics after 2 Gy, no clear cell population could be gated for 
analysis of irradiated cells at 24 hours. The same was also true at the 18 hour time-point. 
This was despite there being a definite cell pellet visible after centrifugation of sample 
tubes at all stages of sample preparation. 
 
In order to facilitate comparison of the kinetics of DSBs and γH2AX, both were plotted as 
proportions of their peak levels against time for the first 6 hours after irradiation (Figure 
5.10). 37% and 42% of DSBs had disappeared by 30 minutes and 1 hour after irradiation, 
with the proportion of DSBs repaired reaching a maximum of 57% at 2 hours after 
irradiation. In contrast the levels of γH2AX were rising rapidly over the first hour after 
irradiation whilst the numbers of DNA DSBs were falling. At 2 hours when the number of 
DSBs had reached its nadir, only 15% of the induced γH2AX had been lost. The 
proportions of DSBs and γH2AX remaining after irradiation only reached equivalence at 
4-6 hours after irradiation. 
 
Annexin-V staining and flow cytometric analysis of unfixed cells 24 hour after irradiation 
suggested that the proportion of cells undergoing apoptosis was significantly increased in 
irradiated compared to non-irradiated cells (Figure 5.11).  
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Figure 5.9 Kinetics of DNA double strand break formation and repair and γH2AX 
induction and loss in PBLs after 20Gy 
DNA DSBs as measured by constant field gel electrophoresis (A) with simultaneous 
measurement of γH2AX induction and loss by flow cytometry (B) in isolated human 
peripheral blood lymphocytes after in vitro irradiation (20 Gy). Each data point represents 
mean +/- standard deviation from 4 experiments. 
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Figure 5.10 Kinetics of DSB induction and repair and γH2AX induction and loss for the 6 
hours immediately post irradiation (20Gy) in isolated human peripheral blood 
lymphocytes. 
The values for each time point are expressed as the proportion of DSBs or γH2AX present 
compared to the peak level of each. The peak level was at 0 hours for DSBs and 1 hour for 
γH2AX. DSBs are falling as γH2AX is rising in the first hour following irradiation (see 
text). 
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A. Non-irradiated:
    FSCvs SSC + gated PBL population
B. 20Gy:
    FSCvs SSC + gated PBL population
C. Non-irradiated: Density plot
    Annexin -V(FL-1) vs PI (FL-3) staining
D. 20Gy: Density plot
    Annexin-V (Fl-1) vs PI (FL-3) staining
E. Non-irradiated:
    Histogram:Frequency and intensity of
   Annexin -V(left) and PI (right) staining
F. 20Gy:
    Histogram:Frequency and intensity of
   Annexin -V(left) and PI (right) staining
 
Figure 5.11 Apoptosis of isolated G0 human peripheral blood lymphocytes held in culture 
24 hours post irradiation (20Gy) 
 
Compared with the non-irradiated control (A), there is more small volume cell debris 
present in the irradiated sample but it is still just possible to gate a lymphocyte population 
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on the FSC/SSC dot plot (B). Density plots show that after 24 hours there is a discrete 
subpopulation of irradiated cells staining with FITC-labelled Annexin-V detected on the 
FL-1 channel (D) compared with the non-irradiated control (C). There is also increased 
staining with propidium iodide (PI) after irradiation (FL-2 channel) suggesting an 
increased number of non-viable cells. Frequency histograms for FITC-labelled Annexin-V 
(FL-1) show a discrete peak at a fluorescence intensity of 1x103 (F) which is not present in 
non-irradiated controls (E), confirming the presence of an Annexin-V positive and 
probably apoptotic cell population induced by irradiation. Frequency histograms of PI 
staining (FL-2) show a very small population of strongly PI positive and therefore non-
viable cells after irradiation only. 
 
5.1.9 Discussion 
Using immunofluorescent staining and analysis by flow cytometry, it is possible to 
measure the kinetics of γH2AX in PBLs after in vitro irradiation with a clinically relevant 
radiation dose. The assay is quick and the ability to store samples between irradiation and 
immunostaining means that it is more convenient than γH2AX focus quantification by 
direct visualisation by microscopy. Assay failure rate is low at 1.16%. 
 
It was disappointing that it was not possible to obtain data for γH2AX levels at 24 hours 
after irradiation. The FSC/SSC characteristics of the particles present in the irradiated 
immunostained samples after 24 hours suggests a population of varying sizes and likely 
represents cellular debris. Lymphocytes are susceptible to apoptosis so it is possible that 
cells were undergoing radiation apoptosis by 24 hours post radiation  - this would result in 
a mixed population of cells of varying sizes as cells shrink and break up into apoptotic 
bodies. The subsequent examination of the kinetics of DNA DSBs and γH2AX after 20Gy 
in section 5.1.8 again found it was difficult to consistently gate a lymphocyte population in 
fixed irradiated cells which corresponded to an increase in DNA DSBs and Annexin-V 
positivity suggesting that at least after 20Gy cells were undergoing apoptosis at 24 hours. 
 
The kinetics of γH2AX induction and loss between 0-6 hours after 2Gy including 
estimation of half life does seem to concur with published data from McPhail et al relating 
to cultured cells and murine normal tissues  and the reported half-life of γH2AX loss of 3 
hours in human PBLs (MacPhail, Banath et al. 2003; Olive and Banath 2004). It also 
corresponds with the limited data that was derived from γH2AX focus quantification by 
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microscopy where peak levels were seen at 1 hour The estimated half-life of γH2AX loss 
was longer in PBLs after 2 Gy analysed by flow cytometry (3.26 hours, 95% CI 2.94-3.58, 
Figure 5.3) than after 0.4Gy when analysed by microscopy (1.74hours, 95% CI 1.11 to 
3.99 hours, Figure 4.10). The half-life estimates from microscopy were based on only 2 
experimental repeats - the 95% confidence intervals are large and overlap with those 
obtained from measurement of half-life of γH2AX loss by flow cytometry so it is unlikely 
that a true significant difference in half-life exists. 
 
Intra- sample-intra- run precision is measured is 8.4%. Intra- sample-inter-run imprecision 
is similar at 8.74%. This suggests that this method of γH2AX quantification is more 
precise than by foci quantification by microscopy. However, these coefficients of variation 
would also suggest that despite following a strict protocol and using the same reagents on 
throughout there are still technical sources of variation in staining or analysis during an 
experimental run and between different experimental runs which lead to inconsistencies in 
results from different sample tubes containing the same sample. The cells in each of the 
different sample tubes were irradiated and fixed in the same batch before separation 
demonstrating that source of variability must be inherent in the storage and/or staining 
and/or flow cytometry analysis. As all samples in the intra-run experiments were treated 
with reagents (including primary and secondary antibody) from the same solutions, 
variation in results must come from small variations in the timings of antibody incubations 
and washings which result from having to handle several tubes at once (although all tubes 
were handled in the same order at each step), or variability at the analysis step, such as 
possible FITC fading in some samples whilst waiting for analysis. There is no clear way of 
accounting for these technical variations and improving intra- sample-intra--run precision. 
 
Intra- sample-inter run variation may have come from the same sources, with possible 
additional confounding by differing environmental conditions within the laboratory  on 
different days for the immunofluorescent staining procedure (such as change in 
temperature or light intensity) or day-to-day inaccuracies in antibody dilution. The other 
possible source of variation is the increasing duration of storage at -20oC over the 4 days 
of the experiment. Data points are limited but there is no clear evidence of a systematic 
drift in results to suggest that samples were degrading in the freezer during storage (Figure 
5.4). 
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There is significant inter-sample variation in results for all assay end-points when 
measured in a single individual over a 12 month period. The lowest inter sample 
imprecision occurs for assay endpoints which examine rate of γH2AX loss (half-life and 
peak: 6 hour ratio). Assays of γH2AX loss seem likely to be most important as potential 
predictive assays of normal tissue radiosensitivity given the correlations between H2AX 
loss and cell survival reported by Olive and MacPhail (MacPhail, Banath et al. 2003; Olive 
and Banath 2004) so the finding that these end-points appear to be the most precise is 
encouraging. Imprecision in measurements at the specific time points is high and this is 
reflected in high inter sample variability in AUC measurements which integrate results 
from all time points.  
 
There is evidence that there is a systematic upwards drift in measured  γH2AX levels after 
irradiation as the sampling period progressed which was statistically significant for the 2 
hour time point (Table 5.3 and Figure 5.5). This apparent systematic drift over time may 
reflect a systematic change in sample handing, irradiation, fixation, storage, 
immunostaining or flow cytometry analysis.  
 
The duration of exposure to radiation was constant throughout the 12 month period - the 
upward drift in results is not likely to be due to radioactive decay of the gamma-irradiation 
source which if anything would have decreased γH2AX induction over the sampling 
period.  
 
Two separate batches of both primary and secondary antibody were used over the 
sampling period – it is possible that differing binding affinities may have affected results 
but if this were the case this would be expected to result in a sudden step wise change in 
results when the batch was changed rather than the slow drift observed.  
Increasing operator experience resulting in faster processing of sample or decreased 
background staining should have been compensated for by the corrections derived from 
simultaneous analysis of non-irradiated and non-stained controls. The CPT tubes used 
throughout were from the same batch number and all were utilised within their expiry date. 
 
It is possible that there was a systematic drift in the performance of the flow cytometer. 
The optimal settings for fluorescence compensation may have changed in time resulting in 
“leaching” of any red fluorescence signal generated by the cells being mistakenly 
135 
 
measured as part of the green FITC fluorescence signal. Fluorescent bead calibration and 
compensation correction was performed when the cytometer was serviced. Recalibration 
and setting of fluorescence compensation parameters should perhaps have been performed 
more regularly perhaps even at the beginning of each experimental run, as would be 
standard with any machine being used in a clinical laboratory.    
 
Finally, there may have been a systematic biological change in the susceptibility to 
radiation DNA damage and response to DNA damage over time in Subject 2. Apart from 
the passage of time no other easily appreciated biological changes occurred in subject 2 
over the 12 month study period with no admission of new medication, illness, or change in 
diet or lifestyle. Background DNA damage as measured by the micronucleus assay does 
increase with increasing donor age (Ganguly 1993; Bolognesi, Abbondandolo et al. 
1997)but no relationship between donor age and response to in vitro irradiation has been 
found (Bishay, Ory et al. 2001). Whilst a biological reason for the systematic drift in assay 
results is possible, it seems less likely than a technical cause. 
 
As well as the systematic drift in assay results there is clearly random scattering of assay 
values over the sampling period which accounts for most of the assay imprecision between 
samples. As discussed in Chapter 4, this random variability may be due to inconsistencies 
in experimental technique or environmental conditions, or random biological variations in 
subject 2 that may influence assay results in an unpredictable fashion. The only obvious 
technical variation between handling of the different samples over the study period was the 
varied duration of storage of fixed samples at -20oC before immunostaining. However, 
there was no evidence of a correlation between length of sample storage and assay result 
for any end point examined (Table 5.4 and Figure 5.6).  
 
Comparison of the kinetics of γH2AX induction and loss after different radiation doses 
shows an increase in detected γH2AX with increased dose for all time points and a 
corresponding increase in AUC (Figure 5.8 A and B). Given that increased radiation dose 
results in an increased number of induced DNA DSBs (Appendix 5) this is not unexpected 
The fact that there is no statistically significant correlation between dose and γH2AX at the 
measured time-points or the AUC of the kinetics experiments as measured by Spearman 
rank correlation (Table 5.5) probably reflects the small number of data points on which the 
analysis was based. There is a suggestion that the dose response relationship for all time-
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points, and consequently the AUC, becomes less steep between 10 and 20Gy, possibly 
implying that the immunofluorescent quantification of γH2AX by flow cytometry is 
saturable at high radiation doses using this technique and these antibody concentrations.  
 
There is no clear relationship between radiation dose and the rate of γH2AX loss measured 
by half-life or the peak: 6 hour ratio (Figure 5.8 C), reflected in the Spearman R values of 
0.6 and -0.6 respectively (Table 5.5). The statistically significant difference between 5 and 
10 Gy for both end-points of γH2AX loss as detected by the Kruskall-Wallis and Dunn’s 
multiple comparisons test is probably due to the lack of data points for the 5 Gy data set 
which has generated a type 1 error. It seems unlikely that the half-life of γH2AX loss 
would significantly increase between 5 and 10Gy only to decrease again for 20Gy. It 
would therefore seem probable that the process of γH2AX removal proceeds at same rate 
irrespective of the initial “concentration” of γH2AX suggesting that the process of γH2AX 
removal had not become saturated at the doses examined.  
 
It is therefore possible to use flow cytometry to measure γH2AX kinetics at 20Gy, which 
is a dose sufficiently high to also allow simultaneous DSB quantification by constant-field 
gel electrophoresis. Simultaneous comparison of the kinetics of γH2AX and DSB 
induction and loss in same cell population after the same radiation dose is therefore 
feasible and can test the assertion that γH2AX foci are equivalent to unrepaired DNA 
DSBs (Rothkamm, Kruger et al. 2003; Rothkamm and Lobrich 2003; Lobrich, Rief et al. 
2005; Takahashi and Ohnishi 2005; Sedelnikova, Nakamura et al. 2007). From Figures 5.9 
and 5.10 it is clear that whilst the number of DSBs in irradiated cells is falling steeply 
between 0 and 1 hour after irradiation, γH2AX levels are rising. When the number of 
DSBs has reached a nadir at 2 hours, 85% of induced γH2AX remains. Equivalence in 
remaining proportions of DSBs and H2AX is only reached between 4 and 6 hours. This 
data would suggest that between 0 and 6 hours following irradiation, in G0 human 
peripheral blood lymphocytes at least, γH2AX levels do not equate to DSBs. This would 
be consistent with evidence suggesting that 53BP1/γH2AX foci do not correspond with 
DSBs in the first 24 hours following irradiation in human fibroblasts (Markova, Schultz et 
al. 2007) and that dephosphorylation of γH2AX and DNA DSB repair can be  independent 
phenomena (Antonelli, Belli et al. 2005)  or at least correlate only at very low radiation 
doses (Bouquet, F., C. Muller, et al. 2006).  
 
137 
 
In this study it was not possible to measure γH2AX in irradiated PBLs 24 hours after 
irradiation due to lack of a clear population in irradiated samples to gate during flow 
cytometry. This disappearance of an analysable cell population for γH2AX quantification 
corresponds to a marked rise in DNA DSBs between 6 and 24 hours in irradiated cells. At 
24 hours there is an increase in Annexin-V staining in irradiated PBLs compared to non-
irradiated cells suggesting that irradiated PBLs are undergoing apoptosis. This would 
explain the rising number of DSBs as DNA is cleaved during the apoptotic process. One 
would expect this to correspond to an increase in γH2AX (Rogakou, Nieves-Neira et al. 
2000) and it was disappointing not to be able to detect this. In non-fixed cells it was 
possible to gate a population for PBLs for analysis in the Annexin-V assay, albeit with 
more difficulty than in non-irradiated cells because of an increased amount of cell debris 
(Figure 5.11 B) The lack of a similar “gate-able” cell population in samples containing 
apoptotic cells prepared for γH2AX quantification and therefore fixed in ethanol may 
reflect a change in cell morphology induced by the fixation process which is pronounced 
in apoptotic cells and makes cells indistinguishable from debris on the FSC/SSC dot plot.  
 
If γH2AX is formed at the sites of DNA DSBs, but the break is actually already repaired 
by the time the phosphorylation of H2AX has occurred H2AX phosphorylation must have 
another role in DNA repair other than simply signalling an unrepaired break. γH2AX may 
act as a signal marking the site of a repaired DSB that may require “checking” to 
determine the fidelity of the repair process.γH2AX is then dephosphorylated once the 
checking process is over. The process by which γH2AX is removed from a cell after DNA 
repair is not completely understood. It does not appear to be due to removal of the whole 
molecule and is probably by in-situ dephosphorylation (Nazarov, Smirnova et al. 2003). 
The trigger for dephosphorylation is unknown. A residual γH2AX focus after irradiation 
may represent a non checked DSB rather than un-repaired DSB. H2AX null cells and mice 
can still repair DNA DSBs but are more prone to genomic instability and tumour 
susceptibility suggesting that H2AX may have a role in maintaining the integrity of the 
genome and reducing mutations resulting from inaccurate repair of DNA damage 
(Bassing, Chua et al. 2002; Bassing, Suh et al. 2003).  
 
How might this relate to the ability of the kinetics of γH2AX loss to predict radiation 
sensitivity of cell lines and normal tissues as previously reported? The ability of a cell to 
label a DSB and mark it for checking and the subsequent rate of fidelity checking and then 
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γH2AX dephosphorylation may determine how many unchecked DSBs are present in a 
cell at time of cell division. If a certain number of γH2AX foci marking non-checked 
DSBs are present the cell may undergo apoptosis rather than divide and produce 
potentially genetically damaged progeny. This is very much speculation  - the molecular 
mechanisms of DNA DSB repair are increasingly understood (Kobayashi, Iwabuchi et al. 
2008), but detailed information about the pathways and interactions of the molecular 
components of the process has not yet been elucidated.   
 
In conclusion: 
• Using flow cytometry it is possible to measure the kinetics of γH2AX induction 
and loss over the 6 hours following in vitro irradiation of isolated human PBLs. 
The intra- sample precision of one off measurements of γH2AX levels at 1 hour 
post irradiation is acceptable. 
• It is not possible to measure γH2AX in human PBLs 24 hours following irradiation 
due to loss of a discernable cell population for gating at flow cytometry. 
• A variety of possible endpoints for a predictive assay of normal tissue 
radiosensitivity can be derived from the kinetics data. Inter –sample precision is 
best for γH2AX at 1 hour (corresponding to peak γH2AX levels), half-life of 
γH2AX loss and the ratio of peak: 6hour γH2AX levels, but the coefficient of 
variation is moderately high for all end-points  
• The assay produces results in a clinically relevant timescale and has a low failure 
rate. 
• If utilised in a clinical study a strict programme of flow cytometer instrument 
calibration would be required. 
• γH2AX foci do not appear to equate to DNA DSBs in human PBLs at 0-6 hours 
following irradiation. 
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6. Inter-individual comparison of kinetics of γH2AX induction and loss 
in irradiated human peripheral blood lymphocytes. 
 
6.1 Introduction 
Further information on the reproducibility of assay endpoints can be derived by measuring 
and comparing intra-individual and inter-individual variation in assay results in a cohort of 
volunteers. Ideally inter-individual differences in assay results should exceed intra-
individual differences suggesting that the assay has sufficient precision and power to 
discriminate between individuals. 
A study of intra-individual and inter-individual variation in the kinetics of γH2AX 
induction and loss in irradiated human peripheral blood lymphocytes from healthy 
volunteers was therefore undertaken. 
 
6.2 Methods: a study of 8 volunteers. 
Eight volunteer subjects were recruited from within the department (Table 6.1.). The sex, 
smoking status and age of each participant was noted as smoking and increasing age have 
both been reported to affect background levels of DNA damage and repair capacity in 
peripheral blood lymphocytes and could represent potential confounding factors in assay 
results (Dhawan, Mathur et al. 2001; Bajpayee, Dhawan et al. 2002; Diem, Ivancsits et al. 
2002; Marcon, Andreoli et al. 2003; Fracasso, Doria et al. 2006; Hofer, Karlsson et al. 
2006). Peripheral blood samples were taken from each on three separate occasions. All 
blood samples were taken in morning within the department and were processed 
immediately. The kinetics of γH2AX induction and loss were measured for each sample 
after 2Gy according to the protocols described in Sections 2.2.6-2.2.9.  
 
The mean value and standard deviation for each potential assay end-point was calculated 
for each individual. One way ANOVA was performed for all potential assay end points to 
determine if there were any statistically significant inter-individual differences in assay 
results. Statistical comparison of results from males vs. females and smokers vs. non-
smokers were performed using an unpaired t-test, and results from volunteers aged <30, 
31-40 and >40 years old were compared by one way ANOVA. Intra- and inter-individual 
variations in assay results were compared by examining the mean squared values for the 
140 
 
ANOVA table for each assay end-point, and calculating the mean intra-individual and 
inter-individual coefficient of variation for each assay end-point 
 
Table 6.1 Basic demographics of the eight volunteer blood donors who participated in the 
study of inter-individual variation in γH2AX kinetics 
 
Subject 1 2 3 4 5 6 7 8 
Age 65 35 32 44 33 28 28 22 
Sex Male Male Female Female Female Female Female Male 
Smoker? No No No Yes No No No No 
 
 
6.3 Results: Individual results for 8 volunteers and intra- and inter-individual 
variation for each assay end-point. 
 
Table 6.2 Summary of results (mean and standard deviation from 3 repeats) for each assay 
end-point examined in 8 individuals 
A. γH2AX levels at 30 minutes post 2Gy (normalised fluorescence ratio) (n=3) 
Subject 1 2 3 4 5 6 7 8 
Mean 7.00 6.52 6.71 6.38 8.07 7.23 8.01 9.31 
SD 1.68 0.95 0.18 0.47 1.51 2.10 1.86 1.02 
 
B. γH2AX levels at 1 hour post 2Gy (normalised fluorescence ratio) (n=3) 
Subject 1 2 3 4 5 6 7 8 
Mean 9.86 10.26 8.60 9.41 11.53 9.71 11.57 12.00 
SD 3.27 1.05 0.58 2.16 4.30 2.72 1.47 3.26 
 
C. γH2AX levels at 2 hours post 2Gy (normalised fluorescence ratio) (n=3) 
Subject 1 2 3 4 5 6 7 8 
Mean 9.25 9.70 7.62 10.07 9.88 10.28 10.26 8.96 
SD 2.61 1.85 0.18 1.72 2.36 0.96 3.19 2.28 
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D. γH2AX levels at 4 hours post 2Gy (normalised fluorescence ratio) (n=3) 
Subject 1 2 3 4 5 6 7 8 
Mean 5.30 5.21 4.81 5.72 6.37 6.87 5.84 5.69 
SD 0.65 0.07 0.57 0.50 1.35 1.89 1.76 1.92 
 
E. γH2AX levels at 6 hours post 2Gy (normalised fluorescence ratio) (n=3) 
Subject 1 2 3 4 5 6 7 8 
Mean 3.61 3.21 2.67 2.96 3.64 3.33 3.79 3.35 
SD 0.46 0.36 0.88 0.05 0.71 1.24 0.55 0.53 
 
F. AUC of γH2AX kinetics post 2Gy (normalised fluorescence ratio) (n=3) 
Subject 1 2 3 4 5 6 7 8 
Mean 33.24 33.4 27.37 34 38.14 37.63 37.80 36.08 
SD 7.82 3.93 1.60 4.08 10.81 6.31 7.33 9.97 
 
G. Half-life of γH2AX loss post 2Gy (hours) (n=3) 
Subject 1 2 3 4 5 6 7 8 
Mean 2.78 3.25 4.37 3.66 3.20 3.59 3.19 3.55 
SD 0.88 0.31 2.25 0.69 0.45 1.14 0.20 0.45 
 
H. Ratio of peak to 6 hour levels of γH2AX post 2Gy (n=3) 
Subject 1 2 3 4 5 6 7 8 
Mean 3.54 3.03 2.90 2.87 3.22 2.99 3.31 3.25 
SD 0.84 0.23 0.44 0.22 0.30 0.50 0.50 0.26 
 
No statistically significant difference could be detected between male and female 
volunteers, or smoker vs. non-smokers (unpaired t test p>0.05 for all end-points) or when 
comparing age below 30 vs. aged 31-40 vs. age >40 years (p>0.05, one way ANOVA) for 
any of the end-points examined  
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Table 6.3  Summary of one-way ANOVA results for each assay end-point.  
 
The intra- and inter-individual variance is taken as within-subject and between subject 
mean square values from the ANOVA table.  
 
 
 
 
Assay end-point 
γH2AX at fixed  time point after 
irradiation (hours) 
AUC Half-life 
γH2AX 
loss 
 
Ratio 
peak:6 
hour 
γH2AX 
0.5 1 2 4 6 
Intra-
individual 
variance 
1.67 6.94 4.45 
 
1.65 0.47 50.70 1.02 0.21 
Inter-
individual 
variance 
3.07 4.38 2.39 1.29 0.70 38.53 0.65 0.16 
Is inter- > 
intra-
individual 
variance? 
Yes No No No Yes No No No 
p- value 0.15 0.72 0.79 0.61 0.24 0.63 0.72 0.61 
 
Within-individual variance is greater than between-individual variance for all end-points 
examined except for time points 30 minutes and 6 hours. For no endpoint is the inter-
individual variance statistically different from the intra-individual variance, and no 
statistically significant difference between individuals could be detected for any assay 
endpoints (p>0.05 for all). 
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Table 6.4 Intra- versus inter-individual variation - coefficients of variation 
To further illustrate that intra-individual variation exceeded inter-individual variation the 
mean intra-individual coefficient of variation and the inter-individual coefficient of 
variation were calculated for each assay endpoint. For all end-points intra-individual 
exceeded inter-individual variation. 
 
Assay end-point Intra-individual variation  Inter-individual variation  
0.5 hours 17.63% 12.48% 
1 hour 22.95%% 11.80% 
2 hours 20.33% 9.43% 
4 hours 21.38% 11.0% 
6 hours 21.06% 14.79% 
AUC 19.49% 10.32% 
Peak:6 hour ratio 22.83% 13.4% 
Half life  13.53% 7.26% 
 
6.4 Discussion 
When the kinetics of γH2AX induction and loss were measured on three separate 
occasions in 8 healthy volunteers no statistically significant differences could be detected 
between individuals for any of the assay end-points examined. There appeared to be no 
statistically significant influence of age, sex or smoking status on results although the data 
sets examined were very small so a possible confounding influence by these factors cannot 
be entirely excluded.  
 
Using ANOVA intra-individual variance exceeded inter-individual variance for all 
endpoints except γH2AX levels at 30minutes and 2 hours post-irradiation but no 
statistically difference in inter- and intra -individual variance could be detected for any 
assay end-point. This suggests that between-sample variation in assay results within the 
same individual whether caused by technical inconsistencies in assay technique or 
confounding biological factors may mask differences between individuals and raises 
considerable doubt as to whether the measurement of γH2AX kinetics using this technique 
will be sufficiently precise to allow discrimination between individuals of differing normal 
tissue radiosensitivity.  
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Of course, the volunteer study reported here sampled blood from individuals of unknown 
intrinsic radiosensitivity. Given that the estimated proportion of highly radiosensitive 
individuals in the population is 5% it is unlikely that this small sample of 8 volunteers 
contained an individual with high normal tissue radiosensitivity. If all the volunteers were 
of average normal tissue radiosensitivity then perhaps no significant difference between 
assay results would be expected. 
 
Ismail et al (Ismail, Wadhra et al. 2007) recently reported a study of γH2AX quantification 
after 8Gy by flow cytometry in cryopreserved human peripheral blood lymphocytes in 20 
volunteer patients and described a two-fold inter-individual difference in the γH2AX 
signal at 0.5 hours and a 0.3-fold difference in DNA repair capacity as measured by the 
ratio of γH2AX signal at 0.5 hours to that at 5 hours after irradiation.  This inter-individual 
variation is considerably higher than demonstrated here for similar estimates of γH2AX 
induction and loss. Ismail et al have not attempted to measure intra-individual variation in 
assay results. Inspection of the crude data from the γH2AX kinetics in the 8 volunteers in 
the current study shows that within an individual the γH2AX levels at fixed time points 
after irradiation and peak: 6 hour ratio can vary between 1.5 and 2-fold over time, and 
without a similar estimate of intra-individual variation it is not possible to be certain that 
that Ismail et al were detecting a true inter-individual variation in γH2AX assay results. 
 
The influence of the high intra-individual variability and poor assay precision on the 
discriminatory ability of γH2AX kinetics in the identification of  individuals of high 
normal tissue radiosensitivity depends on the magnitude of any difference in assay results 
that might exist between an individual of high and an individual of “average” normal 
tissue radiosensitivity. If the difference is very large, the poor assay precision” will be less 
important and the assay may well possess discriminatory ability. If, however, the 
difference in assay results is small, then poor assay precision will be of major importance 
as  the high intra-individual variation in results may well reduce or negate any 
discriminatory power the assay may possess. In a crude estimate of how large the 
difference in assay results between non-radiosensitive and radiosensitive individuals would 
need to be for the assay to achieve some discriminatory power, a ROC analysis was 
performed using hypothetical data. Individual results from the three repeats of γH2AX 
kinetics in the 8 volunteers in this study were taken as the results from “non-
radiosensitive” controls with the spread of results giving a crude indication of the 
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variability in assay results or “noise”. Hypothetical values of assay results were generated 
for a “radiosensitive population” with hypothetical assay results being 5, 10, 25, 50 and 
100% greater than those for the “non-radiosensitive” controls. ROC analysis was then 
performed and the AUC of the ROC curve calculated (Table 6.5). As discussed in Chapter 
3, if the AUC of the ROC curve is 0.5 the assay possesses no discriminatory power, 
whereas an AUC of 1.0 represents an assay with perfect discriminatory ability. As the 
AUC rises from 0.5 to 1.0 the discriminatory values of the assay improves. As seen in the 
table the assay results for all potential end-points in radiosensitive individuals would need 
to be at least 50% greater than that of controls to result in an AUC consistently greater than 
0.8. This hypothetical model is very crude and underestimates the negative affect 
confounding “noise” from intra-individual variation in assay results will have on assay 
discriminatory power. It also makes the assumption that the volunteers in this study were 
all individuals of normal intrinsic radiosensitivity which may not be true, and which again 
may have led to an overestimate of assay discriminatory power in this hypothetical data 
set. This hypothetical data does suggest however that the true difference between non-
radiosensitive and radiosensitive individual will have to be at least 50%, and probably 
higher to overcome the “noise” generated by high intra-individual variation in assay 
results. Given the results from other studies of functional cell-based assays reported in 
Chapter 3 the existence of a consistent difference of this magnitude would seem unlikely. 
 
The only way of truly determining the magnitude of any difference in assay results in 
individuals of high and average normal tissue radiosensitivity and to properly assess its 
discriminatory power is to perform a clinical study comparing assay results from 
individuals previously treated with radiotherapy (and who therefore have known normal 
tissue sensitivities) and looking for differences in assay results in patients with high versus 
normal levels of toxicity after apparently identical radiotherapy regimens and correction 
for other confounders that may influence normal tissue response.  ROC analysis of the 
results should then give a true idea of whether this assay has any clinical utility. 
  
The most efficient way to achieve this goal would be to perform a retrospective case-
control study which would require relatively small numbers of patients and could give 
answers quickly. If ROC analysis yielded a value for AUC close to 0.5 then it would be 
clear that either there is no relationship between γH2AX kinetics and normal tissue toxicity 
or that the poor assay precision was masking such a relationship, and it would then be 
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inappropriate to spend further time and resources on its investigation as a predictive assay 
of normal tissue radiosensitivity 
 
 
Table 6.5 ROC analysis for hypothetical differences in assay results between 
radiosensitive and non-radiosensitive individuals. 
Table shows the AUC of the ROC curve and 95% confidence intervals (in brackets) for the 
different assay endpoints for different hypothetical percentage differences in assay results 
between radiosensitive and non-radiosensitive individuals 
 
Assay end-
point 
Hypothetical % difference in assay results between radiosensitive 
and non-radiosensitive individuals 
 5% 10% 25% 50% 100% 
0.5 hours 0.57 
(0.45-0.71) 
0.65 
(0.52-0.79) 
0.79 
(0.67-0.90) 
0.93 
(0.67-0.99) 
1.00 
(0.99-1.00) 
1 hour 0.57 
(0.43-0.71) 
0.63 
(0.49-0.76) 
0.76 
(0.64-0.88) 
0.92 
(0.85-0.98) 
0.99 
(0.97-1.01) 
2 hours 0.58 
(0.43-0.72) 
0.61 
(0.47-0.75) 
0.76 
(0.64-0.88) 
0.90 
(0.83-0.97) 
0.99 
(0.98-1.01) 
4 hours 0.59 
(0.45-0.73) 
0.63 
(0.50-0.77) 
0.76 
(0.64-0.88) 
0.89 
(0.81-0.97) 
0.99 
(0.96-1.01) 
6 hours 0.57 
(0.43-0.72) 
0.63 
(0.49-0.70) 
0.75 
(0.63-0.88) 
0.87 
(0.78-0.97) 
0.96 
(0.90-1.01) 
AUC 0.57 
(0.43-0.72) 
0.65 
(0.51-0.78) 
0.77 
(0.65-0.88) 
0.92 
(0.85-0.98) 
0.99 
(0.98-1.01) 
Peak:6 
hour ratio 
0.59 
(0.45-0.73) 
0.65 
(0.51-0.78) 
0.79 
(0.68-0.90) 
0.98 
(0.83-1.00) 
0.97 
(0.93-1.01) 
Half-life (h) 0.63 
(0.49-0.79) 
0.71 
(0.58-0.84) 
0.90 
(0.81-0.98) 
0.98 
(0.96-1.01) 
1.00 
(1.00-1.00) 
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7. Effect of blood sample storage duration and conditions on γH2AX 
induction in vitro. 
 
7.1 Rationale for investigation of effects of sample storage on assay results. 
The high intra-individual variation of assay results demonstrated in the volunteer study 
raises concern about the potential clinical utility of the examination of γH2AX kinetics in 
PBLs after in vitro irradiation as a predictive assay of normal tissue sensitivity. Before 
firm conclusions about the clinical utility of assay can be made, the discriminatory ability 
of the assay must be tested in a population of individuals of known normal tissue 
radiosensitivity. A study population of known radiosensitivity would consist of patients 
who had already been treated with radiotherapy and whose normal tissue toxicity had been 
documented. 
 
All measurements of γH2AX kinetics up to this point have been performed using fresh 
blood samples, with PBLs separated, irradiated and fixed immediately following blood 
sample collection. Realistically immediate processing of blood samples would not be a 
feasible option when collecting samples from patients. Blood samples would be collected 
at hospital outpatient clinics when patients were attending for follow-up and would need to 
be transported to the laboratory which is situated 15 miles from the nearest oncology 
outpatients department. As samples would not always be taken in the morning they will 
likely need to be stored overnight prior to cell preparation. For any study comparing results 
from different samples it is important to assess whether blood sample storage and storage 
conditions could potentially affect assay results and confound the study outcome. If 
storage does affect results it is also important to determine if it does so in a predictable 
fashion which would mean that sample handling could be standardised to minimise 
differences in assay results between individuals caused by differences in sample handling 
rather than a difference in normal tissue radiosensitivity. 
 
7.2 Method 
As in the studies of assay precision, γH2AX induction in PBLs at 1 hour after 2Gy was 
taken as the end-point for experiments examining the effects of sample storage and storage 
conditions on assay results. Although ideally the kinetics of γH2AX induction would have 
been measured for different storage durations and conditions it was not feasible to collect 
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the large quantity of blood that would have been required for such an experiment from one 
individual at one time. It would also have required simultaneous handling of an 
excessively large number of sample tubes during subsequent analysis. 
 
In order to determine if blood sample storage affected assay results γH2AX induction in 
PBLs  at 1 hour after 2Gy in blood taken from a single individual and stored at room 
temperature or at 4oC for up to 24 hours. Peripheral blood (13 x8ml CPT tubes) was 
collected from a single volunteer (Subject 2). PBLs from 1 tube were separated, irradiated 
and fixed immediately as per the usual protocol outlined in Chapter 2. Six tubes were 
centrifuged and the resulting monocyte layer re-suspended in plasma by inversion of the 
tubes. The remaining six tubes were not centrifuged before storage. Three pre-separated 
tubes and three tubes containing whole blood were refrigerated (4oC) and three pre-
separated tubes and three tubes containing whole blood were stored at room temperature 
(21oC), all with light excluded. At pre-specified time points (2, 6 and 24 hours) PBLs were 
isolated, irradiated and fixed from one pre-separated and one tube of whole blood from 
each storage temperature.. All samples once fixed were then stored at -20oC for up to 14 
days. All were immunostained and analysed simultaneously. The experiment was repeated 
7 times.  
 
The measured radiation-induced γH2AX level for each storage condition was plotted 
against storage time. The Area Under the Curve (AUC) for each was calculated. The 
Kruskall-Wallis test followed by Dunn’s multiple comparison tests were performed to 
determine if storage conditions and duration had a statistically significant effect on the 
levels of γH2AX induced 1 hour after 2 Gy. Spearman rank correlation was performed to 
examine if there was a relationship between duration of storage and assay results for the 
four different storage conditions. 
 
7.3 Results  
For all seven repeated experiments it was not possible to obtain results for the whole blood 
sample stored at 21oC for 24 hours. Although a normal cell yield was obtained following 
separation from whole blood, only cell debris was evident at flow cytometry following 
irradiation, fixation and immunostaining and no consistent lymphocyte population could 
be gated. Lymphocytes could be consistently gated in the 24 hour samples for whole blood 
samples stored at 4oC and for the pre-separated samples stored at both temperatures. 
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Table 7.1 Mean/standard deviation γH2AX levels 1 hour after 2Gy in PBLs from blood 
stored between 0 and 24 hours under different conditions before analysis 
Also shown are the AUC and Spearman correlation coefficients for γH2AX levels with 
increasing storage duration (n=7) 
 
 
Whole blood 
21oC 
Pre-
separated 
21oC 
Whole blood 
4oC 
Pre-
separated 
4oC 
Fresh sample 12.01/2.32 
 
12.01/2.32 12.01/2.32 12.01/2.32 
Stored for 2 hours 14.82/2.44 
 
13.60/2.72 12.22/1.67 12.77/1.61 
Stored for 6 hours 16.12/3.99 13.18/2.24 11.49/3.14 12.83/1.68 
Stored for 24 hours Not available 15.93/1.11 9.99/3.53 8.49/2.6 
AUC 0-24 hours Not available 342.2/39.5 267.1/52.45 268.8/22.54 
AUC 0-6 hours 85.13/16.74 80.19/12.56 72.46/12.48 75.48/12.92 
Correlation (0-24 
hours) Spearman r 
and  p-value 
Not available 0.8, p=0.33 -0.8, p=0.33 -0.8, p=0.33 
Correlation (0-6 
hours) Spearman r 
and p-value 
0.5, p=1.0 0.5, p=1.0 -0.5, p=1.0 -0.5, p=1.0 
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Figure 7.1 Effect of storage temperature and duration on γH2AX levels in isolated human 
PBLs 1 hour after 2Gy in whole and pre-separated blood samples 
 
There is a statistically significant difference in γH2AX levels 1 hour after 2Gy in blood 
samples stored for different durations under different storage conditions (p=0.0057, 
Kruskall-Wallis test). Dunns multiple comparison tests show that radiation-induced  
γH2AX levels are significantly higher in pre-separated blood samples stored at room 
temperature for 24 hours compared with pre-separated samples refrigerated for the same 
duration and this is confirmed by Mann-Whitney test on the same data (p=0.0286). There 
were no other significant differences between γH2AX levels induced following irradiation 
in samples stored under different conditions. There was no significant correlation between 
assay results and duration of storage for any of the storage conditions (p>0.05 for all) and 
no significant difference between assay result at any time point for any storage condition 
and the results obtained from fresh samples. There was, however, a trend for γH2AX 
levels 1 hour after irradiation to increase with duration of storage in samples stored at 
room temperature and to decrease with duration of storage in refrigerated samples.  
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7.4 Discussion. 
 
Blood sample storage conditions and duration of storage do appear to influence the levels 
of γH2AX induced in isolated human peripheral blood lymphocytes after in vitro 
irradiation. 
 
 It is not possible to obtain results for samples stored as whole blood at room temperature 
for 24 hours due to the absence of a clearly defined lymphocyte population on flow 
cytometric analysis despite an apparent normal yield of mononuclear cells from the CPT 
tubes after storage. Storing whole blood at 4oC or separating the mononuclear cells from 
whole blood by centrifugation and re-suspension in plasma before storage at room 
temperature seems to protect against this effect. The main effect of centrifugation within 
the CPT tubes is to separate the monocyte population and plasma from erythrocytes and 
granulocytes which are trapped below the gel layer within the tubes and prevented from re-
mixing with the monocytes layer. The protective effect of separating the granulocytes and 
erythrocytes before blood storage at room temperature suggest that these cells are exerting 
an influence on the lymphocyte population during storage that results in their loss during 
the subsequent irradiation, fixation and staining procedure. The fact that storage of whole 
blood at 4oC also protects against loss of analysable cells after irradiation suggest that the 
effect of granulocytes and erythrocytes is a temperature-dependent process possibly 
enzyme-mediated. It has been reported that lysis of erythrocytes can exert oxidative 
damage on lymphocytes with lymphocytes analysed by the alkaline comet assay 
manifesting a 10-fold increase in DNA damage if analysed in the presence of red blood 
cells compared to isolated lymphocytes (Narayanan, O'Donovan et al. 2001). This DNA 
damage increases with increased duration of blood storage, is more pronounced if samples 
stored at room temperature compared to refrigerated samples but does still occur even of 
whole blood is stored at 4oC.  
 
Radiation-induced γH2AX levels increased with increased duration of storage up to 6 
hours in whole blood samples stored at room temperature suggesting that during storage 
lymphocytes became more prone to radiation DNA damage or that the enzymes involved 
in H2AX phosphorylation became more rapidly able phosphorylate H2AX. Cells stored in 
whole blood at room temperature under oxidative stress with ongoing DNA damage such 
as that due to lysis of granulocytes or erythrocytes will perhaps have increased induced 
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levels of ATM/ATR and hence increased ability to form γH2AX after irradiation. It is 
possible that with longer duration of oxidative stress these cells will also be more 
susceptible to apoptosis after irradiation. The lack of cells for analysis in the irradiated 
lymphocytes stored at room temperature for 24 hours may have been due to rapid cell 
death after in vitro irradiation in pre-stressed cells. Exploration of this hypothesis would 
require analysis of apoptotic profiles of irradiated and non-irradiated lymphocytes 
following different storage conditions and duration. 
 
The apparent decrease in γH2AX induction in refrigerated samples either stored whole or 
pre-separated  implies that cells stored at low temperatures are either less susceptible to 
DNA damage or that they are less able to respond by enzymatic phosphorylation of H2AX 
than cells stored at room temperature. Storage at low temperatures does lead to decreased 
enzyme activity. Although cells were incubated at 37oC for 30 minutes prior to irradiation 
it is possible that this time was insufficient to allow full recovery of enzyme activity. An 
alternative explanation is that the extreme cold may induce stress response genes whose 
products then act to protect the cell against subsequent radiation-induced DNA damage. 
Cold- induced proteins such as HSP-70 and HSP-90 have been shown to be upregulated in 
mammalian cells when returned to 37oC after transient cold shock at 4oC (Cox, Moseley et 
al. 1993; Liu, Bian et al. 1994). There is some evidence that HSP 70 protects against DNA 
damage caused by ionising radiation (Calini, Urani et al. 2003; Hunt, Dix et al. 2004). 
 
It does seem clear that if patient blood samples are not to be analysed immediately after 
blood collection, storage must be standardised for any clinical study as storage conditions 
do seem to affect γH2AX levels. Given that storage of whole blood at room temperature 
for 24 hours yields no results and that there is a possibility that granulocyte and 
erythrocyte lysis may exert oxidative stress on lymphocytes which may occur even at low 
storage temperatures it would seem sensible to separate the mononuclear cells before 
storage by centrifugation of the CPT tubes immediately after blood collection. A major 
advantage of using the CPT tubes system is that separation can be performed quickly and 
safely without opening of tubes and exposure of staff to blood biohazard or potential 
bacterial contamination of blood samples prior to storage.  
 
As storage temperature seems to affect results the samples must then be stored at a 
standardised temperature prior to analysis. After 24 hours there was a significant 
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difference between induced γH2AX in separated samples stored at room temperature or 
refrigerated but no difference between either and fresh samples. It would therefore be 
reasonable to store samples at either temperature as long as the temperature was 
standardised and controlled. Refrigeration of blood samples is probably the easiest way to 
do this as room temperatures within different hospital departments or laboratories can vary 
significantly and may even vary overnight depending on hospital heating policy (!).  
 
In conclusion: 
 
• for the purposes of a clinical study requiring blood samples to be taken from 
patients and stored before preparation and analysis, peripheral blood samples 
should be immediately centrifuged to separate out the erythrocyte and granulocyte 
population and then stored at 4oC for up to 24 hours until ready for further 
preparation and analysis..  
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8.  Final discussion  
 
Despite over a decade of research, mostly involving assays testing the response of a cell to 
a test dose of radiation in vitro, no predictive assay of normal tissue radiosensitivity has 
been developed and incorporated into clinical practice. 
 
The majority of studies of functional cell-based assay identified in this systematic review 
are of poor methodological design, or have been reported with insufficient detail to 
convince clinicians that possible confounding factors and sources of bias have been 
sufficiently taken into account and therefore that the conclusion of the study, whether it be 
positive or negative, is valid. Heterogeneity of assay techniques, the patients recruited, the 
radiotherapy delivered, assessment of toxicity and statistical analysis makes it difficult to 
compare studies of different assays or combine the results from studies which are 
examining the same assay. This heterogeneity may also account for the inconsistency of 
study results and conclusions. Overall, it is impossible to come to any firm conclusions 
about the discriminatory ability of functional cell based assays in the prediction of normal 
tissue radiosensitivity on the current evidence base and the increasingly held perception 
that they have no potential clinical utility cannot be justified on this evidence alone. 
 
By analysing individual patient data extracted from the published studies and calculation 
of diagnostic odds ratios (DOR) it is possible to remove at least the heterogeneity of 
statistical analysis in those studies which report individual patient data . Although for most 
the DOR suggest that the assays perform poorly, a small number were shown to possess a 
DOR and 95% CI which suggest possible discriminatory power, at least within the context 
of the study from which the data was extracted. Perhaps the most convincing DOR was for 
a study of DNA DSB induction in peripheral blood lymphocytes and the prediction of 
acute normal tissue toxicity in radiotherapy for head and neck cancer (Wang, Chen et al. 
2005). It should be noted, however, that this result has not been validated in subsequent 
studies. 
 
Nevertheless this observation does justify the attempt to develop another cell-based assay 
based on the detection of γH2AX foci and their subsequent loss in irradiated human 
peripheral blood lymphocytes. Clearly any such assay needed to be developed in a 
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methodical fashion with sufficient attention to and reporting of the technical parameters, 
such as reproducibility, important in Level 1 assay development.  
 
The data presented here show that it is possible to measure and follow the kinetics of 
γH2AX after a clinically relevant test dose of in vitro radiation in isolated human 
peripheral blood lymphocytes using immunofluorescent staining and analysis by flow 
cytometry. Assay failure rate is low and results are produced within a clinically useful time 
frame. The assay clearly measures a response to radiation but, at least in the first 6 hours 
after irradiation, it may not simply reflect DNA DSB rejoining as discussed in Section 
5.1.10. 
 
The high intra-individual variation in γH2AX induction and loss exceeds inter-individual 
variation and immediately raises concerns that the power of the assay to discriminate 
between individuals of differing normal tissue radiosensitivities may be low. As the 
individuals studied in Chapter 6 were of unknown radiosensitivity the discriminatory 
power of the assay must be tested in a population of known radiosensitivities with 
appropriate attention to confounding factors to be certain that the high intra-individual 
variation in assay results really does limit its clinical utility. As blood sample storage 
duration and conditions seem to affect assay results any such study must include 
standardised sample storage conditions in its protocol and ensure to report this 
subsequently. 
 
Unless there is a significant difference (at least 1.5-fold) in assay results between 
individuals of high and normal intrinsic radiosensitivity, it seems likely that the intra-
individual variability will mask any differences in assay results between individuals of 
differing radiosensitivities. This intra-individual variation between samples, whether 
caused by day to day variations in technical performance, such as subtly varying 
laboratory conditions, or day to day biological variation within an individual potentially 
caused by diet, concurrent illness or stress, will be very difficult to reduce. Intra-individual 
variation is also evident in other studies of cell-based assays which (when documented) 
report an inter-sample coefficient of variation of 15%. It must be  likely that even if future 
studies of cell-based assays of normal tissue radiosensitivity are designed and conducted 
with flawless attention to study design and confounding factors that the inherent and 
difficult to control for biological and technical day-to-day variations may render cell-based 
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assays insufficiently reproducible and therefore precise to be of any clinical value. Proven 
lack of reproducibility resulting in low diagnostic accuracy in otherwise well designed 
studies may ultimately be the justification for the abandonment of functional cell-based 
assays in the prediction of normal tissue radiosensitivity. 
 
A problem with assay reproducibility notwithstanding, it is unclear as to whether the 
principle of measuring the response of a surrogate solitary cell type (e.g. a fibroblast or 
lymphocyte) to a single test dose of radiation to predict tissue response is a valid one. 
Clinical fractionated radiotherapy schedules involve repeated exposure of normal tissues to 
radiation on a daily basis often for 4-6 weeks and measuring cellular response to a single 
test dose of radiation in vitro does not reflect this process of repeated radiation insult.  
 
Although the pathophysiology underlying the normal tissue response to radiation is not 
completely understood, radiation normal tissue injury is thought to behave like a complex 
wound with the severity of expression of injury related to damage to a large number of cell 
types (Denham and Hauer-Jensen 2002). Radiation injury occurs in organised tissues 
comprising a large number of interactive mutually dependent cell lineages that, along with 
the extracellular stroma, all contribute individually to the welfare of the tissue as a whole. 
Whilst ionising radiation can cause the specific cellular responses as tested for in cell-
based predictive assays, it has been increasingly recognised that it is the differing but 
interacting responses of all of the cell types within tissue and modification of extracellular 
stroma that dictates the severity of normal tissue injury after radiotherapy (Denham and 
Hauer-Jensen, 2002). 
 
Acute radiation toxicity has classically been attributed to loss of functional cells due to the 
death or proliferative arrest of stem cell populations (Stone et al, 2003).  However, the 
acute effects of radiation do not appear to depend entirely on the lethal effects of radiation. 
Radiation causes an immediate increase in tissue blood flow and vascular permeability via 
indirect radiation effects on mast cells and endothelial cells, resulting in generation of 
thrombin and release of histamine and prostaglandin I2 and E2 and neutrophil adhesion to 
the endothelial cell surface in the hours following radiation exposure (Potten et al, 1978; 
Dunn et al, 1986; Panes et al, 1995; Park et al, 2000). Histologically the features are of an 
acute inflammatory response. As treatment continues, the acute inflammatory response 
builds due to a combination of direct and indirect cell injury and death, with each fraction 
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of treatment adding another insult to an already damaged tissue. Microscopically acutely 
irradiated tissues demonstrate margination of neutrophils and perivascular infiltration 
(Slauson et al, 1976; Narayan et al, 1982; Reinhold et al, 1990). Radiation endothelial cell 
apoptosis may cause increased vascular permeability and micro vascular thrombosis 
(Fajardo and Stewart, 1971; Rubin and Greim, 1998). Leucocytes drawn to the site of 
injury adhere to the endothelium, migrate into the extracellular matrix and release 
proteolytic enzymes and reactive oxygen species. Necrosis of other parenchymal and 
inflammatory cells will exacerbate the acute inflammatory response. Increased levels of 
cytokines such as TGF-β may delay re-epithelialisation (Denham and Hauer-Jensen, 
2002). Loss of barrier function may also predispose to further injury, both physical and 
microbial which if persistent may lead to consequential late damage.   The clinical 
phenotype of acute radiation injury in normal tissue is therefore due to a combination of 
cell loss due to radiation cell killing of stem cells, and the acute inflammatory response, 
which is triggered and sustained by radiation cell killing and vascular changes.  
 
The mechanisms that lead to late normal tissue injury are likely to involve death of 
functional parenchymal cells as classically described by the radiation target theory. There 
is increasing evidence, however, that non-lethal damage to endothelial cells and fibroblasts 
within the irradiated volume play a significant role. In many respects the tissue response to 
radiation has similarities to the wound healing response to traumatic injury (Denham and 
Hauer-Jensen 2002). The genetic and molecular events triggered by the initial radiation 
injury may be sustained for many months if not years with ongoing production of pro-
inflammatory cytokines, and chemokines produced by macrophages, epithelial cells and 
fibroblasts. The cytokines lead to an adaptive response within the tissue and cellular 
infiltration. There is strong evidence that TGF-β1 is over expressed in irradiated tissues 
and this induces fibroblast proliferation – these fibroblasts may be post-mitotic but retain 
ability to produce collagen and so lead to fibrosis (Rodemann and Bamberg, 1995). 
Vascular sclerosis is a recognised feature of late radiation injury, and may have a major 
role in its pathogenesis. The capillary network is particular vulnerable to injury. 
Obstruction of the lumen follows swelling of the endothelial cell cytoplasm (Reinhold, 
1972; Reinhold and Buisman, 1973) , followed by detachment of proliferating endothelial 
cells (Hopewell et al, 1986; Kwock et al, 1998), thrombosis, rupture of the capillary wall 
and loss of entire capillary segments (Fajardo, 1997). Arterioles show subendothelial and 
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adventitial fibrosis (Sams, 1965). In addition to apoptosis, radiation is thought to induce 
long-term phenotypic changes in endothelium up regulating expression of cell adhesion 
molecules, chemokines and cytokines, which can then promote further thrombosis, 
recruitment of inflammatory cells and fibrosis (Law, 1981). Hypoxia may result from 
progressive endothelial and vascular damage and ischaemia – this hypoxia may result in 
the continuous overproduction of ROS which can lead to further molecular injury, 
effectively causing a vicious circle of ongoing injury for months if not years Vujaskovic et 
al, 2001). Hypoxia itself may promote inflammation and activate the pro-fibrotic cytokine 
TGF β. Late normal tissue damage may become clinically apparent when a critical 
threshold of normal tissue dysfunction is reached after a latent period during which tissue 
injury is ongoing. Alternatively, further injury to the irradiated tissue, perhaps in the form 
of surgery may trigger another cascade of inflammation and cytokine production resulting 
in sudden exacerbation of normal tissue damage and its clinical manifestation.  
 
In theory there could be inter-individual variation in any of the molecular, cellular and 
tissue responses to ionisation radiation that contribute towards acute and late normal tissue 
toxicity and it seems unlikely that a single cellular response in a single cell type will in 
isolation predict normal tissue radiosensitivity. 
 
Assays of gene expression profiling go some way to measuring the complex nature of 
cellular radiation responses, aiming to recognise differences in patterns of radiation-
induced gene expression in cells derived from radiosensitive and non-radiosensitive 
individuals. Their advantage is that the expression pattern of thousands of genes can be 
measured simultaneously without even having to know the function of the genes being 
examined, which is useful given that the molecular pathophysiology of radiation toxicity is 
not completely understood. There is increasing evidence that gene expression profiling is 
reproducible within and between laboratories (Canales, Luo et al. 2006; Patterson, 
Lobenhofer et al. 2006; Shippy, Fulmer-Smentek et al. 2006; Tong, Lucas et al. 2006; 
Chen, Hsueh et al. 2007; Fuscoe, Tong et al. 2007).However, these gene expression 
profiling assays are still susceptible to the criticism that they are analysing radiation 
response in a solitary surrogate cell type and that this cellular response may not reflect the 
tissue response (Begg 2006).  
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The move to radiogenomics avoids the problems associated with lack of assay 
reproducibility due to biological variation and the issues of surrogate tissue analysis since 
the genetic code being analysed should be the same in all cell types and not susceptible to 
the influences of biological or environmental conditions. By detecting single nucleotide 
polymorphisms in candidate genes likely to be involved in the tissue response to radiation 
it is hoped to develop a genetic profile associated with increased intrinsic normal tissue 
radiosensitivity (Andreassen, Alsner et al. 2002). This profile can then be measured in any 
easily accessible cell type including peripheral blood lymphocytes and with the advent of 
high throughput technology results should be available within a clinically useful time 
frame. One of the current limitations of this technique is choosing the appropriate genes 
for analysis given the lack of understanding of the molecular, cellular and tissue response 
to radiation. Gene expression studies may help guide researchers to appropriate targets. 
The radiogenomics approach has had limited success so far with some studies reporting an 
association between genetic polymorphisms and radiosensitivity (Andreassen, Alsner et al. 
2003; Andreassen, Alsner et al. 2005; Cesaretti, Stock et al. 2005; Chang-Claude, Popanda 
et al. 2005; De Ruyck, Van Eijkeren et al. 2005; Alsner, Andreassen et al. 2008) 
Hypothesis generating studies have not been validated in independent subjects so far 
(Andreassen, Alsner et al. 2006). 
 
The establishment of tissue banks with associated detailed information regarding tumour 
type, radiotherapy details, standardised and accurate normal tissue toxicity reporting and 
recording of patient and therapy related confounding factors means that studies based on 
genotyping assays can proceed quickly now with positive or negative results being likely 
to convince clinicians of assay utility due to improved study design assuming these 
confounding factors are dealt with appropriately. 
 
The development of predictive assays of normal tissue radiosensitivity illustrates the need 
for translational research in radiotherapy and radiobiology and illustrates how interested 
parties (clinicians, biologists and statisticians) must cooperate to generate useful results 
quickly and efficiently. The purpose of the research strategy is to produce a diagnostic test 
which can influence clinical decision making and patient management.  
 
The clinician must specify the maximum degree of invasiveness of tissue sampling before 
a test becomes unacceptable, e.g.an assay requiring a brain biopsy be unlikely to be taken 
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up in routine clinical practice unless samples could be taken at the time of surgical tumour 
resection. The clinician must also specify the maximum acceptable period between 
sampling and results before the assay becomes of no clinical use. The collection of robust 
and reliable data regarding radiotherapy dosimetry, patient characteristics, toxicity, and 
potential confounders is incumbent on the clinician. The clinician must also define the 
potential use of the assay result in the clinical decision making process, as this will 
influence the assay performance requirements – if the results are being used to screen out 
radiosensitive individuals for treatment with a lower radiation dose or alternative non-
radiotherapy treatment without making any change to the treatment for the reminder, the 
assay specificity may be more important than sensitivity to avoid erroneous screening out 
of an individual of normal radiosensitivity and perhaps subjecting them to radical surgery 
when an organ-preservation approach may have been feasible. On the other hand if 
individuals identified as non-radiosensitive are to be treated with dose-escalated 
radiotherapy then sensitivity may be more important than specificity in order to ensure that 
all sensitive individuals have been identified and screened out of dose escalation, which 
for them would potentially be extremely toxic if not life-endangering. 
 
The biologist’s pivotal role is to determine which biological parameters are likely to be 
useful predictors of normal tissue radiosensitivity and to determine how to measure these 
parameters reliably and reproducibly. The drive to develop a predictive assay will 
hopefully generate more knowledge about the biological processes underlying the normal 
tissue radiation response. 
 
As is considered routine in the development of clinical randomised controlled trials a 
statistician must be involved in developing study design including power calculations for 
adequate sample size and analysis of results to maximise the potential to generate useful 
and convincing results and therefore maximise research efficiency. 
 
This cooperation and thorough attention to study design is vital – the consequence to an 
individual patient of changing therapy based on the result of a predictive assay can be 
profound if the assay does not perform well. Therefore clinicians and ethics committees 
will require robust and convincing evidence of the diagnostic performance of a predictive 
assay before patients will be recruited into any studies of assay-directed therapy and this 
evidence will only be generated by well conducted adequately powered research studies. 
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Equally, if an assay really has no potential clinical utility it is important to provide 
convincing evidence of this quickly to prevent on-going and wasted devotion of time and 
financial resource. 
 
As the technical and physical individualisation of radiotherapy treatment reaches its 
maximum capabilities with the advent of intensity-modulated and image-guided 
radiotherapy, the pursuit of biological individualisation of treatment to try to further 
improve the therapeutic index of radiotherapy is clearly a worthwhile goal. The current 
literature on cell-based predictive assays of normal tissue radiosensitivity is of insufficient 
quality to make any firm conclusions about their potential utility but the inherent 
susceptibility to biological and environmental influences, as evident in the γH2AX assay, 
is likely to limit their usefulness. Whilst the establishment of tissue bank data-bases such 
as those associated with the GENEPI project (West, McKay et al. 2005) will hopefully 
mean that progress in the field of radiogenomics and the prediction of normal tissue 
radiosensitivity will be made, the advent of assay-directed therapy and attainment of levels 
5 and 6 on Fryback and Thornbury’s hierarchy with improved patient outcomes and 
societal gains in population tumour control rates and reduced rates of toxicity seems some 
way off. 
 
8.1 Future work 
As discussed earlier final conclusions about the potential utility of measuring γH2AX 
induction and loss in peripheral blood lymphocytes can only be made after testing for a 
difference in assay results between individuals of known high normal tissue 
radiosensitivity and normal or low radiosensitivity. 
 
The ROSES study, which recruited patients from radiotherapy centres in Dundee and 
Edinburgh between 2000-2002 (Wells, Macmillan et al. 2004) examined the role of skin 
care in the management of acute skin toxicity during and following radiotherapy for breast, 
head and neck and some anal cancers. During this study skin toxicity data was collected 
prospectively using reflectance spectrography and RTOG/EORTC scoring. Radiotherapy 
details were recorded as were details regarding BMI, smoking, blood pressure, 
haemoglobin, breast size, and chemotherapy, and concurrent medications. 
  
162 
 
It should be possible to perform a case-control study examining the role of γH2AX in the 
prediction of acute skin toxicity by identifying living patients who experienced severe 
acute skin toxicity (RTOG/EORTC grade 3 or 4) and matching then to one or ideally two 
individuals who experienced RTOG 0-2 toxicity. Matching criteria would be for tumour 
site, stage, radiotherapy schedule, chemotherapy, smoking status, haemoglobin, skin care 
regimen, BMI and (for breast radiotherapy) breast size. Sufficient time has now elapsed for 
late toxicity to have developed. Collection of late toxicity data then matching of cases with 
severe late toxicity with controls without toxicity using similar matching criteria as for 
acute toxicity as well as for duration of follow up may help determine if γH2AX induction 
and kinetics in PBLs can predict late skin/subcutaneous toxicity. Clearly this study would 
be susceptible to the potential bias introduced by the attrition of patients from the original 
ROSES study due to progression of their disease or other factors, but may give sufficient 
information to either confirm the lack of utility of the γH2AX assay or justify the 
establishment of a larger prospective study if any signs of discriminatory power were 
evident. 
 
As a clinician, my most important contribution to the process of predictive assay 
development is likely to be the prospective collection of high quality information 
regarding radiotherapy, confounding therapies and patient related factors and high quality 
acute and late toxicity data from patients receiving treatment under my care, which then 
has the potential to be used in future studies of predictive assays, along with the 
establishment and maintenance of useful working relationships with biology colleagues as 
part of a translational research team to help guide assay development from the perspective 
of the clinician who might one day use it in day to day practice. 
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10. Appendices 
 
Appendix 1 : Materials 
 
1.1 Laboratory equipment 
Centrifuge  Heraeus Labofuge 400R (Heraeus, Thermo Scientific) 
CO2 cell incubator (Heraeus, Thermo Scientific) 
Coulter counter - Z2™ COULTER COUNTER® Cell and Particle Counter (Beckman-
Coulter, Fullerton, USA) 
Cytocentrifuge - Shandon Cytospin 2 (Thermo Inc, USA) 
Dynal Magnetic Particle Concentrator (MPC) MPC –L (Dynal, Oslo, Norway).  
Flow cytometer - Becton Dickinson FACScan Analytic Flow Cytometer (Becton, 
Dickinson and Company, Franklin Lakes, USA) 
Gamma irradiator (IBL437C Cis Bio International, High Wycombe, UK).  
Gel documentation and analysis system (SynGene, Synoptics, Cambridge, UK) 
Gel mould (Bio-Rad Laboratories Ltd, Hemel Hemstead, UK) 
General glass wares (Schott) 
Horizontal Electrophoresis apparatus - Bio-Rad Sub-Cell 96 (Bio-Rad Laboratories Ltd, 
Hemel Hemstead, UK) 
Humidified chamber (made in-house) 
Laminar Flow Hood Class 2   - Herasafe HSP 12 (Thermo Kendro) 
Motorized Pipette Controller – Pipetboy (IBS Integra) 
One-channel Air-Displacement Pipette, various sizes (Pipetman, Gilson, Wisconsin, USA) 
Power Pack (Bio-Rad) 
UV Spectrophotomer  
Weigh machine (Sartorius) 
Zeiss Axioplan fluorescence microscope (Carl Zeiss Ltd) 
 
1.2 Chemicals and enzymes 
EDTA (0.5M for molecular biology, Sigma-Aldrich) 
Ethanol (BDH Laboratory Supplies, UK) 
Ethidium Bromide, 1% solution (Sigma) 
ii 
 
Low melting point agarose (Sigma-Aldrich) 
MOWIOL-DAPI (1 microgram/ml) (prepared in-house by biochemistry department) 
Paraformaldehyde (Sigma-Aldrich)  
Proteinase K (Sigma-Aldrich) 
Sodium N-lauryl sarcosine (Sigma-Aldrich) 
Triton X-100 (Sigma-Aldrich) 
Ultrapure agarose (Life Technology LTD, Paisley, UK) 
Vectashield (Vector Laboratories, Burlingame, USA) 
 
1.3 Kits 
CD4 positive isolation kit (Dynal Biotech, Oslo, Norway) 
CD8 positive isolation kit (Dynal Biotech, Oslo, Norway) 
CaliBrite two-colour kit (containing 3 individual vials of polymethylmethacrylate 
microspheres - unlabelled, FITC labelled and PE-labelled) (BD Biosciences, Becton, 
Dickinson and Company, Franklin Lakes, USA) 
Annexin V-FITC apoptosis detection kit (BD Pharmingen, BD Biosciences, Becton, 
Dickinson and Company, Franklin Lakes, USA) 
 
1.4 Consumables 
BD Vacutainer 5ml draw lithium heparin blood collection tubes, BD (Becton, Dickinson 
and Company, Franklin Lakes, USA) 
BD Vacutainer 8ml draw sodium citrate CPT tubes, BD (Becton, Dickinson and Company, 
Franklin Lakes, USA) 
BD Vacutainer one-use holders, BD (Becton, Dickinson and Company, Franklin Lakes, 
USA) 
BD Vacutainer one use sterile needles, BD (Becton, Dickinson and Company, Franklin 
Lakes, USA) 
1.5 ml safe lock tubes (Eppendorf) 
Cell culture flasks, filter capped, 80cm2 (Nunc) 
Disposable cytofunnels with filter cards (Shandon, Thermo Inc, USA) 
Disposable pipette tips, various sizes (VWR) 
Disposable sterile pipettes, 1ml, 5ml and 10ml, (Sterilin) 
Glass slides and coverslips 
Laboratory film (Parafilm) 
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Sterile polypropylene 15 and 50 ml tubes (Falcon), (BD Bioscience, Becton, Dickinson 
and Company, Franklin Lakes, USA) 
5ml polystyrene tubes for flow cytometry sample injection (BD Bioscience, Becton, 
Dickinson and Company, Franklin Lakes, USA) 
 
1.5 Cells and antibodies 
Muntjac fibroblast cell line (kindly supplied by Dr Peter Bryant) 
Anti-phosphohistone H2AX (Ser 139) clone JBW301 mouse monoclonal IgG1, (Upstate, 
Lake Placid, USA) 
Fluoroscein (FITC)-conjugated Affinipure Donkey anti-mouse IgG (H+L) (Jackson 
Immunoresearch Laboratories Inc, Westgrove, PA, USA)) 
FITC-labelled Mouse anti-human CD3 IgG (BD Bioscience, Becton, Dickinson and 
Company, Franklin Lakes, USA) 
PE-labelled Mouse anti-human CD19 IgG (BD Bioscience, Becton, Dickinson and 
Company, Franklin Lakes, USA) 
Becton Dickinson Simultest™ LeucoGATE™ (CD45/CD14) (BD Bioscience, Becton, 
Dickinson and Company, Franklin Lakes, USA) 
FITC-labelled Mouse IgG1 Isotype Control (BD Bioscience, Becton, Dickinson and 
Company, Franklin Lakes, USA) 
 
1.6 Solutions, sera, buffers and media 
Minimal Essential Medium (For Muntjac cell culture): 
Minimal Essential Medium x1(Gibco, UK) 
+ 0.3g/litre L-glutamine (Gibco, UK) 
+ 10% foetal calf serum (Gibco, UK) 
 
RPMI 1640 (for re-suspension of peripheral blood lymphocytes after isolation from whole 
blood): 
RPMI 1640 Media x1 without L-glutamine (Gibco, UK)  
+ 0.3g/litre L-glutamine (Gibco, UK) 
+ 1% foetal calf serum (Gibco, UK) 
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Sera: 
Foetal calf serum (Gibco, UK) 
Donkey serum (Sigma, St Louis, USA) 
Flow cytometry sheath fluid: 
FACSFlow, BD (Becton, Dickinson and Company, Franklin Lakes, USA) 
 
Phosphate Buffered Saline: 
Phosphate Buffered Saline 10x w/o Mg2+, Ca2+ (Gibco, UK) diluted to 1x in sterile 
deionised H2O, pH 7.4 
 
50x TAE buffer: 
242 g Tris base 
57.1 ml Glacial acetic acid 
100 ml 0.5 M EDTA pH 8.0 
In 1 litre deionised H2O 
 
Fricke stock solution:  
0.9804 g ammonium ferrous sulphate (Fe(NH4)2 (SO4)2 
0.1460g sodium chloride 
3.1668g caesium sulphate (Cs2 SO4 
6.93ml concentrated sulphuric acid (H2SO4) "Superpure" 
in 250ml deionised H2O 
 
1.7 Software 
Laboratory systems 
Cellquest Version 3, (Becton, Dickinson and Company, Franklin Lakes, USA) 
Cytovision System Version 3(Applied Imaging, Sunderland, Tyne & Wear, UK) 
FACSComp (Becton, Dickinson and Company, Franklin Lakes, USA) 
Syngene Genetools software (Syngene, Synoptics, Cambridge, UK) 
 
Statistical analysis: 
GraphPad Prism version 5.00 for Windows, GraphPad Software, San Diego California 
USA, www.graphpad.com 
Stats Direct Version 2.6.6. (www.statsdirect.com) 
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Appendix 2 : Gamma Irradiator Dosimetry. 
 
2.1 Results from Fricke dosimetry of gamma irradiator.  
 
Calibration of 137Cs irradiator by Fricke dosimetry
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2.2 Theoretical isodose distribution within the irradiation chamber (taken from 
manufacturer’s information – Cis Bio International) 
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Appendix 3 : Immunophenotyping of cell population under investigation 
 
Immunophenotyping of fixed mononuclear cell preparations was performed as described 
in Section 2.2.8. 
 
Analysis as shown below confirmed that the gated population that was analysed in the 
γH2AX quantification experiments was CD45 positive i.e. made up of leucocytes, and 
CD14 negative (i.e. did not contain monocytes) (see Figure C below). Given that 
centrifugation in CPT tubes had removed the granulocyte population it is reasonable to 
assume that this non-monocyte population consists of lymphocytes. From Figure D it can 
be seen that the majority of the gated cells were CD3 positive (i.e. were T-lymphocytes), 
and a clear population of CD19 positive cells (B-lymphocytes) was also present. Some of 
the gated cells did not stain for either CD3 or CD19 despite all staining for CD45 and not 
for CD14. This may be because of decreased antibody/receptor affinity in fixed samples 
(the antibodies to cell surface antigens for leucocyte immunophenotyping are 
recommended for use in fresh unfixed blood samples for this reason), or because of the 
presence of a  population of non-B and non-T lymphocytes or other  white cells with the 
same FSC and SSC characteristics as lymphocytes. Natural killer cells are lymphocytes 
which lack the characteristic B and T cell surface antigens – and may make up some of this 
non-stained population.  
 
Analysis of the sample stained with the FITC-conjugated mouse antihuman isotype control 
showed a minor degree of non-specific binding only. 
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Forward and side scatter characteristics of isolated monocytes 
after fixation and immunostaining
The red oval surrounds the gated population taken forward for 
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Green vs red fluorescence of gated population of non-stained 
sample confirming no background red or green fluorescence
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C.
Gated population stained with FITC-conjugated anti CD45 and
PE-conjugated anti CD14.
Cells within the gated region are CD45+ve confirming that they
are leucocytes, and CD14 –ve, confirming that they are not
monocytes
 
D.
Gated population stained with FITC-conjugated anti CD3 and
PE-conjugated anti CD19.
Cells within the gated region are CD3+ve (bottom right quadrant)
confirming that they are T-lymphocytes (and representing the
majority), and CD19 +ve, confirming that they are B-lymphocytes
(top left quadrant). A number of cells remain unstained (bottom left).
These must represent either B or T lymphocytes to which antibody
has not bound or a separate white cell population without CD3 or
CD19 antigens, possibly natural killer cells.
CD3 (Green fluorescence)
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4.2 DATA EXTRACTION PROTOCOL FOR SYSTEMATIC REVIEW 
 
Reference: 
 
Predictive Assay under investigation: 
Stated study objectives: 
 
MATERIALS AND METHODS SECTION 
Patients 
Source 
Inclusion/exclusion criteria: 
Disease sites TNM or AJC stage: 
 
Radiotherapy details – site, dose, fractionation, energy, treatment centre/s, field sizes 
and planning techniques 
 
Toxicity scoring details: 
System used e.g. RTOG/EORTC: 
Endpoint assessed: early, late: 
Median time from radiotherapy to toxicity scoring. 
Who is the person recording toxicity? Have they been trained? 
Scorer blinded to assay result?  - if so, how was this achieved? 
Inter-scorer variability assessed? – if so how was this done? 
 
Specimen characteristics: 
Biological material used 
Methods of sampling/ transport/storage. Is this the same for both cases and controls? 
 
Assay methods: 
Is a detailed protocol or reference for protocol included? 
Brief summary of technique 
How long is the interval between taking the sample and obtaining a reliable result? 
For the investigating laboratory are: 
quality control procedures reported? 
xvii 
 
reproducibility assessments reported? 
quantification methods reported? 
scoring and reporting protocols reported? (give details) 
Has technique been reported before by other groups? 
Have effects of blood/tissue sampling conditions and sample storage been assessed? 
For subjective assays – has inter-scorer variability been assessed and reported? 
Are assays performed blinded to patient outcome? If so- how was this achieved? 
 
Study design: 
Prospective or retrospective 
Method of case selection – e.g.  definition of case vs. control 
Case matching/stratification employed? 
Period over which cases taken/recruited 
Sample size 
Rationale for sample size (including power calculations) 
Hypothesis generating set/ test set (or other method for avoiding recursive reasoning) 
 
Statistical analysis:  
Specify all statistical methods used 
Is appropriate statistical analysis used?  
Is a statistician involved? 
Has ROC analysis been performed? 
Is sensitivity/specificity/PPV reported? 
 
RESULTS SECTION 
Data Reporting 
How many patients are included at each stage of analysis and what are the reasons for drop 
out (e.g. failure to get assay result, patients died before late toxicity could be assessed)  
Basic demographic characteristics reported for cases and controls?  
Potential confounding factors reported for cases and controls? 
e.g. concurrent chemotherapy, gaps in treatment, bolus, comorbidity, smoking 
Are cases and controls well matched for basic demographic characteristics and potential 
confounding factors? 
How are the assay results reported?  (e.g. table, histogram etc)  
xviii 
 
Is individual patient data reported? 
Are the number of missing values reported? 
 
Analysis 
Is there a difference in assay result between individuals with “normal radiation toxicity and 
individuals with “increased” radiation toxicity? 
What is the size of the difference?  
Is the difference statistically significant? 
Give p values and 95% CI 
Does the analysis account for all potential confounding factors? 
Has ROC analysis been performed? If so what is the AUC? 
Have optimum cut off values been determined? 
xix 
 
4.3 SCORING SYSTEM FOR QUALITY OF PREDICTIVE ASSAY STUDY 
DESIGN AND REPORTING 
 
Radiotherapy homogeneity 
15: Radiotherapy delivered to the same single site in all patients.  
Patients treated prospectively with dose, fractionation, beam energy, field size, boost, 
bolus, planning technique, concurrent or subsequent chemotherapy listed for all and clearly 
homogenous OR case-control study with matching of cases and controls for the above 
features 
5: Radiotherapy delivered to the same single site in all patients. 
No matching or listing of features to confirm but homogeneity likely 
0: Multiple sites treated, or same site treated with multiple different radiotherapy schedules 
with no subsequent adjustment in analysis or no description of radiotherapy or 
chemotherapy 
Patient homogeneity 
15: Patients recruited prospectively into study fulfilling clear entry and exclusion criteria 
to reduce presence of confounders with all remaining potential confounders (e.g. smoking 
status) listed and accounted for in subsequent analysis OR matched case control study with 
careful matching of confounding factors in cases and controls 
5: Apparent homogeneity of patient population but insufficient documentation of 
demographics, inclusion/exclusion criteria to be certain 
0: Clear heterogeneity of patient population or no description on any patient demographics 
or potential confounders 
Toxicity Scoring 
10: Toxicity measured as a single end-point in a single tissue with matching or subsequent 
adjustment for follow up duration for late toxicity 
5: Toxicity measured as multiple end points in a single tissue 
0: Toxicity measured in multiple tissues, no adjustment for follow up time between cases 
and controls or no definition of “case” or “control” with respect to toxicity 
Inter-scorer reproducibility assessment 
3: only one scorer for toxicity, or if more than one inter-scorer reproducibility conformed 
0: no reporting of scorer number or reproducibility 
 
 
xx 
 
Assay intra-sample reproducibility assessment 
5: Assay technique optimised and intra-sample reproducibility assessments performed by 
same group before study commenced 
2: Inter-sample reproducibility assessed during the clinical study 
Assay inter-sample reproducibility assessment 
5: Assay technique optimised and inter-sample reproducibility assessments performed by 
same group before study commenced 
2: Intra-sample reproducibility assessed during the clinical study 
Sample handling 
5: clear description of sample handling prior to analysis, whether it is stored, whether 
storage affects results and if handling is the same for all specimens 
0: no description of sample handling 
Blinding 
2: Scorer of toxicity blinded to results of assay and scorer of assay blinded to results of 
toxicity 
1: one of the above criteria fulfilled 
0: No report of scorer blinding 
Treatment for possible confounding factors 
10: possible confounding factors accounted for in study design or analysis 
0: no attempt to account for confounding factors 
Sample size 
10: >50 
5: >20 
1 :< 20 
Statistical analysis 
20: construction of ROC curve, selection of cut offs and calculation of sensitivity and 
specificity 
10: appropriate analysis e.g. correlation, comparison of means, Kaplan-Meier with 
adequate reporting of results 
0: no reporting of statistical methods or results 
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Appendix 5 : DNA DSB induction by ionising radiation in isolated 
human peripheral blood lymphocytes  
 
Human peripheral blood lymphocytes were isolated from fresh peripheral blood samples, 
irradiated with increasing doses of ionising radiation (137Cs gamma source) and then 
analysed for the presence of DNA double strand breaks as per the method described in 
Section 2.2.11. The number of DNA DSBs was calculated as the Fraction of DNA 
Released (FDR) from each well with the subtraction of results from non-irradiated control 
samples– the mean of results and standard deviation from 3 independent experiments using 
PBLs from the same volunteer (subject 6) are plotted against radiation dose and is shown 
below. This confirms a linear dose response in DNA DSB induction between 0 and 30Gy 
(r2 0.9752, linear regression analysis). Examples of the images of the gel after 
electrophoresis used for image analysis are also shown) 
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